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Hypoxia has emerged as a crucial part of the aetiology of tumours. It is a negative prognostic 
factor of breast cancer and is associated with alterations of multiple metabolic pathways. This 
thesis uses NMR as a tool both to investigate the static metabolome by measuring metabolite 
concentrations, as well as to determine the 13C metabolic fluxes using stable isotope tracers to 
reveal metabolic pathway alterations by hypoxia in vitro and by tumour growth in vivo. 
 
We develop the 13C isotopomer distribution (CID) analysis to quantify 13C metabolic flux. 
This is achieved by following the evolution of some specific isotopomers for some pathways 
of interest. MCF7 breast cancer cells are analysed in hypoxia using an integrated approach, 
which uses gene expression, steady-state metabolite levels and 13C metabolic flux analysis. 
This approach enables us to pinpoint hypoxia-induced metabolic alterations. Our results 
indicate that the most significant alterations are an up-regulation of the pentose phosphate 
pathway (PPP) and a down-regulation of mitochondrial oxidative metabolism, which occurs 
via a lowering of the 13C flux through pyruvate dehydrogenase (PDH) pathway. The latter is 
partially compensated by carbon entry into the mitochondria, which increases flux through 
pyruvate carboxylase (PC). 13C metabolic labelling experiments are conducted using [1,2-
13C]glucose and [3-13C]glutamine as precursor nutrients to reveal the 13C carbons transitions 
in the PC inactivated systems. In MCF7 cells, the activation of PC is only found in hypoxia 
and the knockdown or inhibition of PC significantly reduces cancer cell growth through a 
pathway that requires aspartate, possibly as a precursor for pathways such as nucleotide 
synthesis. In addition, 13C glucose labelling strategy is applied to MMTV-PyMT breast 
cancer mice model by infusing the mice with [1,2-13C]glucose. The 13C glucose 
administration protocol is optimised in order to enable an investigation of 13C metabolic flux 
in tumour tissue. The goal of such investigation is to identify metabolic pathway differences 
between early and advanced stage of mammary gland tumours. Our initial findings suggest an 
increase of 13C fluxes through PPP and a decrease of 13C flux through glycolysis in the 
advanced stage of mammary gland tumours. 
 
In this thesis, we provide some examples of the application of NMR metabolomics. In doing 
so, we are able to investigate the metabolic alterations in hypoxia-induced cell lines as well as 
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1. General Introduction 
 
 
1.1 Breast cancer 
1.1.1 Breast cancer characteristics 
The breast consists of ducts, lobules and surrounding adipose tissue. The ducts and lobules 
are composed of two layers of epithelial cells. These are the luminal cells and 
basal/myoepithelial cells, which lies at the basement membranes (Clarke, Anderson et al. 
2004). Premalignant and invasive carcinomas in breast originate from the epithelial cells. 
During invasive carcinomas, it is thought that the neoplastic cells are invading through the 
basement membrane (Rivenbark and Coleman 2012). However, it has also been suggested 
that specific breast cancer stem cells may serve as the origin of cancer cells (Oliveira, Jeffrey 




Figure 1-1: The classical main subtypes of breast cancer including luminal A, luminal B, Her2-enriched, 
and basal like (adapted from (TheCancerGenomeAtlasNetwork 2012). 
 
Each year, there are more than 1,700,000 new breast cancer cases with approximately 
522,000 deaths worldwide (Ferlay J 2013). Despite the significant improvement in survival 
rates over the past two decades, the greatest obstacle in combating breast cancer is the 
complexity of the disease with heterogeneous groups of subtypes (Bertos and Park 2011). 
These groups exhibit variable molecular characteristics and result in disparate clinical 
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outcomes (Rivenbark, O’Connor et al. 2013). Historically, categorisation of breast tumours 
has been based on histological analysis and limited molecular sub-typing (for example: 
luminal, basal-like, HER2+), enabling short-term responses of patient to therapy. A better 
understanding of tumour characteristics, such as genetic changes and tumour 
microenvironment underlying this heterogeneous disease, is therefore essential to enable long 
term success of treatments (Polyak 2011).  
 
1.1.2 Breast cancer treatment 
 
The adjuvant and neo-adjuvant treatment options for breast cancer classically include 
radiotherapy, chemotherapy and targeted drug therapy. To guide treatment, the presence or 
absence of histopathological and molecular markers are assessed such as estrogen receptor 
(ER), progesterone receptor (PR), HER2 and the proliferation marker Ki67. The endocrine 
receptor (i.e. ER, HER2 and PR) positive group is the most common and diverse (Habashy, 
Powe et al. 2012). These tumours are commonly associated with low proliferation and better 
overall prognosis (Ross, Linette et al. 2003) with patients now receiving endocrine therapy in 
the form of tamoxifen or other anti-estrogen agents (Cole, Jones et al. 1971, Clarke, Liu et al. 
2003). The HER2 (also called ERBB2) amplified group is often linked to higher grade 
tumours (Ross, Linette et al. 2003, Fan, Oh et al. 2006). Recent advances in monoclonal 
antibody technologies have led to treatment of these tumours with anti-HER2 therapeutic 
antibodies (such as trastuzumab or lapatinib), which has been seen as a significant success 
story (Jahanzeb 2008, Slamon, Eiermann et al. 2011, Viale 2012). However, molecular-based 
targeted therapy and selective treatment for the basal-like subtype (also known as triple 
negative breast cancer, TNBC) remain challenging (Lehmann, Bauer et al. 2011, Rody, Karn 
et al. 2011). These tumours are known as TNBC as they do not express ER, PR and HER2. 
Chemotherapy is the therapeutic option for TNBC patients and unfortunately nearly 30% of 
these patients die within 5 years (Dent, Trudeau et al. 2007, Ovcaricek, Frkovic et al. 2011).  
 
1.1.3 Resistance to breast cancer treatment 
 
One of the challenges to finding a suitable, effective therapy for a patient is to overcome 
resistance against existing drugs. Resistance can exist as a pre-existing tumour phenotype, or 
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can be acquired over the course of a therapeutic regime (Gonzalez-Angulo, Morales-Vasquez 
et al. 2007). For example, some patients have been reported to lose HER2 amplification after 
HER2-targeted therapy, which could be attributed to factors such as the expression of a 
truncated HER2 receptor (Dawood, Resetkova et al. 2007, Scaltriti, Rojo et al. 2007). 
However, there are many other known downstream resistance mechanisms, including the loss 
of phosphatase and tensin homolog (PTEN) as the tumour suppressor gene, mutations in 
phosphatidylinositol 3-kinase/ protein kinase B (P13K/AKT) signalling pathway that prevent 
the inhibition of HER2 dependent P13K/AKT signalling (Berns, Horlings et al. 2007, Razis, 
Bobos et al. 2011) and activation of cyclin E thereby promoting cell proliferation 
independently of HER2 signalling (Scaltriti, Eichhorn et al. 2011). 
 
Despite advances in targeting the ER-positive patient group, many patients also present 
primary resistance or acquire resistance to endocrine therapy. Multiple mechanisms have 
been proposed for ER resistance. Among these, the remarkable complexity of the ER 
signalling (with crosstalk between itself and multiple growth factor signalling pathways) have 
been associated with both experimental and clinical endocrine therapy resistance (Schiff, 
Massarweh et al. 2003, Schiff, Massarweh et al. 2004, Heldring, Pike et al. 2007, Massarweh, 
Osborne et al. 2008, Shi, Dong et al. 2009). In addition to the transcriptional activity of ER 
which involves the translocation of ligand-bound ER to the nucleus and transactivation of its 
target genes, a proportion of the ER may also be localised in the cell membrane or cytoplasm 
and interact with a variety of signalling pathways (Knowlden, Hutcheson et al. 2003, Schiff 
and Osborne 2005). Therefore, these complex signalling networks (which include an 
elaborate interdependence and interaction with other growth factor signalling pathways) 
complicate the targeting strategy, limit the effectiveness of the therapy and may provide some 
of the reasons behind the varying results obtained via endocrine therapy (Knowlden, 
Hutcheson et al. 2003, Tsonis, Afratis et al. 2013).  
 
Among other factors causing development of resistance to treatment, inadequate 
vascularisation leading to regions of low oxygen (hypoxia) has increasingly been linked to 
development of resistance to many forms of anti-cancer therapy (refer to Section 1.4 for more 
details) (Harrison, Chadha et al. 2002, Sullivan, Paré et al. 2008, Lin, Chien et al. 2011, 




1.1.4 Refinement of breast cancer classification 
During recent years, genomics and/or transcriptomics data have been integrated to investigate 
factors that initiate the disease progression of breast cancer (Leary, Lin et al. 2008, Bignell, 
Greenman et al. 2010, Shah, Roth et al. 2012). Using large-scale gene expression and 
DNA/RNA copy number studies, the classification of breast cancers has been refined within 
the classical breast cancer subtypes (Curtis, Shah et al. 2012).  
 
Recent publications from the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) about high throughput studies of genetics and epigenetics of 
primary breast cancer cells further refined breast cancer into 10 clusters, each associated with 
distinct clinical outcomes and potential molecular drivers (Curtis, Shah et al. 2012, Dawson, 
Rueda et al. 2013). In this landmark study, the authors conducted both DNA and RNA 
sequencing on breast cancer to examine the genome copy number alterations (CNA) and its 
association with gene expression. By pairing the DNA–RNA profiles, the analysis 
demonstrated the heterogeneity present within tumours classified according to ER, PR and 
HER2 expression. The analysis also divided all of the previously identified intrinsic subtypes 
into separate groups. Some of these clusters were previously known subtypes such as the 
HER2-enriched group (cluster 5). In addition, the analysis revealed some novel breast cancer 
subgroups such as the high risk ER+ group (cluster 2) and the intermediate risk ER+ group 
(cluster 6) (Curtis, Shah et al. 2012).  
 
Another recent publication by The Cancer Genome Atlas established a comprehensive 
molecular profiling of breast cancers by integrating genomic, transcriptomic, DNA 
methylation and proteomic data (TheCancerGenomeAtlasNetwork 2012). From these 
experiments, they found that the commonly mutated genes in breast cancer such as TP53 
were prominently represented, but with varying frequencies among various breast cancer 
subtypes. Such findings highlight the difficulties in exploiting common tumour suppressor 
genes such as TP53 as a therapeutic target. 
 
Despite these comprehensive analyses, two major issues remain. The first is how these 
findings can be translated into treatments that target different tumour subtypes as a separate 
entity. The second is that breast tumours appear to be heterogeneous in the sense that more 
than one subtype may exist within a single cancer mass (Al-Hajj, Wicha et al. 2003, 
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Shipitsin, Campbell et al. 2007, Shah, Morin et al. 2009, Pece, Tosoni et al. 2010, Polyak 
2011, Cleary, Leonard et al. 2014). This latter issue suggests that a single agent targeted 
against an upstream signalling pathway may not be enough to adequately treat a tumour, and 
that a holistic approach that treats the overall phenotype of the cancer, rather than specific 
mutations, may be more appropriate. 
 
1.2 Overview of cellular metabolism  
Cells accomplish daily operation through cellular metabolism. Metabolism involves turning 
on or off biochemical reactions in response to the cell's immediate requirements and overall 
functions. Therefore, cellular metabolism involves complex sets of controlled metabolic 
pathways. Metabolic pathways involve building up and breaking down of cellular 
components and have to be regulated and balanced in response to changes in the cell's 
environment. These metabolic pathways can be simple linear sequences of a few reactions or 
they can be complex branched pathways such as the pentose phosphate pathway  (PPP) or 
can also be cyclic reactions such as the tricarboxylic acid (TCA) cycle. 
 
To achieve cell homeostasis, cells fine-tune metabolic reactions into various enzymatic-
controlled pathways. Overall, cellular metabolism can be classified into two major categories: 
anabolism and catabolism. Anabolism is the metabolic process by which energy is used to 
construct molecules such as nucleic acids and proteins. On the other hand, catabolism is the 
metabolic process by which the cells break down complex molecule to provide energy and 
components needed by anabolic reactions.  
 
Unlike normal cells, cancer cells thrive in hostile environments such as hypoxic and  acidosis 
conditions. The survival of cancer cells depends on the selection of cells that harbour 
modifications of both gene regulation that shifts the balance between cell cycle and apoptosis 
and metabolic alterations that displays metabolic plasticity to generate enough energy and 
continue to become viable. With regard to metabolism, cancer cells seem to preferentially use  
some metabolic pathways that can generate enough ATP and other macromolecules even 
under tumour microenvironment stresses such as nutrients depletions and hypoxic conditions 
that would be harmful to normal cell. As a result, cancer cells can be viable through a 
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selection of metabolic pathways and can display metabolic plasticity that is not normally 
possible or seen in normal cells.  
 
1.3 Rewiring of metabolism in cancer 
 
Despite the numerous genetic and epigenetic changes that are observed in tumours, the basic 
phenotype underpinning them all – regardless of whether a tumour is proliferative, invasive 
or resistant to therapy – is that all these phenotypes must be supported by a change in the 
metabolism of the tumour. The renaissance of interest in metabolism and bioenergetics in 
cancer has once again brought metabolic research in the cancer field to the fore. Almost a 
century ago, Otto Warburg discovered that the alteration of glucose metabolism is a 
fundamental phenotype of cancer (Warburg 1924, Warburg, Wind et al. 1926, Warburg 
1956). In this pioneering work he revealed that tumour cells have high preference for 
glycolysis, which they use to ferment glucose into lactate under normoxic conditions – a 
process known as aerobic glycolysis (Warburg, Wind et al. 1927).  
 
In numerous studies the metabolic properties in cancer have been shown to significantly 
differ from normal cells, a phenomenon described as metabolic transformation (Tennant, 
Durán et al. 2009). This phenomenon extends to almost all known metabolic pathways, 
including fatty acid synthesis, glutamine metabolism and mitochondrial oxidative 
phosphorylation (Formentini, Sánchez-Aragó et al. , Kondoh, Lleonart et al. 2005, Nieman, 
Kenny et al. 2011, Solaini, Sgarbi et al. 2011, LeBleu, O’Connell et al. 2014, Yang, Moss et 
al. 2014). It is now commonly accepted that the metabolic characteristics of a tumour can be 
considered as the readout of its phenotype (Jones and Thompson 2009, Dang 2012, Galluzzi, 
Kepp et al. 2013, Zhao, Butler et al. 2013). 
 
It is well known that oncogene activation alters cellular metabolic pathways both directly or 
indirectly (Hsu and Sabatini 2008, Kawauchi, Araki et al. 2008, Levine and Puzio-Kuter 
2010, Munoz-Pinedo, El Mjiyad et al. 2012, Li and Simon 2013). Interestingly, some tumour 
suppressor genes are primarily metabolic enzymes (e.g. succinate dehydrogenase subunits 
and fumarate hydratase). More generally, oncogenes and tumour suppressor genes can result 
in direct metabolic enzyme upregulation and activation of post-translational modifications. 
For instance these effectors can regulate protein kinase phosphorylation (e.g. AKT enhances 
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phosphofructokinase-2 (PFK2) enzyme activity by phosphorylating PFK2; (Novellasdemunt, 
Tato et al. 2013)) and increase activity through alteration of the sub-cellular localisation of 
metabolic enzymes (e.g. AKT increases translocation of glucose transporter 4 (GLUT4) to 
the cell membrane and translocation of hexokinase-2 to mitochondria) (Gottlob, Majewski et 
al. 2001, van Dam, Govers et al. 2005). However, the metabolic transformation induced by 
oncogene activation is often through indirect means – for example, through higher demand on 
anabolic metabolic pathways due to their increased proliferation (e.g. redirecting glucose 
metabolism intermediates into ribose synthesis downstream of both KRAS and MYC 
oncogenes) (Gordan, Thompson et al. 2007, Morrish, Isern et al. 2009, Ying, Kimmelman et 
al. 2012).  
 
Many signalling pathways known to be involved in cancer have been found to affect cellular 
metabolism, providing the tumour with a selective advantage for cell growth and 
proliferation. For instance, signalling through the PI3K/AKT/mTOR axis has been shown to 
affect metabolism through several mechanisms. As previously mentioned, AKT has been 
shown to upregulate cell surface expression of glucose transporters (Elstrom, Bauer et al. 
2004), and to stimulate the phosphorylation of hexokinase, thereby increasing the flux of 
glucose into glycolysis (Majewski, Nogueira et al. 2004). Signalling through the mechanistic 
target of rapamycin (mTOR) has also been shown to be a metabolic control hub through its 
regulation of a number of metabolic pathways such as glycolysis, pyrimidine synthesis and 
lipid synthesis (Porstmann, Santos et al. 2008, Shackelford, Vasquez et al. 2009, Duvel, 
Yecies et al. 2010, Peterson, Sengupta et al. 2011, Ben-Sahra, Howell et al. 2013).  
 
c-Myc associated signalling pathway is another well-known oncogenic signalling pathway 
that can regulate a number of aspects of cancer metabolism by activating key genes involved 
in mitochondrial biogenesis, glucose and glutamine metabolism (Dang and Semenza 1999, 
Jones and Thompson 2009). c-Myc induces the expression of enzymes involved in nucleotide 
synthesis such as inosine 5’-monophosphate dehydrogenase, serine hydroxymethyl 
transferase, adenosine kinase and adenylate kinase 2 (O'Connell, Cheung et al. 2003). c-Myc 
also regulates glycolysis through increasing the expression of GLUT1 and lactate 
dehydrogenase A (LDHA) (Osthus, Shim et al. 2000, O'Connell, Cheung et al. 2003). In 
addition to these effects on glucose metabolism, c-Myc amplification has been often 
associated with glutamine dependence in some tumour cells by upregulating the expression of 
glutamine transporters, upregulating glutaminase (GLS) (Wise, DeBerardinis et al. 2008, Le, 
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Lane et al. 2012) and inhibiting microRNA-23a/b that also results in increased expression of 
GLS (Gao, Tchernyshyov et al. 2009).  
 
The most frequently mutated gene in human tumours, TP53, also has close associations with 
metabolic alterations. Mutations in TP53 have been shown to increase glycolysis by 
promoting GLUT1 translocation (Zhang, Liu et al. 2013). TP53 regulates cancer metabolism 
via several other means. For instance, TP53 regulates the transcription of TIGAR (TP53-
induced glycolysis and apoptosis regulator; a fructose 2,6- bisphosphatase) leading to the 
inhibition of glycolysis (Bensaad, Tsuruta et al. 2006). Also, TP53 regulates synthesis of the 
protein SCO2, which is required for the correct assembly of the cytochome c oxidase (COX) 
complex in the electron transport chain, thereby directly regulating the ability of the cell to 
produce ATP through oxidative phosphorylation (Matoba, Kang et al. 2006). In addition, 
TP53 has also been reported to suppress biosynthesis through inactivating glucose 6 
phosphate dehydrogenase (G6PD) (Jiang, Du et al. 2011) or through enhancing hexokinase 2 
(HK2) mRNA by reducing miR143-mediated mRNA (Wang, Xiong et al. 2014). Despite 
strong evidences demonstrating alterations of metabolic enzymes by various oncogenic 
signalling pathways, the degree of alteration varies between different human tumours and the 
underlying molecular mechanisms behind these oncogene-induced alterations remains to be 
elucidated. 
 
In fact, the phenotype of a cancer is imparted by a combination of endogenous mutations, 
epigenetic alterations and microenvironmental influences (Elstrom, Bauer et al. 2004, Wise, 
DeBerardinis et al. 2008, Hanahan and Weinberg 2011, Haq, Shoag et al. 2013). For instance 
TP53 exhibits a number of different mutations that could affect its trans-activation activity 
(Hainaut and Hollstein 2000). Therefore, a drug may only be effective in cancer patients with 
a particular p53 mutant. p53 together with its transcription targets such as p21, MDM2 and 
insulin-like growth factor-binding protein 3 (IGFBP3) regulate cellular functions like the cell 
cycle, apoptosis, senescence and angiogenesis (Menendez, Inga et al. 2009). As a result, the 
option to target individual signalling pathways may not represent the most effective solution 
for the cancer treatment, as it is unlikely that a single signalling pathway underpins the whole 
phenotype of a particular cancer. This issue is likely to be further complicated by acquired 
therapy-evasion mechanisms whereby cancer treatment can change signalling pathway 
activity within a tumour. However, anti-metabolism therapies target the pathways required 
9 
 
for phenotype (such as proliferation), rather than upstream signalling processes, hence this 
approach may well avoid acquired evasion.  
 
In addition, to support or perhaps to acquire the hallmarks of cancer, as postulated by 
Hannahan and Weinberg (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011), 
tumour cells must alter their core metabolism to provide the required metabolites to satisfy 
increased demand (Lunt and Vander Heiden 2011, Cantor and Sabatini 2012). Alterations in 
metabolism in response to transformed intracellular signalling are important to fulfil the 
cellular need for energy, essential macromolecules and to maintain redox balance to support 
survival and the malignant progression of tumour cells in a dynamic and often hostile 
microenvironment. As a consequence of tumour progression, some regions of a tumour will 
gradually develop regions of low O2 (hypoxia), acidosis and increased reactive oxygen 
species (ROS) levels. Such a microenvironment naturally selects for phenotypes that have 
adapted to the tumour environment through resistance to these stress factors. 
 
1.4 Hypoxia and tumour metabolism 
 
Hypoxia is one of the most important environmental stress factors during tumourgenesis 
(Gatenby and Gillies 2008, Rankin and Giaccia 2008, Chang and Erler 2014). It  has been 
shown to be a key factor associated with malignant phenotypes such as acquired resistance to 
radiotherapy and chemotherapy, increased invasion and metastasis (Brizel, Sibley et al. 1997, 
Zhong, De Marzo et al. 1999, Harris 2002, Schnitzer, Schmid et al. 2006, Lara, Lloret et al. 
2009, Ghattass, Assah et al. 2013). During the growth of a tumour, the cells outgrow their 
nutrient supply, and hence must resolve the issue of supply and demand via various strategies 
such as angiogenesis, neovascularisation and metabolic transformation. A consequence of 
this growth is the development of regions that are hypoxic. Importantly, it is this hostile, 
dynamic and low oxygen microenvironment that favours malignancy and aggressive 
phenotypes. Given that a large functional group of genes regulated by hypoxia are associated 
with metabolic pathways affecting metabolism of glucose, lipids, amino acids and oxidative 
metabolism (Kuhajda, Jenner et al. 1994, Tennant, Durán et al. 2009, Santos and Schulze 
2012, Wallace 2012, Sun and Denko 2014), the association of hypoxia with metabolic 




1.4.1 Hypoxia inducible factors 
 
In an attempt to efficiently modulate cellular metabolism in a microenvironment when 
oxygen is limited, hypoxic tumour cells initiate a global transcription response, largely 
mediated through the stabilisation of Hypoxia Inducible Factors (HIFs). HIFs, as a 
heterodimeric transcription factor, consist in two subunits: an oxygen-labile α and a 
constitutively expressed β subunit (Wang, Jiang et al. 1995). HIFs comprise three members 
(HIF-1α, HIF-2α and HIF-3α), with HIF-1α and HIF-2α having been studied more 
thoroughly while HIF-3α has been considered as a negative regulator of HIF-1α (Semenza 
2010). HIF-1α and HIF-2α have differences in terms of tissue expression, although both of 
these two members of HIFs share some similarities in terms of their architectural and 
transcriptional activities (Kaelin and Ratcliffe 2008). However, HIF-1α is thought to trigger 
acute hypoxic response while HIF-2α is thought to be associated with chronic hypoxic 
response (Kaelin and Ratcliffe 2008). 
  
Under normal oxygen tension, HIFs are unstable and targeted for degradation. The 
degradation of HIFs' α subunits is mediated through the hydroxylation of conserved residues 
within the oxygen dependent degradation domain (ODD) (Srinivas, Zhang et al. 1999, 
Masson, Willam et al. 2001). The hydroxylation is carried out by three enzymes, prolyl-
hydroxylase domain 1-3 (PHD1-3) with PHD2 having the highest affinity for HIF-1α 
(Huang, Zhao et al. 2002, Berra, Benizri et al. 2003). This process uses molecular oxygen, α-
ketoglutarate (α-KG) and a prolyl residue as co-substrates and ascorbate and iron as co-
factors (Ratcliffe, O'Rourke et al. 1998). The hydroxylated form of HIFs are 
polyubiquitylated by the von-Hippel Lindau E2 ubiquitin ligase (pVHL), a tumour suppressor 
protein, which targets the protein for proteosomal degradation. In addition, further oxygen-
mediated control of HIF-1α lies within the activity of Factor Inhibiting HIF-1 (FIH-1). FIH-1 
hydroxylates an asparaginyl residue (N803 in humans) and reduces the transcriptional 
activity of HIFα by interfering with the binding of their co-activator (namely p300/CBP) 
(Lando, Peet et al. 2002). Under hypoxia there is inadequate oxygen for PHD activity 
resulting in HIFs stabilisation. HIFs are then free to bind the beta subunit and can translocate 
into the nucleus. Subsequently, the heterodimeric complex binds hypoxia response elements 
(HREs) (Wang, Jiang et al. 1995) to transactivate its target genes (Semenza 1998). For 
instance, HIF-1α upregulates a diverse transcriptional targets, ranging from energy 
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metabolism and cell proliferation to cell migration (Figure 1-2) (Semenza and Wang 1992, 
Liu, Cox et al. 1995, Schofield and Ratcliffe 2004). 
 
 
Figure 1-2: HIF-1α regulation in normoxia and hypoxia.  In normoxia, HIF-1α is hydroxylated (OH) 
within the oxygen dependent degradation domain. The hydroxylated form of HIF-1α is then targeted for 
ubiquitin (Ub) mediated protein degradation. In hypoxia, the HIF-1α is not targeted for protein 
degradation and can initiate a selection of biological processes including pH regulation, glycolysis 
pathway, mitochondrial metabolism, glucose transporters and angiogenesis.  
 
 
1.4.2 Metabolic alterations in response to HIF-1α 
Through the activation of HIFs, the adaptive response of cells leads to transcriptional control 
of genes involved in angiogenesis and pH regulation. HIF-1α and HIF-2α are tightly 
associated with angiogenesis by activation of genes including vascular endothelial growth 
factor (VEGF), the vascular endothelial growth factor receptor 1 (FLT1) and angiopoietin 1 
(Ang1) and Ang2 (Enholm, Paavonen et al. 1997, Oh, Takagi et al. 1999, Giordano and 
Johnson 2001, Jones, Fujiyama et al. 2001). Among them, VEGF has been shown to directly 
stimulate cell proliferation and formation of blood vessels through promoting endothelial 
cells into hypoxic and avascular areas (Forsythe, Jiang et al. 1996, Enholm, Paavonen et al. 
1997, Pugh and Ratcliffe 2003, Morfoisse, Kuchnio et al. 2014). Hypoxic cancer cells also 
upregulate the expression of carbonic anhydrase IX (CA9), a transmembrane protein that 
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prevents intracellular acidosis by hydrating CO2 to form H+ and HCO3- in the extracellular 
space (Wykoff, Beasley et al. 2000, Ivanov, Liao et al. 2001). As a consequence, CA9 
enables tumour cells to survive with the mild alkaline intracellular conditions they require to 
continue glycolytic activity while also promoting tumour growth through extracellular 
acidosis (Gillies, Martinez-Zaguilan et al. 1990, Martinez-Zaguilan, Seftor et al. 1996, 
Wykoff, Beasley et al. 2000). In a study analysing CA9 expression in breast cancer cohorts, 
CA9 was found to strongly correlate with HIF-1α expression as well as tumour size and grade 
(Brennan, Jirstrom et al. 2006). In a further study of 187 breast cancer patients, both CA9 and 
HIF-1α were associated with treatment resistance (Generali, Berruti et al. 2006). 
 
One of the largest functional groups of genes regulated by HIF-1α is associated with glucose 
metabolism (Figure 1-3) (Wenger 2002, Semenza 2003, Kim, Hahn et al. 2004). Under 
hypoxia, HIF-1α induces the expression of genes encoding for glucose transporters, 
glycolytic enzymes, lactate dehydrogenase A (LDHA) (Firth, Ebert et al. 1994, Ebert, Firth et 
al. 1995). For instance, HIF-1α increases glucose uptake through the induction of glucose 
transporters GLUT1 and GLUT3 (Ebert, Firth et al. 1995). Furthermore, the increase in 
glucose consumption in hypoxia also directly yields more glycolytic pathway intermediates 
that can serve as precursors for subsequent biosynthetic pathways (Figure 1-3). These 
include: (i) glucose-6-phosphate, which is utilised to make ribose-5-phosphate for nucleotide 
synthesis (Gao, Mejias et al. 2004, Jiang, Du et al. 2011), (ii) dihydroxyacetone phosphate as 
a precursor for triglycerides and phospholipid synthesis (Puleo, Ananda Rao et al. 1970), and 
(iii) pyruvate for acetyl-coA synthesis (Bauer, Hatzivassiliou et al. 2005). High rates of 
glycolysis provide an essential prerequisite for fine tuning the biosynthesis pathways 






Figure 1-3: Simplified scheme highlighting how HIF-1α promotes the expression of glycolytic enzymes. 
The upregulated glycolysis is a biosynthesis hub for generating intermediates that are involved in 
nucleotide synthesis, triglycerides, phospholipids and acetyl-Co in TCA cycle. The glycolytic enzymes that 
have been shown to be regulated by HIF-1α are highlighted in red boxes (Wenger 2002, Semenza 2003, 
Calvert, Cahill et al. 2006). Glycolysis is an energy-producing pathway, which breaks down glucose units 
into pyruvate. The first stage of glycolysis requires ATP and forms glyceraldehyde 3-phosphate (GA3P). 
This involves the phosphorylation of glucose to glucose 6-phosphate (G6P) carried out by hexokinase, 
transformation of G6P into fructose 6-phosphate (F6P) by glucose 6-phosphate isomerase (GPI), 
phosphorylation of F6P to fructose 1,6-bisphosphate (F16BP) by phosphofructokinase 1 (PFK1) (a tightly 
regulated process) and cleavage of F16BP into GA3P and dihydroxyacetone phosphate (DHAP) by 
aldolase (ALD) and tightly controlled by triose phosphate isomerase (TPI).  The second stage of glycolysis 
produces ATP, a process that requires glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to oxidise 
and phosphorylate GA3P into 1,3-bisphosphoglycerate (13BPG), subsequently followed by ATP-yielding 
steps to form pyruvate catalyzed by phosphoglycerate kinase (PGK), phosphoglycerate mutase (PGM), 
enolase (ENO) and pyruvate kinase (PK) and using 3-phosphoglycerate (3GP), 2-phosphoglycerate (2GP) 
and phosphoenolpyruvate (PEP) as substrates. Other abbreviations: GLUT1, glucose transporter 1; 
GLUT3, glucose transporter 3; LDH, lactate dehydrogenase; ALT, alanine transaminase. 
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In addition to significant modulation of cytosolic central carbon metabolism, hypoxic cells 
also alter mitochondrial carbon flux and respiration in a HIF-dependent manner. HIF-1α 
directly induces pyruvate dehydrogenase kinase 1 (PDK1), which inactivates pyruvate 
dehydrogenase (PDH) by phosphorylation thereby inhibiting the oxidative decarboxylation of 
pyruvate to form acetyl-coA (Kim, Tchernyshyov et al. 2006, Wigfield, Winter et al. 2008) 
(Figure 1-4). Through this inactivation, the TCA cycle and oxidative phosphorylation in 
mitochondria are affected while glycolysis remains highly active. In normoxia, the NADH 
produced during glycolysis in the cytosol is oxidised through activity of mitochondrial redox 
shuttles such as the malate-aspartate shuttle. Malate-aspartate shuttle reduces oxaloacetate 
(OAA) to malate by utilising cytosolic NADH before transporting malate into the 
mitochondrial matrix for the re-oxidation into OAA and the consequent production of NADH 
(Greenhouse and Lehninger 1976, Lopez-Alarcon and Eboli 1986). However, due to a 
lowering of the activity of these shuttles in hypoxia (Figure 1-3), the regeneration of NAD+ 
in hypoxia is achieved by other cytosolic pathways. The major route for this redress is via the 
reduction of pyruvate to lactate in the cytosol  (Semenza, Jiang et al. 1996) where NAD+ is 
generated from NADH via lactate dehydrogenase (LDH).  
 
Lipid metabolism is also significantly altered in hypoxia (Figure 1-5). Fatty acids are the 
major building blocks for triacylglycerides and can be obtained both from the diet and de 
novo fatty acid synthesis (i.e. the acetyl groups for fatty acid biosynthesis are supplied by 
citrate, which is produced by the TCA cycle). In several studies, tumour cells have 
demonstrated a higher tendency for generating fatty acids from de novo sources (Ookhtens, 
Kannan et al. 1984, Kuhajda, Pizer et al. 2000, Zhou, Han et al. 2007, Rysman, Brusselmans 
et al. 2010) while normal cells prefer to take in exogenous fatty acids. Both endogenous and 
exogenous lipid sources can result in the accumulation of lipid droplets in cells under hypoxia 
to potentially increase the biosynthesis of triglycerides or as a protective mechanism against 
reactive oxygen species in conditions of fluctuating oxygen tension (Bensaad, Favaro et al. 
2014). However, this is not a binary system, as some cancer cell types have been shown to 
utilise both de novo fatty acid synthesis and exogenous lipids for cell proliferation and 
survival (Nomura, Long et al. 2010, Kuemmerle, Rysman et al. 2011). The source of fatty 
acids in hypoxia has been demonstrated to be altered by utilising glutamine to produce α-KG, 
which is then converted to citrate by isocitrate dehydrogenase and aconitase (Metallo, 
Gameiro et al. 2011, Wise, Ward et al. 2011). By shunting away from glucose derived 
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pyruvate, the citrate pool is substituted by reductive glutamine metabolism as the source of 
acetyl-CoA for lipid synthesis.  
 
Figure 1-4: Hypoxia affects mitochondrial carbon flux in cancer cells. HIF-1α expression, via multiple 
target genes such as pyruvate dehydrogenase kinase 1, restricts the entrance of acetyl-CoA into the TCA 
cycle for oxidative phosphorylation, thereby protecting cancer cells against excessive reactive oxygen 
species. The incoming acetyl-CoA molecule enters TCA cycle and produces other TCA cycle metabolites 
(marked in green) (figure modified from Lehninger et al. 2008). For succinate, fumarate, malate and 
oxaloacetate, the contribution of the newly entered acetyl-CoA was not marked in green because of the 
symmetrisation that occurs at succinate dehydrogenase. Abbreviations: Ac-CoA, acetyl-CoA; α-KG, 




Figure 1-5: Hypoxia affects lipid and glutamine metabolism in cancer cells. To sustain TCA cycle and 
biosynthesis demands, fatty-acid synthesis and reductive carboxylation of glutamine can be activated in 
hypoxia. The enzymes involved in these pathways are shown in green. Reductive carboxylation of alpha-
KG by IDH1 is found in cancer. Reductive carboxylation and TCA cycle produces citrate. Citrate had 
been found to be used for lipid synthesis in hypoxic cells. Abbreviations: Ac-CoA, acetyl-CoA; α-KG, 
alpha-ketoglutarate; Succ-CoA, succinyl CoA; OAA, oxaloacetate; IDH1, isocitrate dehydrogenase 1; 




1.5 Metabolomic and metabolic flux investigations using NMR 
 
Rewiring of metabolism is an important hallmark of cellular transformation in which the 
transformed cells alter their cellular metabolism to meet the requirements for rapid cell 
proliferation and activation of invasion and metastasis (Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011). To understand these shifts in metabolism, metabolomic 
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investigations are used to enable better understanding of the cancer phenotype through 
correlating the disease phenotype to metabolite profiles. Recent innovations in 
instrumentation and bioinformatic tools have facilitated a more comprehensive and unbiased 
analysis of cellular metabolism. Despite the advancement in enabling technologies such as 
nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), many of the 
molecules detected are currently not included in databases and metabolites repositories, 
indicating that our ability to analyse cellular metabolism is incomplete (Bowen and Northen 
2010, Haug, Salek et al. 2013, Wishart, Jewison et al. 2013). What complicates the matter 
even more is the largely unknown dynamic exchange of metabolites between intracellular 
compartments (Zwingmann, Richter-Landsberg et al. 2001, Jorgensen, Rasmussen et al. 
2005, Agapakis, Boyle et al. 2012, Lewis, Parker et al. 2014). Thus, to achieve a better 
understanding of metabolic pathways that are involved in cancer metabolism and for 
providing new biological insights, a combination of metabolic flux profiling of nutrients 
entering the cell is required. This could be achieved by using isotopically labelled 
compounds, by sophisticated analytical methods such as NMR and MS to detect and identify 
metabolites as well as by novel computational approaches to assemble the data into a 
coherent cellular metabolic model.  
 
Metabolomic analysis using MS approaches detects ionised compounds according to their 
mass/charge (m/z) ratio, often following a chromatographic separation step. MS is a very 
sensitive technique and can detect a broad range of metabolites, which can be assigned with 
reference to internal or external standards (Dunn and Ellis 2005, Wilson, Plumb et al. 2005). 
Commonly, MS techniques are combined with a chromatography step: LC (liquid 
chromatography) or GC (gas chromatography). The GC-MS method is a well-established 
method that is commonly used for small molecule quantification but is often biased against 
non-volatile and high molecular weight molecules. This method requires derivatisation to 
create and ionise non-volatile compounds. The LC-MS is gradually becoming a popular 
method where the derivatisation step is not required. Continuous improvements in column 
chemistry by using ultra high pressure chromatographic systems enable to solve issues such 
as ionisation suppression due to matrix effects and complications with quantification when 





NMR spectroscopy is usually based on the magnetic resonance phenomena of spin-½ nuclei 
such as protons (1H), 31P or 13C. Under the influence of a constant magnetic field, the nuclear 
spins align in the magnetic field, creating two different energy states: one parallel and one 
anti-parallel with the magnetic field (Figure 1-6). When a radiofrequency (RF) pulse is 
applied (equal to the energy difference of the two levels), nuclei can absorb the energy and 
move to the higher energy spin state. Following the RF pulse, the spin systems resonate and a 
free induction decay (FID) can be detected. Different atoms have different electronic 
environments, which shield the spins against the main magnetic field. This effect causes 
different resonance frequencies for different nuclear spins in a different chemical 
environment. An NMR spectrum contains information such as chemical shifts and peak 
splitting (also known as spin-spin coupling where the resonance frequency is affected by 
nearby NMR-visible nuclei). This information can be used to identify individual molecules 
(Figure 1-7). Furthermore, the peak intensity is proportional to the number of protons 
contributing to the signal and therefore can be used to quantify the concentration of samples. 
This technique allows structure elucidation of molecules that can be used for identification 
purposes.   
 
NMR spectroscopy is a powerful tool for metabolomics studies. It has advantages over other 
methods such as the ability to provide specific atom positional information, the possibility to 
acquire multinuclear (e.g. 1H & 13C) and multidimensional (e.g. 2D 1H/13C) spectra, to study 
more than one type of nucleus simultaneously and the possibility for sample analysis with 
minimal or no initial separation. Despite recent innovations that have increased sensitivity, 
using NMR-based approaches to study metabolism suffers from limited sensitivity due to the 
small relative population differences of the energy levels. Another limitation is the lack of 
spectra resolution for nuclei in similar chemical environments such as the highly redundant 
methylene group in long fatty acid chains (as they are magnetically equivalent). Also, issues 
could arise from the paramagnetic substances such as the iron in deoxyhemoglobin in blood 
that could cause line broadening in the spectra (Finnie, Fullerton et al. 1986). For lipids, a 
complementary approach using MS is more useful than NMR to determine various CH2 chain 
lengths within a lipid molecule.  
 
One of the main motivations for employing NMR as the primary tool for investigations in 
cellular metabolism is that NMR offers non-destructive and rigorous structural analysis. 
Using various one-dimensional (1D) and two-dimensional (2D) NMR methods, combining 
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structural information from different but complementary experiments, it is feasible to identify 
previously unknown metabolites. This process is usually facilitated by integrating 
information from various NMR and MS methods. At the same time, NMR continues to 
improve its resolution and sensitivity. High field magnets (usually 600 to 800 MHz for 
metabolomic studies) equipped with cryoprobe platforms have been used to improve the 
signal to noise ratio in order to enhance the information content for metabolic studies. 
Moreover, miniature NMR probe coils such as a 1.7 mm probe which only requires 30 μL 
sample volume (Martin and Hadden 1999) have been used to improve sensitivity or to solve 
the issue of sample availability. In addition, automated NMR methods have been developed 
for high-throughput spectral acquisition and robotic sample handling for metabolomics 
analysis (Da Silva, Godejohann et al. 2013). Although ultra high field NMR (>1 GHz) will 
improve the sensitivity, the added sensitivity over a 600 MHz magnet does not create 
substantial sensitivity improvements for metabolomics studies. The relatively new benchtop 
NMR platform could also be a great addition in a clinical setting for the identification of 
some high abundance metabolites. In combination with the sensitivity from MS-based 
analysis, using both NMR and MS complementarily by integrating data from the two 








Figure 1-6: Nuclear spin and the splitting of energy levels in a magnetic field. When the nucleus is in a 
magnetic field (Bo), lower energy level (magnetic quantum number, ms = 1/2) and higher energy level (ms 
= -1/2) are aligned. By applying a RF pulse, it is possible to excite the nuclei at the lower energy level into 





Figure 1-7: 1H NMR spectrum of lactate showing its specific chemical shifts and spin-spin couplings 
(adapted from The Human Metabolome Database: http://www.hmdb.ca/). Each peak has a different 
chemical shift corresponding to different hydrogen chemical environments of this molecule. For lactate, 
the hydrogen atoms in the methyl group (at 1.32 ppm) (the presence the methyl group as a less 
electronegative group produce a shielded environment) resonate at a lower chemical shift, whereas the 
proton, which is attached to a carbon atom bound to a COOH group (the presence of the more 
electronegative group, COOH, produces a more deshielded environment) appears at 4.10 ppm. The peak 
splitting reflects the spin-spin coupling that is observed in a NMR spectrum. This can be explained by 
interactions between neighbouring nuclei following the 'n+1' rule. The peak at 1.32 ppm is split into a 
doublet because the methyl protons are coupled to a single-proton neighbour whereas the peak at 






1.5.1 1D NMR spectroscopy experiments 
One of the most common metabolomics experiments using NMR is 1D 1H NMR. 1H is the 
most sensitive nucleus due to its high gyromagnetic ratio and is ideal to observe, being 
present in most metabolites. Therefore, this experiment has emerged as the main tool for 
high-throughput profiling and fingerprinting of biofluids (Lindon, Nicholson et al. 2000). 
There are, however, several issues with the measurement of 1D 1H NMR. First of all, the 
non-selective proton pulse excites all the spins leading to a congested spectrum including the 
large solvent signal (usually H2O). This is a problem because the frequency range of 1H 
spectra is small (about 12 ppm) and large molecules such as lipid molecules generate broad 
signals that overlap with narrow signals of other metabolites containing protons with similar 
chemical shifts. 
 
The 1D NOESY (nuclear Overhauser effect spectroscopy) presaturation experiment is 
perhaps the most popular type of 1D 1H experiment (McKay 2011). The main advantage of 
the NOESY presaturation sequence (Figure 2-1) is its improved radiofrequency field 
homogeneity while achieving good water suppression. Moreover, common NMR 
spectrometers have optimised oversampling during digitisation to obtain an almost perfect 
spectrum baseline. This experiment yields an unedited spectrum with water suppression 
which requires little optimisation of water suppression pulses and hence permits a 
straightforward setup.  In the case of blood or serum samples, metabolites may be bound to 
lipoprotein particles, which can cause substantial line broadening due to slow tumbling of 
these large molecules. A way to deal with this problem is to edit the spectrum with a pulse 
sequence such as the Carr Purcell Meiboom and Gill (CPMG) train, which removes large line 
width components by a T2 filter. Through removing spectral components from large slowly 
tumbling macromolecules, the CPMG pulse sequence allows for the selective detection of 
resonances with longer T2 relaxation times and smaller line widths (Beckonert, Keun et al. 
2007, Soininen, Kangas et al. 2009, Graham, Ruiz-Aracama et al. 2012).  
 
1D experiments performed on samples that have been incubated with a metabolite containing 
one or more "stable isotopes" such as 13C can be very informative. A 1D 13C NMR spectrum 
with 1H broadband decoupling has the advantage of a larger chemical shift dispersion of 13C 
resonances compared to 1H, with less spectral overlap. However, the lower sensitivity for 13C 
(25% of 1H) and its low natural abundance (1%) limits its use for unlabelled compounds. 
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Although the effect of an adjacent 13C nucleus can be observed as a spin coupling in a 1D 1H 
experiment giving rise to the 13C satellite signals, this is often obscured by other larger 
signals in the 1H spectrum which already suffer from significant signal overlap. This problem 
can be overcome by the use of two-dimensional spectra in which a second dimension can be 
used.  
1.5.2 2D NMR spectroscopy experiments 
The low chemical shift dispersion of 1D 1H spectra results in extensive signal overlap in 
spectra of mixtures of many different compounds. This problem can be overcome by 
chromatographic separation techniques but most of those have the disadvantage of diluting 
samples considerably. 2D NMR methods can be used to overcome some overlap in spectra.  
J-resolved experiments for instance reduce overlap in a 1D 1H experiment by removing the 
scalar coupling between protons in the directly observed dimension but retain the coupling 
information in the second dimension (Ludwig and Viant 2010). Such an implementation 
retains the 1H sensitivity and improves the confidence in metabolite identification by 
removing scalar spin couplings from NMR signals.  
 
COSY (correlation spectroscopy) and TOCSY (total correlation spectroscopy) provide scalar 
information and connectivity information to resolve structural information, thereby aiding 
metabolite identification. The COSY experiment shows scalar coupling between adjacent 
coupled nuclei while the TOCSY experiment displays the covalent network of individual 
molecule (i.e. how different protons are linked within the same spin system). Other than for 
the structural analysis of unlabelled metabolites, the TOCSY experiment has been employed 
for isotopomer determination (Lane and Fan 2007). For instance, if 13C-containing molecules 
are incorporated, satellite peaks appear as distinct cross peaks in a TOCSY spectrum (Figure 
1-8). Using this type of 2D homonuclear experiment, a wide variety of metabolites can be 
identified by logical pattern recognition (Lane and Fan 2007, Fan and Lane 2008). However, 
due to the severe overlap of proton resonances in the region of 3 to 5 ppm, 2D heteronuclear 
experiments would be suitable to resolved metabolites in this region. 
 
There are several 2D heteronuclear experiments available to assist the investigation of cell 
metabolism. The choice of heteronuclear experiments include HSQC (heteronuclear single 
quantum coherence) spectroscopy, HMQC (heteronuclear multiple quantum coherence) 
spectroscopy and HMBC (heteronuclear multiple bond) spectroscopy, in which the 
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correlation of 1H to 13C resonances via scalar coupling is employed. Often HSQC is the 
preferred experiment for small molecules and direct 1J coupling detection as it allows the 
identification of 13C-13C couplings together with isotopomers when a large number of 
increments in the indirect dimension (≥ 2048 increments) is acquired. In order to reduce off-
resonance effects in the 13C-dimension and thus to enable quantification (Lewis, Schommer 
et al. 2007) it is necessary to use adiabatic 13C pulses which are different from the 'ordinary' 
amplitude modulated rectangular RF pulse (Koskela, Heikkila et al. 2010, Vander Heiden, 
Locasale et al. 2010).  
 
Additional resolution can be gained by combining multiple approaches in higher dimensional 
spectra, including HSQC and TOCSY experiments to produce TOCSY-HSQC or HCCH-
TOCSY. In the case of the TOCSY-HSQC a TOCSY is carried out over a chain of connected 
protons. Subsequently magnetisation is transferred to 13C-attached protons via the HSQC 
step. In the case of the HCCH-TOCSY the TOCSY transfer is carried out via 13C rather than 
1H nuclei. This requires a reasonably high level of 13C labelling as these heteronuclear 
experiments essentially initiate from the proton to 13C and transfer back to proton. Such 
proton to 13C magnetisation transfer gain sensitivity indirectly and at the same time filter the 
spectrum by selecting those molecules that contain 13C atoms which are scalar coupled to the 
proton. However, such multi-dimensional experiments require excessively long measurement 
periods and are not suitable for metabolomics analyses where a large number of samples are 
being measured. 
 
A way to shorten the measurement time is to use a pseudo 3D experiment such as the TILT 
(Time domain Increments Linked Together) TOCSY-HSQC and TILT HCCH-TOCSY 
experiment. Similar to 3D TOCSY-HSQC and 3D HCCH-TOCSY, these pseudo 3D 
experiments encode TOCSY signals from adjacent protons or 13C nuclei, respectively. The 
TILT approach applies an incrementation scheme which increments 1H and 13C 
simultaneously by a tilt angle α. The resulting  TILT spectrum can be deconvoluted 
computationally (Kupce and Freeman 2005) to resolve signals in complex metabolite 





Figure 1-8: Cross peak patterns arising from different 13C isotopomers in TOCSY spectra. The open 
circles symbolise proton attached to 12C and filled circles symbolise the satellite peak due to proton 
attached to 13C. The 13C labelling fraction at each position can be determined from the ratio of peak areas 
of the satellite peaks to the total peak areas (figure modified from Lane and Fan 2007). 
 
1.6 Stable isotope labelling investigation 
 
Stable isotope tracers have been used in mammalian models since the 1930s. Early studies by 
Schoenheimer and Rittenberg, that investigated amino acid metabolism in mice using 
deuterated amino acids, demonstrated the relevance of stable isotopes for biological and 
clinical research (Schoenheimer and Rittenberg 1935). Nowadays, tracer methods are applied 
in many scientific disciplines, including medicine, physiology, nutrition, toxicology, 
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chemistry, agriculture, and geosciences. The widespread use of tracer methods can be 
attributed in some part to the improved availability of stable isotopes since the 1970s and 
advances in detection methods by MS or NMR. Stable isotope tracers have a significant 
advantage over other unstable isotopes as they are not radioactive and mainly have negligible 
biological side effects (Jones PJ 1991). However, it is important to consider the isotope effect 
when designing a stable isotope experiment. For instance deuterium, which has twice the 
mass of hydrogen could cause a reduction in the kinetics of some enzymatic reactions (Cook, 
Yoon et al. 1993) whereas 13C is less disruptive in this case, due to the small relative mass 
increase of 1 part in 12 (Koletzko, Demmelmair et al. 1998). 
 
Stable isotopes have been used in metabolomic studies to investigate metabolic pathways by 
analysing the fate of a metabolic precursor (such as glucose) and quantitatively to determine 
metabolic fluxes arising from the metabolite (Gruetter, Novotny et al. 1994, Wiechert 2001, 
Sauer 2006). Commonly, 13C-labelled precursors such as [U-13C]glucose (glucose with all 6 
carbons are 13C labelled) are added to in vitro cell systems. Subsequently the cell content and 
the medium can be analysed using either NMR or MS. Using a method such as NMR as a 
detection technique, 13C incorporation into downstream metabolites can be quantified and 
reveals transformation of the 13C label into different members of various metabolic pathways. 
 
Stable isotope labelling studies can therefore be used to trace the use of nutrients through 
pathways, and not only provide information about the flux through the pathway, but allow 
more in-depth analyses of other branching pathways. An example of this can be shown for 
the metabolism of glucose. When cells are incubated with [1,2-13C]glucose, it is taken up and 
converted sequentially into [1,2-13C]glucose-6-phosphate (G6P), [1,2-13C]fructose-6-
phosphate (F6P) and then [1,2-13C]fructose-1,6-bisphosphate (F16BP) (Figure 1-9 and Figure 
1-10). After splitting into two 3-carbon units, carbons 1 and 6 of F16BP are converted to 
carbon 3 of glyceraldehyde-3-phosphate (GA3P), producing a population of GA3P of which 
50% is labelled in the carbon 2 and 3 positions. Labelling in positions 2 and 3 of GA3P 
results in labelled in [2,3-13C]pyruvate and eventually [2,3-13C]lactate. The end points of 
glycolysis can also be followed from other pathways branching from glycolysis, such as 





Using [1,2-13C]glucose, one can also distinguish between the carbon that travels directly 
through glycolysis, as described above, and the molecules of G6P that are diverted through 
the oxidative PPP for the production of reducing equivalents, before re-entering glycolysis as 
F6P and GA3P (Figure 1-9 and Figure 1-11). Using [1,2-13C]glucose, this route can be traced 
as [1,2-13C]G6P oxidatively metabolised via the oxidative arm of the pentose phosphate 
pathway (PPP) forms [1-13C]ribulose 5-phosphate. The  [1-13C]ribulose 5-phosphate can 
either be used for nucleotide synthesis, or returned to the glycolytic pathway through the non-
oxidative PPP. If all molecules are returned to glycolysis, for every three molecules of [1,2-
13C]glucose used, one molecule of [1-13C]fructose-6-phosphate, one molecule of [1,3-
13C]fructose-6-phosphate as well as one unlabelled GA3P can be produced. Therefore, 
subsequent glycolytic activity (using one [1-13C]fructose-6-phosphate, one [1,3-13C]fructose-
6-phosphate and one unlabelled GA3P)  leads to the formation of five molecules of pyruvate, 
i.e., three unlabelled pyruvate, one [3-13C] and one [1,3-13C] labelled. These pyruvate 
molecules can be converted to lactate exhibiting the same labelling pattern (three unlabelled 
lactate, one [3-13C]lactate and one [1,3-13C]lactate) as described in Figure 1-9 and Figure 
1-11. The relative abundance of [2,3-13C]lactate compared with [1,3-13C] and [3-13C]lactate 
in the total lactate population is therefore a readout of the relative rates of glycolysis and PPP.  
 
The pyruvate from labelled [1,2-13C]glucose can also enter the tricarboxylic acid (TCA) cycle 
through one of two pathways: either by oxidative decarboxylation by PDH to produce acetyl-
CoA, or by carboxylation via pyruvate carboxylase (PC) to produce oxaloacetate. Figure 1-12 
shows the transition of label from [2,3-13C]pyruvate into the TCA cycle.  If [1,2-13C]glucose 
is metabolised via PDH, [2,3-13C]pyruvate forms [1,2-13C]acetyl-CoA (Ac-CoA). Upon 
condensation of labelled acetyl-CoA with unlabelled oxaloacetate, [1,2-13C]citrate is formed 
as citrate is a chiral molecule (Klinman and Rose 1971). Citrate is converted via several steps 
to α-ketoglutarate, which can be converted to [4,5-13C]glutamate. The 13C labelling of the 
TCA cycle is complicated by the presence of two symmetrical molecules, fumarate and 
succinate. Any metabolites formed from an asymmetrically labelled succinate that flux 
through succinate dehydrogenase (SDH), will become symmetrically labelled due to the 
symmetrical fumarate. Therefore [4,5-13C]α-ketoglutarate, becomes 50% [1,2-13C]succinate 
and 50% [3,4-13C]succinate, which is eventually oxidised to produce 50:50 ratios of the 
asymmetric molecules malate and oxaloacetate. These different forms are visible using NMR 
experiments, but not through normal MS-based methods. This becomes important when 
investigating the use of PDH and PC: if [2,3-13C]pyruvate enters the TCA cycle via PC, upon 
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condensation with CO2, [2,3-13C]oxaloacetate is formed. The labelled oxaloacetate can then 
either be condensed with acetyl-CoA to produce [2,3-13C]glutamate, or can be directly 
transaminated to give [2,3-13C]aspartate. Hence, the flux though PDH can be probed by 
studying the time evolution of [4,5-13C]glutamate formation while the flux through PC can be 






Figure 1-9: General overview of labelling patterns from [1,2-13C]glucose resulting from the pentose 
phosphate pathway (PPP) and glycolysis activity (Boros, Serkova et al. 2004). When cells were fed with 
[1,2-13C]glucose, [2,3-13C]lactate can be produced from glycolysis while [1,3-13C]lactate and [3-13C]lactate 
can be produced from PPP. A more detailed representation of 13C carbon flow from [1,2-13C]glucose 
through glycolysis is shown in Figure 1-10 and through PPP is shown in Figure 1-11. The circles 
symbolise the carbon backbone of the molecules. Black circles mark the position of 13C label. The 
numbering next to the carbon backbone symbolised the numbering position of ... (continued on next page)  
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13C carbons. The blue colour path symbolised the PPP and the green colour path symbolised glycolysis. 
The enzymes involved in PPP are shown in red boxes. Other abbreviations: glucose 6-phosphate 
dehydrogenase, G6PD; 6-phosphogluconate dehydrogenase, 6PGD; ribulose 5-phosphate isomerase, Rpi; 






Figure 1-10: Detailed carbon flow from [1,2-13C]glucose through glycolysis. From [1,2-13C]glucose, 
metabolites in glycolysis can be labelled. The formation of [2,3-13C]lactate can be used as a readout of 
glycolysis. Orange fill indicates 13C atoms labelled. The carbon numbering follows the international union 
of pure and applied chemistry (IUPAC) nomenclature (figure modified from Lehninger et al. 2008) 




Figure 1-11: Detailed carbon flow from [1,2-13C]glucose through pentose phosphate pathway (PPP). From 
[1,2-13C]glucose, metabolites in PPP can be labelled. [1,3-13C]glyceraldehyde 3-phosphate and [3-
13C]glyceraldehyde 3-phosphate can be formed when [1,2-13C]glucose flow through PPP and these 
glyceraldehyde 3-phosphate can be used in glycolysis to produce     ...(continued on next page)              
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[1,3-13C]lactate and [3-13C]lactate. Orange fill circles indicate 13C atoms labelled. Green squares mark the 
[1-13C]ribose 5-phosphate and the [1-13C]xylulose 5-phosphate that are subsequently entering the non-
oxidative arm of PPP. Red fill squares mark the 13C labelled glyceraldehyde 3-phosphate that 
subsequently enter the glycolysis. The enzymes involved in PPP are marked in green. The carbon 
numbering follows the international union of pure and applied chemistry (IUPAC) nomenclature. Other 
abbreviations: glucose 6-phosphate dehydrogenase, G6PD; 6-phosphogluconate dehydrogenase, 6PGD; 
ribulose 5-phosphate isomerase, Rpi; ribulose 5-phosphate 3-epimerase, RPE; transketolase, TKT; 





Figure 1-12: 13C labelling patterns of TCA cycle metabolites from incubation with [1,2-13C]glucose. The 
carbon atom transitions from [2,3-13C]pyruvate into the TCA cycle via the PC and PDH pathways are 
considered. When [2,3-13C]pyruvate (pink fill circles) enters the TCA cycle via PC, upon condensation 
with CO2, [2,3-13C]oxaloacetate is formed and [2,3-13C]glutamate (red fill square) can be used as a 
readout of PC pathway (purple fill circles). When [2,3-13C]pyruvate (orange fill circles) enters the TCA 
cycle via PDH, [2,3-13C]pyruvate forms [1,2-13C]citrate and then produced [4,5-13C]glutamate (green fill 
square). [4,5-13C]glutamate can be used as a readout of PDH pathway. Orange fill circles indicate that 
atoms can be 13C labelled via PDH and purple fill circles represent those positions that can be 13C labelled 
via PC. The incoming acetyl-CoA enters TCA cycle and produces other TCA cycle metabolites (marked 
in green). For succinate, fumarate, malate and oxaloacetate, the newly entered acetyl-CoA was not 
marked in green because of the symmetrisation that occurs at succinate dehydrogenase. The carbon 
numbering follows the international union of pure and applied chemistry (IUPAC) nomenclature (figure 
modified from Lehninger et al. 2008). Abbreviations: Ac-CoA, acetyl-CoA; α-KG, alpha-ketoglutarate; 
Succ-CoA, succinyl CoA and OAA, oxaloacetate. 
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1.6.1 Metabolic flux analysis 
Metabolic flux analysis (MFA) is a way to calculate the rate of turnover of molecules through 
a metabolic pathway and often 13C tracers are used (13C-MFA) to determine the 13C 
metabolomic flux. By following the rate of change of characteristic labelling patterns of 
stable isotope-labelled metabolites over time though metabolic pathways, 13C metabolic 
fluxes can be inferred. Classically, there are few prerequisites for determining metabolic 
fluxes: a model of the metabolic network, a set of system balance equations given by rates of 
substrate uptake or secretion, and the isotope labelling pattern of metabolic intermediates or 
endpoints (Nielsen 2003, Zamboni, Fendt et al. 2009). By integrating information from (i) 
isotopomer distributions in intracellular and extracellular stable isotope-labelled metabolites, 
cellular growth rates, (ii) biomass composition, (iii) extracellular uptake and (iv) secretion 
rates into the predefined network, MFA can be computed. This is achieved using 
computational frameworks such as OpenFLUX (Wiechert, Mollney et al. 2001, Quek, 
Wittmann et al. 2009), 13CFLUX2 (Weitzel, Noh et al. 2013), Isodyn (Selivanov, Puigjaner 
et al. 2004, Selivanov, Marin et al. 2006) and METRAN (Antoniewicz, Kelleher et al. 2007, 
Antoniewicz 2013). 
 
The majority of published MFA studies have been classically applied to microbial or yeast 
systems which are cultured in minimal media containing few nutrients using a closely defined 
system in a bioreactor. Such an approach minimises the complexity involved in 
reconstructing the metabolic network. For mammalian cells it is more challenging to establish 
growth conditions with sufficient rigour to allow for a quantitative computational MFA. This 
is because the growth medium is more complex (usually containing serum), as it is a mixture 
of amino acids and other small molecules that mammalian cells cannot synthesise. Most 
studies in mammalian systems have adopted the stationary 13C MFA method in which a 
metabolic steady-state is assumed and a restricted experimental condition is applied. By 
assuming an isotopic steady-state, alternative pathways converge to a common downstream 
metabolite and its unique isotopomer pattern is resolved from various combinations of 
reaction branch points (Wittmann 2007). However, it is not necessarily true that the 
conditions to reach the steady-state exist in tissue culture conditions for mammalian cells. 
This could be due to a number of factors, for instance, cultures being maintained in growth 
medium that is supplemented by non-refined serum which does not allow the input to be 
accurately defined, and the time required to reach isotopic steady-state might be excessively 
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long (for example it could take days to reach the isotopic steady-state for nucleotide synthesis 
pathways).  
 
More recently, non-stationary 13C-MFA methods have been developed to follow the 
dynamics of 13C propagation over time in the mammalian system (Selivanov, Vizan et al. 
2010, Possemato, Marks et al. 2011). In this type of analysis, there is no requirement to reach 
an isotopic steady-state but it is possible to effectively probe the dynamically changing 
fluxes. However, this method is confined to smaller metabolic networks than those based 
around steady-state assumptions and the computational analyses are more demanding because 
this type of analysis requires multiple sampling times, metabolite pool-size data, and relies on 
the solution of numerous coupled differential equations. Consequently, these approaches are 
less easily applicable for large-scale studies which involve numerous pathways for multiple 
species/strains. Each individual approach has its advantages and limitations, and combining 
multiple approaches should yield a more robust method. 
 
 
1.6.2 13C isotopomer analysis 
A vital component for 13C-MFA is to detect the isotopomer distribution pattern that emerges 
in the downstream metabolites arising from different metabolic reactions. After labelling with 
a 13C precursor, the 13C label distributes into metabolic intermediates and could give rise to 
various isotopomers. This labelling readout from 13C-labelled metabolic intermediates is 
dictated by the metabolic pathways that the labelled precursors have been metabolised 
through, examples of which are shown in Figure 1-9, Figure 1-10, Figure 1-11 and Figure 
1-12.  
 
The isotopomers give rise to specific NMR multiplets arising from specific 13C-13C spin 
couplings. These couplings can be measured using 13C- 1D spectra or 13C-HSQC spectra. For 
example, lactate which has 3 carbon, has 23 possible isotopomers (i.e. 12C1-12C2-12C3, 13C1-
12C2-12C3, 12C1-13C2-12C3, 12C1-12C2-13C3, 13C1-13C2-12C3, 13C1-12C2-13C3, 12C1-13C2-13C3, 
13C1-13C2-13C3). When a 13C-13C pair is present the covalent bond will lead to a doublet with 
a coupling constant the size of which depends on the individual chemical functional group. 
For instance, carbon 2 of [1,2,3-13C] glutamate produces a doublet of doublets because J12 of 
the C2 is influenced by the COOH group which is about 53 Hz and J23 of C2 is influenced by 
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the CH3 group which is about 34 Hz. Thus, the 13C-13C spin coupling can be used to help 
distinguish the different groups of isotopomers (Figure 1-13).  
 
13C NMR isotopomer analysis have been applied in multiple research studies to understand  
metabolic pathway alterations (Cohen, Ogawa et al. 1979, Malloy, Sherry et al. 1988, 
Gruetter, Novotny et al. 1994, Lane and Fan 2007, Jiang, Du et al. 2011). Isotopomers 
distributions are useful to decode metabolic pathway changes not only because they "record" 
13C flows through metabolic pathways but also because they are sensitive to the relative 
concentration of various isotopomer species as showed in Figure 1-14 for 13C-HSQC 
spectrum acquired at 16K or 4K data points at the indirect dimension. Hence, isotopomer 
analysis is also being used to determine the relative metabolic flux by quantifying the relative 
concentration of isotopomers groups (Sherry, Malloy et al. 1992, Cheng, Sudderth et al. 
2011). For instance, the isotopomer analysis of C4 glutamate has been used to infer the flux 
through PDH in the TCA cycle as the multiplet structure of C4 glutamate can provide the 
information about the fraction of labelled acetyl-CoA that entered the TCA cycle as 
illustrated in Figure 3-10 to Figure 3-15 (Sherry, Malloy et al. 1992, Cheng, Sudderth et al. 
2011). 
 
Some quantitative information arising from individual multiplets can be identified using a 1D 
directly observed 13C spectrum. 1D 13C spectra are often used to extract the isotopomer 
distributions due to the simplicity of the experiment. However, its low sensitivity limits the 
number of metabolites that can be quantified and large sample sizes are required. 
Alternatively, the 1D 13C slices from a 1D HSQC spectrum can be used. The advantage of 
acquiring HSQC spectra is their considerably higher sensitivity. However, quaternary 13C 
nuclei are not observed. Additional isotopomer information can arise from 13C satellite peaks 
in 1D 1H spectra, from 13C slices in 2D 13C-HSQC spectra (if those were acquired with 
sufficient resolution in the indirect dimension) or from satellite peaks in a 2D TOCSY spectra 
(Zwingmann, Chatauret et al. 2003, Lloyd, Zeng et al. 2004, Lane and Fan 2007, Mashimo, 
Pichumani et al. 2014). Alternatively, observing the 13C satellite peaks  arising from the 1J1H-
13C coupling in a normal 1D 1H spectrum allows us to determine 13C labelling information for 
protons with  attached to 13C. However, the satellite peaks might not be accurately quantified 




2D NMR spectra such as TOCSY and 13C-HSQC offer alternate solutions for 13C isotopomer 
analysis. When a metabolite contains the 13C moiety, satellite cross peaks appear on a 2D 
TOCSY spectrum. The different combinations of isotopomers produce various cross peak 
patterns in a TOCSY spectrum as shown in Figure 1-8. However, in the crowded regions (e.g. 
3 to 4 ppm in the proton dimension) signals cannot be resolved for typical metabolite 
mixtures even though the TOCSY experiment provides cross peaks across its entire spin 
system. The 2D 13C-HSQC has considerably good sensitivity due to its proton to 13C 
magnetization transfer. Therefore, this experiment can also be used for isotopomer analysis 
by selecting specific 1D projections from the 13C dimension of 2D HSQC spectra. Again, 
using the HSQC spectrum limits the analysis to protons bound to the 13C moiety and a high 
number of increments (4096 - 16384) in the 13C dimension are required for 13C isotopomer 
analysis, leading to prolonged acquisition times.   
 
Overall NMR 13C isotopomer analysis benefits from site-specific information and is highly 
selective to measure isotopomer distribution. Moreover, when a non-labelled internal 
standard is added (normally non-labelled metabolites are easily found in cell extracts after the 
peak assignment has been made), the natural abundance of 13C (1.1%) of non-labelled 
metabolites readily serves as internal standard. Having these internal standards as self-
consistent checkpoints help to improve the reproducibility of quantification. However, 
sufficiently high 13C labelling (at least 2% enrichment compared to the natural abundance of 








Figure 1-13: 13C slices of a 13C-HSQC spectrum of MCF7 cells exposed to [1,2-13C]glucose. The projection 
of the 13C slices of glutamate C2 show multiplets that consist of various isotopomers. These are the [2-
13C]glutamate (a singlet), [1,2-13C]glutamate (a doublet with coupling constant of 52.5 Hz), [2,3-
13C]glutamate (a doublet with coupling constant of 34.0 Hz) and [1,2,3-13C]glutamate (a doublet of 
doublets with coupling constants of 52.5 Hz and 34.0 Hz). 13C-HSQC spectra was acquired with 16384 






Figure 1-14: Comparison of 13C slices of two 13C-HSQC spectra with different isotopomer distributions 
acquired at 16K (A) and 4K (B) data points at the indirect dimension. Overlays of 13C slices of lactate C3 
region that consists of [3-13C]lactate (singlet) and [2,3-13C]lactate (doublet) are sensitive to differences in 
the isotopomer distribution. The blue spectrum has a lower amount of [3-13C]lactate than the red 
spectrum. (A) Spectra of 13C-HSQC spectra acquired with 16384 increments in the indirect dimension. 
(B) Spectra of 13C-HSQC spectra acquired with 4098 increments in the indirect dimension.  
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1.7 Tracer studies for in vivo models 
 
Studies in standard cell cultures can be carried out under well-defined and controlled 
experimental conditions. Use of such two-dimensional models have generated important 
fundamental understandings of mammalian metabolic pathways. At the same time, cell 
culture conditions, by their very nature, result in cells being selected for growth in these 
conditions, and therefore are highly unlikely to represent the true in vivo phenotype (Hausser 
and Brenner 2005, Lee, Kotliarova et al. 2006). For instance, as demonstrated by Cukierman 
et al., primary cells maintained in cultures can differ considerably in their morphology and 
cell-matrix integration from their parental origin and thus lack the ability to represent 
microenvironment influences on cellular metabolism (Cukierman, Pankov et al. 2001).  
 
Tracer studies have been implemented in humans giving direct insight into our metabolism 
(Schoenheimer and Rittenberg 1935, Mason, Petersen et al. 2007, Fan, Lane et al. 2009).  
However, their utilisation is challenging due to the cost of isotopically labelled molecules and 
the complex regulatory ethics for clinical trials or medical diagnostic procedures on human 
subjects. Moreover, studies on human subjects often suffer from considerable experimental 
variability due to confounding factors such as lifestyle, adding complexity to both the 
experimental design and validity of the results (Schellekens, Stellaard et al. 2011). Animal 
models are therefore an appreciable solution to translate metabolic functions from model cell 
systems into mammalian metabolism especially for preclinical drug response testing.  
 
1.7.1 Aspects to consider for implementing tracer studies for in vivo models 
Conducting stable isotope tracer analysis in mammalian living subjects whether in humans or 
mice, is a relatively new emerging research area compared to the much more established in-
vitro cell line method. Animal models present a useful compromise between cell culture and 
human studies by mimicking some of the genetic modifications observed in various diseases, 
as well as the complex interactions between tissues and within the tissue microenvironment. 
However, one needs to consider factors such as routes of tracer induction, duration of 
labelling and whether to introduce anaesthesia when implementing the in vivo labelling 




One of the most frequently used methods for introducing stable isotope precursors is 
sustained (for up to several days) infusion of nutrients containing labelled material (Alonso, 
Yokoe et al. 2007). This method has been applied in diabetes research where mice were 
induced with mild sustained hyperglycaemia and hyperinsulinemia to assess the loss of 
functional of β-cells (Bandsma, Grefhorst et al. 2004, Alonso, Yokoe et al. 2007). In cancer 
metabolomic studies, the perturbation of glucose homeostasis in response to insulin 
sensitivity is unfavourable and a modified protocol is necessary. However, finding a means to 
use comparable and sufficiently high concentrations of 13C precursors to the target organ in 
different models is required. Hence, quite often continuous infusion under anaesthesia has to 
be used for achieving the isotopic steady-state of the 13C precursor even though there are 
concerns over the potential metabolic changes arising from use of the anaesthetic agent 
(Brown, Umino et al. 2005, Tanaka, Kawano et al. 2009).  
 
Previous 13C labelling studies using in vivo mice models were centred on stationary 13C MFA 
methods in which an isotopic steady-state is assumed. This procedure restricts the 
experimental setup, as the labelled nutrient has to be infused into the animal over a prolonged 
period in order to reach a steady-state. In most cases, this requires the animal to be under 
anaesthesia for a significantly long time (>1 hour), which may itself alter the animal 
physiology. Moreover, the conditions to reach the steady-state are likely to vary with the 
animal strain, and therefore will need to be optimised for each model used. 
  
Fan et al. reported a metabolomic study of lung cancer using stable isotope resolved 
metabolomics on a xenograft mouse model (Fan, A. Lane et al. 2011). In that study, mice 
received a bolus injection of [U-13C]glucose followed by metabolite extraction of various 
tissues and plasma in order to determine the best time point for label incorporation. 
Following the bolus injection, 13C label was passed on to various organs such as the brain, 
heart, kidney, liver, lung and muscle. The authors found that 13C glucose label incorporation 
changed over the duration of the experiment. For organs with fast glucose absorption such as 
liver, heart and muscle, the 13C-labelled glucose followed a trend of exponential decay. 
However, for other organs such as brain, heart and kidney the 13C label was sustained steadily 
during the duration of the experiment of 25 minutes. This indicates the need to select the 
most suitable route and duration for introducing a 13C labelled precursor to achieve the 
isotopic steady-state for each study. For example, for fast glucose absorption tissues such as 
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solid tumour, continuous intravenous infusion could be required to achieve the isotopic 
steady-state.  
 
Recently, non-stationary 13C-MFA methods have been developed to follow the dynamics of 
13C propagation over time (Yuan, Bennett et al. 2008, Jazmin and Young 2013). In this type 
of analysis, there is no requirement for an isotopic steady-state as it is possible to effectively 
follow the dynamic change of label incorporation over time. Because this type of analysis 
requires multiple time courses and individual metabolite pool size data, it is therefore 
experimentally and computationally more challenging. Nevertheless, combining multiple 
approaches should yield a more robust method. 
 
1.7.2 Using mouse models for breast cancer in vivo 13C labelling studies  
In the investigation of breast cancer using in vivo models, both xenograft and GEM 
(genetically engineered mouse) models have been used to study tumour metabolism. 
Xenograft models have classically relied on the use of breast cancer cell lines that have been 
in culture for many years and therefore may not represent accurate in vivo conditions, but are 
highly reproducible and permit studies that involve whole animal systems (Kluger, 
Chelouche Lev et al. 2005, Moestue, Borgan et al. 2010). However, it is important to 
recognise that xenograft models have fallen short of predicting breast cancer therapeutic 
responses because of the use of immuno-compromised mice which have close to an absence 
of an immune system (Sharpless and DePinho 2006).  
 
Advances in genetic engineering have allowed more precise control of the loss or gain of 
gene function to more accurately replicate the development of human breast cancer in a 
mouse model. From a study comparing the molecular markers of 13 GEM models of breast 
cancer with various human cancer subtypes, it was concluded that several GEM models 
together shared common features compared to human breast cancer. For example, a number 
of GEM models were found to be very similar to the luminal type human breast cancer 
(Herschkowitz, Simin et al. 2007). In a larger scale study, the US National Institutes of 
Health Breast Cancer Think Tank and Annapolis Pathology Panel compared the genetic 
variation among a panel of breast cancer GEM models. They found that even though 39 
individually investigated GEM models could not fully represent human breast cancer 
histologically, tumour formation from multiple genetic mutations in these GEM models do 
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recapitulate regions that resemble human breast cancer (Cardiff, Anver et al. 2000). These 
studies together demonstrated the applicability of different GEM models and therefore are 
very useful for studying distinct signalling interactions that develop during breast cancer 
disease progression. 
 
There are few studies using 13C based tracers for investigating breast cancer mice models in 
vivo. A recent study has attempted to apply this method to identify the roles of pyruvate 
kinase isozyme M2 (PKM2) in converting glucose to lactate using a GEM model (Israelsen, 
Dayton et al. 2013). Their results suggested that PKM2 knockout mice have a similar ability 
to convert labelled glucose to lactate and have similar cell proliferation using the in vivo 13C 
labelling model. This result was in contrast to the in vitro results obtained in PKM2 
knockdown cell lines. The authors found heterogeneous expression of pyruvate kinase 
isozyme M1 (PKM1) in the PKM2 knockout mice, and these PKM1 proteins are associated 
with non-proliferating tumour cells. The authors speculated that PKM2 is associated with 
proliferating tumour cells whereas the heterogeneous PKM1 expression in breast cancer 
tumour and together with PKM2 activity could symbiotically support metabolic requirements 
for tumour cells. This study highlighted the complexity in tumour cell heterogeneity that is 
present in vivo and that cancer metabolism studies entirely reliant upon in vitro cell cultures 
may not be able to recapitulate all tumour metabolic phenotypes.  
 
1.8 Aims and objectives 
 
The aim of this research was to investigate the metabolic pathway alterations in MCF7 cells 
in hypoxic and the MMTV-PyMT breast cancer mouse model using both metabolomic and 
13C metabolic flux analysis measured with NMR spectroscopy. 
To achieve this aim, the research was divided into the following six steps. 
1. Metabolomics analysis of hypoxic MCF7 cells using 1H-NMR spectroscopy. 
Measurement of 13C metabolic fluxes of hypoxic MCF7 cells.  
2. In Chapter 3, the 13C isotopomer distribution (CID) analysis was developed to 
measure the 13C metabolic fluxes of the MCF7 cells in hypoxia. 
3. Comparison of the 13C metabolic flux results with gene expression analysis.  
In Chapter 3, the gene expression changes in hypoxic MCF7 cells were determined 
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using RNA sequencing. The gene expression results were then mapped onto the 13C 
metabolic flux results. 
4. Identification of the metabolic consequences of pyruvate carboxylation (PC) in 
hypoxia. 
In Chapter 4, PC knockdown and PC inhibited systems were established. 13C labelling 
experiments using [1,2-13C]glucose and [3-13C]glutamine were conducted to 
determine the metabolic effects of PC inhibition. Cell viability was tested in the PC 
knockdown and PC inhibited systems. 
5. Development of 13C in-vivo metabolic flux analysis in breast cancer mouse model.  
In Chapter 5, the [1,2-13C]glucose labelling strategy was applied to MMTV-PyMT 
mice. The intraperitoneal (IP) and intravenous (IV) glucose administration protocols 
were compared. 
6. Identification of metabolic pathway differences measured with the 13C in-vivo 
metabolic flux analysis. 
In Chapter 5, the metabolic pathway differences between early and advanced stages of 















Table 2-1: Details about the buffers used in this work. 
Chemical Dilution Company Details 
PBS 10x Sigma 
Aldrich 
Dissolved in ddH2O to yield a phosphate 
buffer concentration of 0.01M and a sodium 
chloride concentration of 0.154M at pH7.4 
PBST - Sigma 
Aldrich 





4% Sodium dodecyl sulphate (SDS), 20% 
glycerol, 10% 2-mercaptoethanol, 0.004% 
bromphenol blue and 0.125 M Tris 




10x - 0.25 M Tris-HCl, 192 mM glycine, 1% SDS 
at pH 8.6. The 10x concentrated buffer was 




10x - 0.25 M Tris-HCl, 192 mM glycine at pH 8.3. 
The 10x concentrated buffer was diluted to 1x 







150 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS, and 50 mM 
Tris-HCl, pH 8.0 
 
...continued on next page 
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TAE buffer 10x - 0.4 M Tris acetate, 0.01 M EDTA, pH 8.3. 




- - 10m M Tris-MOPS and 1mM of EGTA-Tris 
and 200 mM sucrose, pH to 7.4.  
 
Blue native-PAGE 
sample buffer  
4x Life 
Technologies 
125 mM Tris-HCl, pH 6.8, 50% glycerol and 
2% bromophenol Blue. The 4x concentrated 
buffer was diluted to 1x buffer following 






500 mM Tris-HCl and 3.8 M glycine pH 8.3. 
The 20x concentrated buffer was diluted to 1x 





Table 2-2: Details about antibodies used in this work. 
Primary antibodies Dilution Company 
Anti-human G6PD (rabbit) 1:1000 Cell Signalling 
Anti-human G6PD (goat) 1:200 Thermo Scientific 
Anti-human VDAC (rabbit) 1:1000 Cell Signalling 
Anti-human AKT (rabbit) 1:1000 Cell Signalling 
Anti-human β-actin (mouse) 1:1000 Thermo Scientific 
Anti-human PC (rabbit) 1:200 Santa Cruz 
 
Secondary antibodies   
Anti-rabbit IgG goat Alexa-Flour-488 1:2000 Life Technologies 
Anti-mouse IgG rabbit HRP 1:2000 Thermo Scientific 





2.2 Mammalian cell biology techniques 
 
2.2.1 Cell culture  
All cells were maintained in high glucose Dulbecco's Modified Eagle's Medium (DMEM 
with 25 mM glucose; Hyclone) with 2 mM glutamine (Thermo Scientific) and 10% foetal 
bovine serum (FBS) (Thermo Scientific) added, and incubated at 37oC in a humidified 95% 
air/5% carbon dioxide incubator unless otherwise specified. MCF10A cells were maintained 
in DMEM/F12 (Invitrogen) supplemented with 5% horse serum (Life Technologies), 100 
μg/mL epidermal growth factor (EGF) (Sigma Aldrich), 1mg/ml hydrocortisone (Sigma 
Aldrich), 1 mg/mL cholera toxin (Sigma Aldrich) and 10 mg/mL insulin (Sigma Aldrich). 
 
2.2.2 siRNA transfection 
Cells were trypsinised and suspended in medium prior to transfection. Cells were transfected 
with 25 nM pyruvate carboxylase (PC) siRNA (Dharmacon) or control siRNA (SMART 
pools siRNA; Dharmacon) using TransIT-siQUEST reagent (Mirus) according to the 
manufacturer’s protocol in 15cm plates at a density of 2.3x106 cells/plate. The resultant cells 
were harvested for the experiments outlined below 72 hours after transfection.  
 
2.2.3 Construction of PC shRNA MDA-MB-231 stable cell lines 
TRIPZ is a lentiviral inducible vector used to produce microRNA-adapted short hairpin RNA 
(shRNA) to create gene silencing. TRIPZ-inducible shRNA for PC and control (non-silencing 
shRNA) (Thermo Scientific) were transfected into MDA-MB-231 using TurboFect 
transfection reagent (Thermo Scientific) according to the manufacturer's protocol. The PC 
shRNA sequence is shown in Appendix 1. The PC and control shRNA transfected cells were 
selected using 2 μg/mL puromycin (Sigma Aldrich) for 72 hours. The cells were then 
maintained in DMEM supplemented with 10% tetracycline-free FBS (Takara) and 2 mg/mL 
puromycin for continuous selection. After 4 weeks of selection in puromycin, three 
independent clones from both PC and control shRNA knockdown cells were established 
based on screening for PC knockdown using qRTPCR. To induce expression, the cells were 




2.2.4 Mammalian cell lysate preparation 
Prior to cell lysis, culture media was removed and the adherent cells were washed with PBS. 
For western blot, cells were lysed in RIPA buffer containing 1x protease inhibitor cocktail 
(Sigma Aldrich). The resultant protein extracts were quantified using a bicinchoninic acid 
(BCA) protein assay (Thermo Scientific). 
 
2.2.5 BCA protein assay 
The bicinchoninic acid (BCA) protein assay is based on the colorimetric detection of Cu1+. 
The detection method relies on the presence of the three amino acid residues, cysteine, 
tyrosine and tryptophan in proteins as these amino acids reduce Cu2+ to Cu1+. BCA chelates 
the Cu1+ to produce the BCA/copper complex that gives linear absorbance at 562 nm. The 
protein concentrations were determined with reference to standard calibration with bovine 
serum albumin standard solutions. After incubating the samples with BCA reagent at 37°C 
for 30 min, the absorbance of samples at 562 nm was measured by spectrofluorometer 
(POLARstar Omega, BMG LABTECH). 
 
2.2.6 Western blot 
After the concentration of protein lysates had been determined, an equal volume of 2x 
Laemmli sample buffer was added to the protein extracts. Protein extracts were separated by 
SDS-PAGE (10% polyacrylamide gel electrophoresis) running under 150 V for 1 hour (or 
when the loaded samples reached the bottom of the gel) before the gel was transferred onto a 
nitrocellulose membrane (GE Healthcare). After blocking for 1 hour in 5% milk/PBST at 
room temperature on a rocker, the membrane was incubated in primary antibody at the 
dilutions shown in Table 2-2 overnight at 4oC with agitation. Following multiple washes with 
PBST, the membrane was then incubated with a horseradish peroxidase (HRP)-conjugated 
secondary antibody appropriate to the species of the primary antibody at 37oC for 1 hour. 
After further washes in PBST at room temperature with agitation, enhanced 
chemiluminescence reagent (GE Healthcare) was incubated with the membrane before 





2.2.7 RNA extraction, cDNA preparation and qRTPCR 
Total RNA was extracted from cells using a Qiagen RNeasy Mini Kit. To do this, cells were 
homogenized and lysed in RLT lysis buffer containing high salt guanidinium 
thiocyanatephenol to break the cell membrane and destabilize RNAses. The suspension was 
then passed through a column using centrifugation in order to separate the RNA from other 
cellular components, before further washes to remove contaminants and then the guanidinium 
salts. Finally, the RNA was eluted from the column using ddH2O and its concentration was 
measured using a Nanodrop ND-1000 spectrophotometer with 260 nm /280 nm at the ratio of  
1.8 to 2.2. 1 µg of RNA was subjected to reverse transcription to produce single-stranded 
cDNA using a cDNA Reverse Transcriptase Kit (Applied Bioscience) according to 
manufacturer’s instructions where Oligo (dT) primers were used to enrich for mRNAs. 
qRTPCR was then conducted using the Taqman gene expression Master Mix with pre-
designed primers and probes (Life Technologies) for PC and beta-actin as control. 
 
2.2.8 Transcriptomics analysis using RNA sequencing 
Total RNA from three biological replicates of MCF7 cells (approximately 1 x 106 cells) each 
from normoxia and hypoxia (maintained for 48 hours) was purified using RNeasy Mini Kit 
(Qiagen). RNA sequencing was carried out by Microsynth AG using the SOLiD system from 
Life Technologies. Total RNA was enriched for mRNA by the poly (A) enrichment method. 
cDNA library was generated by reverse-transcription including specific sequencing adaptors 
with barcodes. Finally, the libraries were pooled and sequenced on the Illumina machine. 
Sequencing reads arising from the instrument were mapped against the human reference 
sequence hg19. The resulting alignment was analysed by counting reads for each feature. The 
differentially expressed features were normalized using the DeSeq package (Anders and 
Huber 2010). The expression variance was later tested for statistical significance using a 5% 
false discovery rate (FRD).  
 
Gene ontology (GO) analysis was carried out using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) program (Huang, Sherman et al. 2008). We 
submitted those genes with significant changes of RNA expression in hypoxia to DAVID 
bioinformatics resources and by using the functional annotation chart, assessed major 
biological functions associated with the submitted gene list. We also classified gene function 
50 
 
based on KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways. Pathways that 
significantly varied between normoxia and hypoxia were determined using a cut-off for 
globally correct enrichment p-value – the Benjamini- Hochberg value of 0.05. 
 
2.2.9 Immunofluorescence staining 
MCF7 cells were allowed to adhere to chamber slides in 21% O2 before incubating at either 
21% or 1% O2 for 48 hours prior to immunofluorescence staining. For mitochondrial 
staining, the cells were incubated with 500 nM MitoTracker Orange (Life Technologies) for 
20 minutes and washed with PBST for several times before fixing the cells. The cells were 
then fixed with 10% formalin for 20 minutes and permeabilised for 10 minutes with 0.1%  
Triton X-100 (Sigma) solubilised in PBS and again washed several times. Before adding 
primary antibody, the slides were blocked with 4% BSA (bovine serum albumin) in PBS for 
at least 20 minutes. To stain for glucose 6 phosphate dehydrogenase (G6PD) localization, 
permeabilised cells were incubated overnight at 4oC with anti-G6PD antibody (concentration 
shown in Table 2-2) and washed with PBST several times after.  Slides were then incubated 
with anti-goat Alexa-Flour-488 labelled secondary antibody at the concentration shown in 
Table 2-2 for 1 hour at room temperature. For ease of visualisation and to preserve the 
staining, a 4’-6-diamidino-2-phenylindole dihydrochloride (DAPI)-containing fluorescence 
mounting medium (Vectashield, Vector Laboratories) was added to the slide before a cover 
slip was placed over the slide. Images were taken using a LSM 510 Meta confocal 
microscope. 
 
2.2.10 Hypoxia experiments 
Hypoxia is defined throughout as 1% oxygen. Cells were incubated in hypoxia at 37oC, 1% 
oxygen, 5% carbon dioxide, balance 94% nitrogen for 48 hours using a Hypoxystation H35 
workstation (Don Whitley Scientific). 
 
2.2.11  13C flux experiments 
After maintaining the cell lines in exponential phase for at least 24 hours, the culturing media 
was changed to flux media to perform the flux analysis. For the adherent cells used in this 
work, the flux experiments were conducted on cells maintained at exponential phase (8 - 10 x 
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106 cells per plate) on a 15 cm (diameter) tissue culture dish. The flux media which consisted 
of DMEM (without glucose, pyruvate, phenol red and glutamine; Sigma Aldrich), containing 
3.7 g/L sodium bicarbonate (Sigma Aldrich), 10% FBS (Thermo Scientific), was 
supplemented with either 2 mM [3-13C]glutamine (Sigma Aldrich) or 10 mM  [1,2-
13C]glucose (Sigma Aldrich) for the 13C flux experiments. During the 13C flux experiment, 
the culturing media was changed to the respective flux media for 1 hour, 3 hours, 6 hours and 
24 hours. For individual time points, a non-enriched (12C - glucose, natural abundance has 
1% 13C) glucose or glutamine media was prepared by supplementing with 2 mM L-glutamine 
(Sigma Aldrich) and 10 mM D-glucose (Sigma Aldrich). A 3 hours [1,2-13C]glucose labelling 
and a 6 hours [3-13C]glutamine labelling time point were chosen for the 13C positional 
incorporation percentage analysis in Section 4.2.1.1. The 3 hours [1,2-13C]glucose labelling 
time point was chosen to allow sufficiently high 13C incorporation (based on initial studies in 
Chapter 3). The 6 hours [3-13C]glutamine labelling time point was chosen. This is because a 
longer time was expected to be needed for TCA cycle metabolites to reach steady state 
compared to most metabolites related to glycolysis (Ahn and Antoniewicz 2013). 
 
2.2.12 Metabolite extraction 
For cell line samples, the medium was first removed before cells were washed twice with ice-
cold PBS. Cell metabolism was quenched by placing the cells on a dry ice-cooled surface 
before scraping into a 55:35:10 acetonitrile:methanol:ddH2O solution. In the case of tissue 
samples. After mincing with scalpel and scissors, tissues samples were homogenised in a 
60:40 mix of acetonitrile:methanol at the ratio of 1 mL per 100mg of tissue using a Precellys 
homogeniser for 2x20 seconds at 5000 rpm. Both cell and tissue extracts were vortexed for 
15 minutes before centrifugation at 15000 x g at 0oC for 15 minutes. The supernatant was 









2.3 Mitochondrial experiments  
 
2.3.1 Mitochondrial isolation 
Mitochondria were isolated from MCF7 cells using the method described by Frezza et. al 
(Frezza, Cipolat et al. 2007). After washing with cold PBS, cells were resuspended in 
mitochondrial isolation buffer (Table 2-1) and homogenised for 50 strokes at 4oC using a 
Potter-Elvejhem homogeniser. In the first centrifugation step, the homogenate underwent a 
differential centrifugation at 13000 x g for 10 minutes at 4oC to remove cellular debris. Later, 
the fractional enriched mitochondria were cleaned with a second centrifugation step 7000 x g 
for 10 minutes at 4oC. Finally, the isolated mitochondria were resuspended in ~100 uL 
mitochondrial isolation buffer. The concentration of mitochondria was estimated from the 
total protein concentration by BCA protein assay (Thermo Scientific) as described in section 
2.2.5. 
 
2.3.2 Blue Native PAGE and 2D Electrophoresis 
Isolated mitochondria fractions were prepared for Blue Native PAGE analysis using the 
NativePAGE sample preparation kit (Life Technologies) to produce the resultant protein 
complexes according to the manufacturer's protocol. In brief, the isolated mitochondrial 
fraction was centrifuged at 20000 x g for 30 minutes at 4oC in a mixture consisting of 1 x 
NativePAGE sample buffer, 1.6 % n-dodecyl-β-d-maltoside (DDM) and 1 x protease 
inhibitor cocktail (PIC). The resultant supernatant containing 30μg protein was combined 
with 0.25% Coomassie blue (G-250) and was loaded on a native PAGE Novex 4-16% Bis-
Tris protein gel (Life Technologies). Electrophoresis was performed in the cold room with 
pre-chilled NativePAGE buffers as tabulated in Table 2-1 (Wittig, Braun et al. 2006, Wittig, 
Karas et al. 2007). The gel electrophoresis consists of two steps. In the first step, the gel was 
run at 150 V for 30 minutes. For the second step the gel was run at 300 V for 3 hours (or until 
the loading reach the bottom of the gel). After resolving the first dimension of the blue native 
PAGE, the single gel lane was cut out and incubated in 1x denaturing buffer (NuPAGE 
lithium dodecyl sulfate (LDS) sample loading buffer, Life Technologies) and 2.5% β-
mercaptoethanol for 20 minutes. For running the second dimension SDS-PAGE, a gel (lane) 
strip was loaded onto a Tris-ZOOM gel (Life Technologies) for SDS-PAGE analysis similar 
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to protocol described in section 2.2.6 where the gel was run at 150 V for 1 hour to resolve the 
second dimension.  
 
 
2.4 Bacterial culture techniques 
 
2.4.1 Preparation, isolation and purification of plasmid DNA 
For plasmid preparation, TRIPZ shRNA was cloned by growing Escherichia coli in sterile LB 
broth (Sigma Aldrich) supplemented with 100 μg/mL carbenicillin. 10 μL of the inoculums 
was added into 1 L of the LB broth and the mixture incubated at 37oC for ~18 hours. DNA 
was amplified and purified using a HiSpeed plasmid maxi kit (Qiagen) according to the 
manufacturer’s instructions. Briefly, after cell lysis the alkaline lysate was passed through an 
anion exchange resin to allow the DNA to bind to the column. After multiple washes with 
low and medium salt buffers, the DNA was eluted in a high salt buffer. The eluted DNA was 
concentrated using isopropanol precipitation, and then washed in ethanol before drying and 
resuspended in 10 mM Tris-HCl, pH 8.5. 
 
2.4.2 Quantification of DNA 
1 µL DNA was quantified using a NanoDrop ND-1000 spectrometer. Distilled, deionised 
H2O (ddH2O) was used for washing and for the reference measurement. The absorbance at 
260 nm was used to quantify DNA and the 260 nm/280 nm ratio was used to test DNA 








2.5.1 MMTV-PyMT mouse model 
The mouse mammary gland tumour virus - polyoma virus middle T-antigen (MMTV-PyMT) 
is a breast cancer mouse model, in which MMTV long terminal repeats is used to drive the 
expression of mammary gland specific polyoma virus middle T-antigen. PyMT is a potent 
oncogene because its product binds to and cause activation several signal transduction 
pathways, including those of the Src family and the ras and PI3 kinase pathways, which are 
altered in human breast cancers (Rodriguez-Viciana, Collins et al. 2006). Wild-type FVB/N 
mice were maintained in a barrier facility at the University of Birmingham according to 
institutional guidelines. MMTV-PyMT transgene-bearing males on the same genetic 
background were mated with FVB/N females to generate a PyMT female study cohort. 
Experiments were conducted in compliance with the Animals Scientific Procedures Act 
(1986) at the Biomedical Services Unit (BMSU) of the University of Birmingham with 
access to food and water ad libitum. 
 
2.5.2 Genotyping 
DNA extraction was carried out using a KAPA Express Extract kit (Kapa Biosystems, 
Woburn, MA). The extractions of DNA were isolated from mice ear clips by incubating the 
tip in DNA lysis buffer (containing the thermostable protease developed by Kapa Biosystem) 
at 75°C for 40 minutes and followed by heat inactivation at 90°C for 10 minutes according to 
KAPA Express Extraction Kit instruction protocol. DNA PCR amplification was conducted 
by using the KAPA2G Fast Genotyping Mix (Kapa Biosystems, Woburn, MA) according to 
the PCR program in Table 2-3 and with the primers below used to specifically amplify the 
PyMT transgene (Table 2-4). The PCR product was examined using 2% Tris-Acetate-EDTA 
(TAE) agarose gel electrophoresis stained with SYBR Safe DNA Gel Stain (Invitrogen). 
 
Table 2-3: PCR program for PyMT genotyping. 
Temperature (°C) Time (s) Number of cycles 
95 60 35 
60 15 
72 15 




Table 2-4: Primers for PyMT genotyping. 
Target Primer Primer sequence 
Primer 1  5′-GGA AGC AAG TAC TTC ACA AGG G-3′ 
Primer 2  5′-GGA AAG TCA CTA GGA GCA GGG-3' 
 
2.5.3 13C flux experiments on mouse model 
In order to assess the use of glucose by the mammary tumours, 100 μL of 1 M [1,2-
13C]glucose (Sigma Aldrich) or natural abundance glucose diluted in 0.9% NaCl was injected 
by either the intravenous or intraperitoneal routes into MMTV-PyMT transgene-bearing mice 
of 11 or 13 weeks of age. Mice were sacrificed 10, 20, 30 or 60 minutes after injection by 
either cervical dislocation or, where blood samples were required, by cardiac exsanguinations 
under terminal anaesthesia followed by cervical dislocation. 
 
2.5.4 Blood serum sample preparation 
Between 0.5 mL and 1 mL of blood was taken from mice through cardiac exsanguinations 
under terminal anaesthesia. 10 μL of 500 mM EDTA was added into the blood samples 
during sample collection before placing the sample on ice. The plasma was later separated 
from the cellular components by centrifugation. The separation process was achieved by 
ultrafiltration though a 3 kD Nanosep Centrifugal Devices (Pall) at 14 000 x g for 15 minutes 
at 4oC. 
 
2.5.5 Tumour sample preparation 
Clear formation of tumour mass around the mammary glands of mice can be observed for the 
11 and 13 week-old MMTV-PyMT mice. Tumour samples were collected from mammary 
gland of MMTV-PyMy mice. Tumour samples were minced, before homogenisation in a 
1:1:1 mix of methanol:choloform:ddH2O at the ratio of 1.7 ml extraction buffer mix per 0.2 g 
of tumour sample. The tumour sample was homogenised using a Precellys tube (Percellys) in 
a Precellys homogeniser at 5000 rpm for 2x20 seconds. The tumour extracts were then 
vortexed for 15 minutes before centrifugation at 15000 x g at 0 oC for 15 minutes. The 
supernatant was collected and dried under an Eppendorf dryer at 30 oC.  The dried extracts 
were finally reconstituted in 100 mM sodium phosphate buffer (pH 7.0) containing 500 μM 
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TMSP (sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4), 1.5 mM sodium azide and 10 % 
D2O. 
 
2.5.6 Tumour volume calculation 
Directly after culling the mice, the tumour volume was measured using digital callipers. The 
volume of the tumour was estimated using the ellipsoid formula (Turkbey, Mani et al. 2012).  
 
 
2.6 NMR Spectroscopy 
 
2.6.1 Sample preparation 
The dried extracts were finally reconstituted in 50 μl of 100 mM sodium phosphate buffer 
(pH 7.0) containing 500 μM TMSP (sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4) (Sigma 
Aldrich), 1.5 mM sodium azide (Sigma Aldrich),  and 10% D2O (Sigma Aldrich). Serum 
samples were diluted 1:1 with 200 mM sodium phosphate buffer (pH 7.0) containing 1 mM 
TMSP (Sigma Aldrich) and 10% D2O. Spectra were recorded on a 600 MHz Bruker 
spectrometer equipped with a 1.7 mm z-PFG cryogenic probe at 300 K. 
 
2.6.2 Pulse program 
NMR experiments can be categorised into different pulse programs. Pulses have different 
parameters like carrier frequency, pulse length and shape. These pulse sequences are 
designed to reveal certain molecular information. The NMR pulse sequences used in the 
present work for metabolomics investigation can be categorised into the following groups: 
 
• 1D 1H experiments to obtain chemical shifts for metabolites, structure identification 
and subsequently as the reference for 2D experiments. This type of experiment is 
mainly used for standard metabolomics samples to measure the concentration of 
metabolites in the whole system. 
• 2D heteronuclear experiments: 1H-13C-HSQC spectra enable the unambiguous 
assignment of all proton spins and allow for investigation of a particular pathway by 
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introducing the 13C tracer precursors. Combining tracer studies with precursors such 
as [1,2-13C]glucose allows the determination of the degree of 13C isotopic enrichment 
and labelling pattern of individual atoms. Such tracer techniques are useful for 
mechanistic understanding of a metabolic phenotype. 
• Pseudo 3D heteronuclear experiments - TILT (time domain increments linked 
together) TOCSY (total correlation spectroscopy) HSQC (heteronuclear single 
quantum coherence) and TILT-HCCH-TOCSY are used to determine long-range 13C-
13C connectivity via the 1H or 13C scalar coupling networks.  
 
2.6.2.1 1H NMR using 1D NOESY (nuclear overhauser effect spectroscopy) 
presaturation 
A simple 1D 1H NMR experiment remains the most popular NMR metabolomic experiment 
owning to its sensitivity and speed. Considering publically available databases for 
assignments (Wishart, Tzur et al. 2007) and effectiveness of water suppression we used the 
1D 1H NMR using a 1D NOESY presaturation pulse sequence implemented by Bruker. This 
sequence combines a recovery delay with a presaturation water suppression in order to 
suppress large water signals in metabolomics samples  (Nicholson, Foxall et al. 1995). For 
metabolomics samples which consist of mixtures of small molecules, this pulse sequence 
uses a small mixing time, improving the radiofrequency (RF) homogeneity and generating an 
unedited spectrum with good water effective suppression. The basis of the pulse sequence is 











Figure 2-1: The basic of pulse sequence of 1D NOESY with presaturation water suppression. During d1, 
the water presaturation is achieved by applying a weak continuous wave radio frequency field (CW). 
Residual water signal is further suppressed by three 90o pulses. The phase cycling is φ1: x, -x ; φ2: x, x,-x,-
x,y,y,-y,-y; φrec: x, -x,-x,x,y,-y,-y,y and tm is the mixing time. 
 
2.6.2.2 13C- heteronuclear single quantum coherence (HSQC) 
NMR metabolomics suffers from overcrowded spin systems arising from complex mixtures 
of small molecules. The information about correlations of 13C and protons from a HSQC 
(Bodenhausen and Ruben 1980) spectrum is very useful to unambiguously assign these 
resonances. Measuring HSQC spectra with large number of increments (2048 - 4096) in the 
indirect dimension allows for the observation of 13C-13C scalar couplings which provide 
valuable information for both adjacent label incorporation and 13C isotopomer distribution 
(CID) analysis in individual spin systems. The basis of a HSQC pulse sequence is shown in 
Figure 2-2. There are several variants of 13C-HSQC pulse sequence. To accommodate the 
high number of increments in the 13C dimension, only 2 scans were used to minimise the 
acquisition time for metabolomics samples. This requires the use of an echo-anti echo 






Figure 2-2: Pulse sequence of the 13C-HSQCexperiment. This pulse sequence can be divided into four 
sections: preparation (p), evolution (e), mixing (m) and detection (d). First the INEPT (insensitive nuclei 
enhanced by polarization transfer) transfers magnetisation from proton to 13C (section p). During t2, the 
single quantum coherence develops the 13C chemical shifts (section e). In section m, the last 90o 13C and 
proton pulses transfer the magnetisation back onto protons 13C before the acquisition. Other additional 
features such as shaped adiabatic pulses (φ4) serve to improve homogeneous excitation over the entire 13C 
range and the gradient pulse gp1 and gp2 serve as the echo anti-echo pulses. 
 
2.6.2.3 TILT HSQC TOCSY and TILT HCCH TOCSY 
The TILT-HSQC-TOCSY and TILT-HCCH-TOCSY used in this work are pseudo 3D 
experiments (Kupce and Freeman 2005).  The implementation of the TILT experiment comes 
at the expense of some extra data processing.  In a TILT-TOCSY spectrum the chemical shift 
in the indirect dimension consists of a mixture of 13C and 1H chemical shifts, i.e. the chemical 
shift (Ω) TILT is given by: 
 
ΩTILT = ΩC×cos(α) + ΩH×sin(α) 
or 




In this work, spectra for one or two projections angles (α) were recorded with a large number 
of increments to reconstruct a 2D spectrum. The difficulty in using this approach for spectral 
analysis is that the resonances will appear at different frequencies compared to a HSQC 
spectrum. However, the true chemical shift information can be computationally decoded from 
the TILT spectrum. Although this extra decoding step complicates the use of this technique, 
this is facilitated by the NMRLab/MetaboLab (Günther, Ludwig et al. 2000, Ludwig and 
Günther 2011) software for analysis of TILT spectra. The two pulse sequences are shown in 
Figure 2-3. 
 
The TILT TOCSY-HSQC experiment can reveal the possible isotopomers of a given 
metabolite, and TILT HCCH-TOCSY is carried out to confirm the sequential site specific 
labelling of atoms.  The TILT TOCSY-HSQC spectrum is used to determine multisite 13C 
labelling incorporation. This is achieved by inserting an additional 13C-editing step to select 
for the molecules with multiple 13C labelling. The generic TILT TOCSY-HSQC (Figure 
2-3A) measures all protons with 13C carbon attached. The multisite labelling is evaluated by 
comparing the cross peak intensities of an additional 13C-edited spectrum (Figure 2-3B, also 
known as double edited TILT TOCSY-HSQC experiment) to the cross peak intensities from 
a TILT TOCSY-HSQC sequence (pulse sequence shown in Figure 2-3A, also known as 






Figure 2-3: Pulse sequence for TILT-TOCSY-HSQC spectroscopy. (A) TILT TOCSY-HSQC pulse 
sequence. (B) TILT TOCSY-HSQC an additional 13C-edited step (highlight in grey). During the indirect 
evolution periods t1 and t2 are incremented simultaneously. The t1 increment (dwell time of the indirect 
proton dimension) is weighted with sin(α), while the t2 increment is weighted with cos(α). 
 
2.6.3 NMR spectrum data analysis 
 
2.6.3.1 Steady-state metabolite quantification from 1H spectrum 
NMR spectra were processed using NMRLab/MetaboLab (Günther, Ludwig et al. 2000, 
Ludwig and Günther 2011). 1H spectra were batch processed to 65536 data points, phase 
corrected and referenced using the TMSP resonance at 0 ppm. Resonance assignments and 
quantification were carried out using the Chenomx NMR Suite 7.1 (Chenomx, Edomonton, 
Canada). PCA (principal component analysis) or PLS-DA (partial least squares discriminant 
analysis) of 1H spectra was carried out using PLS toolbox 4.1 (Version 4.1; Eigenvector 




2.6.3.2 13C positional incorporation percentage of metabolites   
The 13C positional incorporation percentage can be calculated using both the 2D 13C-HSQC 
spectrum and 1D 1H-13C heteronuclear spin echo experiment. When the natural abundance 
(non-13C enriched sample) and 13C labelled sample pairs were available (i.e. for the cell line 
models), the incorporation of 13C nuclei into a metabolite was determined by dividing the 
13C-HSQC peak intensities in the 13C-labelled spectra by those in non-labelled spectra.   
 
When the natural abundance (non-13C enriched sample) and 13C labelled sample pairs were 
hardly available (i.e. for the 13C glucose animal model infusion models) the percentage of 12C 
versus 13C labelled metabolites were calculated using two variants of the 1D 1H-13C  
heteronuclear spin echo experiment (Katarzyna Koczula 2015) (unpublished results). The 12C 
spectrum (13C natural abundance) contains 1H signals originating from all protons while the 
13C labelled spectrum contains only signals from protons attached to a 13C nucleus. The 13C-
editing was achieved by adding a 13C 180 degree pulse on 13C. Spectra were processed using 
NMRLab/MetaboLab (Günther, Ludwig et al. 2000, Ludwig and Günther 2011). Using 
MetaboLab (Ludwig and Gunther 2011), 1H spectra were processed to 65536 data points, 
phase corrected, and referenced to TMSP at 0 ppm. Resonance assignments and 
quantification were carried out using the Chenomx NMR Suite 7.1 (Chenomx, Edomonton, 
Canada). The concentration corresponding to a peak in the 13C spectrum divided by that of 
the 12C spectrum was used to calculate the 13C percentage incorporation.  
 
2.6.3.3 13C  isotopomer analysis from 13C-HSQC spectra 
The 13C isotopomer distribution (CID) information was extracted from a 13C HSQC 
spectrum. Using MetaboLab (Ludwig and Gunther 2011), 13C HSQC spectra were processed 
to 1024 x 16384 data points and corrected for phasing, and zero referencing. Using the 
hsqcMA module in NMRlab (Ludwig C, unpublished results), we fitted the experimental 
spectrum to the simulated spectrum. The fitting process was done by using a user defined 
spin system (including information such as the possible isotopomers, chemical shift and J-
coupling) to generate a py-gamma spectrum (a spectrum simulated using py-gamma library). 
Then, using a simplex algorithm (error minimising algorithm) taking into account all the 
carbon spin system information (i.e.: chemical shift, J-coupling) to iteratively minimise the 
error function. Simulations were conducted using 13C HSQC spectra acquired with 1024 x 
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4096 data points. A 1024 x 16384 data points spectrum was first used to determine the J-




2.6.3.4 Flux determination from 13C HSQC 
The population of specific labelling patterns is indicative of individual pathway fluxes (for 
example: [2,3-13C]JC2C3 glutamate for PC flux and [4,5-13C]JC4C5 glutamate for PDH flux) 
and is reflected in the 13C multiplet pattern for these nuclei. To obtain the time evolution of 
label incorporation, 13C tracer experiments were conducted at 1, 3, 6 and 24 hours. The 13C 
labelling percentage contribution to an individual multiplet was plotted against the time and 
the plot was fitted with a single exponential saturation-binding curve. The resulting rate 
constant and maximum 13C labelling percentage was determined. The flux was determined 
from the rate constant multiplied by the pool size (maximum labelling percentage). In cases 
where the number of available time points was limited, the relative flux was determined by 
comparing the specific multiplet proportion at the point with similar nutrient availability.   
 
 
2.7 Statistical analysis 
 
To test for statistical significance, two way repeated measures analysis of variance (ANOVA) 
was conducted using GraphPad Prism version 5.00 for Windows. All numerical data are 






3. Transcriptomics, Metabolomics and Metabolic 





In order to efficiently modulate cellular metabolism in a fluctuating oxygen 
microenvironment, hypoxic tumour cells initiate a global transcriptional programme, much of 
which is regulated by HIFs (Wang and Semenza 1995). The net effect of HIFs activation is 
an orchestrated alteration in expression of diverse transcriptional targets, ranging from those 
involved in energy metabolism, cell proliferation and cell migration to metastasis (Semenza 
and Wang 1992, Liu, Cox et al. 1995, Schofield and Ratcliffe 2004, Wong, Gilkes et al. 
2011). The effect of these transcriptional changes is that carbons arising from glucose 
metabolism are diverted away from the oxidative TCA cycle metabolism while glycolytic 
rates are enhanced. Since mitochondrial respiration is often a major source of reactive oxygen 
species (ROS) production (Loschen, Azzi et al. 1974, Murphy 2009), higher dependency on 
glycolysis associated with decreased flux through the TCA cycle is thought to lower ROS and 
therefore cell stress (Huang, Li et al. , Kim, Tchernyshyov et al. 2006, Vaughn and 
Deshmukh 2008). Coupling high glycolysis and low mitochondrial respiration under the 
direct influence of HIFs therefore reprogrammes central carbon metabolism in hypoxia. 
 
The study of metabolism is closely linked to metabolomics. The metabolome can be defined 
as the combined pool of endogenous metabolites, and metabolomics looks at the overall 
composition of this system. This has become an important tool to assess physiological states 
of organisms and metabolic profiling is now increasingly used to identify biomarkers as 
clinical parameters for disease states, or to predict responses to treatment (Boros, Cascante et 
al. 2002, Ellis, Dunn et al. 2007, Cuperlovic-Culf, Ferguson et al. 2012, Lodi, Tiziani et al. 
2013, Vermeersch and Styczynski 2013, Santagata, Eberlin et al. 2014). Metabolic profiles 
reflect an organism’s overall metabolite composition, which in the context of cancer is 
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closely linked with the tumour phenotype (Zhou, Schmid et al. 2006, Wong, Gilkes et al. 
2011, Hiller and Metallo 2013).   
 
A number of studies have investigated the metabolic profile of breast cancer by 
metabolomics. Hilvo et al. characterised the lipid profiles of breast cancer tumours and 
compared the results with an in silico transcriptomic database and identified several genes 
such as elongation of very long chain fatty acid–like 1 (ELOVL1), fatty acid synthase 
(FASN), insulin-induced gene 1 (INSIG1) and thyroid hormone–responsive protein (THRSP) 
which the authors attributed to breast cancer progression (Hilvo, Denkert et al. 2011). 
Moreover, the elevation of total choline-containing metabolites and lipid droplet levels has 
been shown to correlate with breast cancer progression in multiple studies (Aboagye and 
Bhujwalla 1999, Glunde, Jie et al. 2004, Glunde, Shah et al. 2008, Sardanelli, Fausto et al. 
2009, Jiang, Greenwood et al. 2012).  
 
While measuring the concentration of metabolite profiles provides clues about the steady-
state of a system, stable isotope tracers can be used to decode the time-dependent passage of 
a metabolite through several reaction pathways and thereby add important information 
towards understanding the biological mechanisms. One reason why tracer experiments 
provide additional information is that metabolites are in constant flux and this may not be 
reflected by measurements of steady-state concentrations. 13C metabolic flux analysis offers 
the advantage of this additional mechanistic viewpoint by showing where atoms go. Previous 
studies have utilised stable isotope tracers to compare metabolic changes associated with 
different breast cancer phenotypes. McGuirket et al. used uniformly 13C labelled glutamine to 
investigate the use of this metabolite by ERBB2+ breast cancer cell lines, and established the 
role of peroxisome proliferator activated receptor gamma coactivator (PGC-1α) in elevating 
the expression of genes associated with glutamine metabolism (McGuirk, Gravel et al. 2013). 
Recently, Terunuma et al. associated the increased level of the putative oncometabolite 2-
hydroxyglutarate (previously not associated with breast cancer) with the c-Myc signalling 
pathway activation using uniformly 13C labelled glutamine studies (Terunuma, Putluri et al. 
2014).  
 
Many studies have already focused on hypoxia induced metabolic alterations. However, our 
current knowledge of the molecular processes associated with the metabolic changes in 
hypoxic breast cancer is insufficient. Most breast cancer hypoxia studies have focused on 
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determining the perturbation in steady-state metabolites and gene expression (El Guerrab, 
Zegrour et al. 2011, Weljie, Bondareva et al. 2011, Tsai, Tien-Chueh et al. 2013) while 
several studies have used metabolic flux analyses to identify key regulators in various breast 
cancer subtypes (Forbes, Meadows et al. 2006, Possemato, Marks et al. 2011, McGuirk, 
Gravel et al. 2013, Terunuma, Putluri et al. 2014). The metabolic pathways alterations vary 
between different cell types and different O2 contents. In this thesis, MCF7 breast cancer cell 
line was used to characterise the metabolic pathway alteration induced by hypoxia. Studies on 
a number of different cancer cell lines have shown that HIF-1α can be stabilised between 6 
and 0.5% O2, with the degree and duration of stabilisation being inversely proportional to the 
O2 concentration (Wang, Jiang et al. 1995, Jiang, Semenza et al. 1996, Denko, Fontana et al. 
2003). Taking into consideration that conditions approaching an anoxic state (~0%) could 
result in complete cessation of mitochondrial respiration (Snyder and Chandel 2009), we 
conducted the hypoxia experiments at an O2 concentration of 1% - a condition that causes 
HIF-1α stabilisation and is permissive for mitochondrial adaptation for respiration (Wang, 
Pakunlu et al. 2004).  
 
MCF7 cells are a widely used epithelial cancer cell line. This cell line is known for closely 
resembling the luminal A subtype - the early carcinomas stage of human breast cancer (Neve, 
Chin et al. 2006). MCF7 cells is also known to form well-differentiated tumours in a 
xenograft animal experimental model (Neve, Chin et al. 2006), making this cell line a model 
for the study of early carcinomas stage breast cancer both in vitro and in vivo. By exposing 
this cell line to hypoxia, we aimed to reveal metabolic pathway changes that are related to 
hypoxic cancer cells at the early carcinomas stage of human breast cancer. Our goal in this 
chapter were twofold: first to conduct gene expression, metabolomics and 13C metabolic flux 
analyses to identify metabolic components that are essential in hypoxia; second to 13C 
correlate metabolic flux and transcriptomic analyses to identify metabolic changes that may 










3.2.1 Metabolic characteristics of hypoxic MCF7 cells 
To characterise the metabolic effect induced by hypoxia, the MCF7 breast cancer cell line 
was used. The basic metabolic phenotype of MCF7 cells was characterised by measuring the 
rate of proliferation, glucose consumption, glutamine consumption and lactate secretion of 
the cells in 21% or 1% O2 (Figure 3-1). After 48 hours at 1% O2, MCF7 cells exhibited 
increased glucose consumption and lactate secretion but showed little effect on glutamine 
utilisation (Figure 3-1). The increased nutrient uptake in hypoxia was not accompanied by 
increasing cell proliferation (Figure 3-2), suggesting that the higher nutrient demand in 




Figure 3-1: The effect of hypoxia on the uptake and excretion of major cellular metabolites. Nutrient 
consumption and lactate secretion of MCF7 in normoxia and hypoxia were obtained by measuring the 
metabolites concentration of the media before and after 24 hours used by the cells in order to quantify the 
changes in concentration (mM /107 cells /hour). The metabolites concentrations were measured via NMR 
1H spectroscopy. Positive values represent consumption and negative values represent secretion. Each 
data point is the average ± SD of three independent experiments. The asterisks represent the significance 
levels calculated by unpaired, two-tail student's t-test *p <0.05; ***p <0.001.  
 








































Figure 3-2: Proliferation of MCF7 cells in normoxia and hypoxia (1% O2). For each of the conditions, 
cells were plated with the same cell number on the same day. After day 1, day 2, day 3 and day 4 of cell 
culturing, the cell number was counted. The number of generations at each time point was calculated 
(Number of generation = log(number of cells at the beginning) - log(number of cells at the end of each 
interval) /0.301). Each time point is the average ± SD of three independent experiments. The asterisks 
represent the significance levels calculated by unpaired, two-tail student's t-test comparing normoxia to 
hypoxia at each time point, *p <0.05; **p <0.01; ***p <0.001. 
 
3.2.2 Gene expression profile of hypoxic MCF7cells 
 
3.2.2.1 Transcriptomic response to changes in oxygen tension 
Changes in the metabolic phenotype of cells exposed to different environmental oxygen 
tensions could occur through a number of means: changes in substrate and product 
concentration, allosteric control, post-translational modifications and alterations in enzyme 
expression through transcriptomic control. Due to the previously described effects of hypoxia 
on the transcriptome through the action of the HIF-1α transcription factors, we investigated 
the contribution of transcriptomic control to the metabolic response of MCF7 cells at 1% O2. 
RNA was extracted from cells incubated in 1% oxygen for 48 hours and from control, 
normoxic cells. Transcriptomic profiling analysis using the RNA sequencing method was 
selected to provide higher sensitivity and reliability (Marioni, Mason et al. 2008) and 




In order to investigate the overall biological processes mostly altered by hypoxia, we carried 
out gene ontology (GO) analysis (Table 3-1). Using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) program (Huang, Sherman et al. 2008), we mapped the 
most significantly changed genes with their associated biological annotation. Out of the 
34208 human reference genes, 293 transcripts were significantly up-regulated by 48 hours at 
1% O2. The proteins encoded by these 293 transcripts were queried for their associated 
pathways. The majority of the GO processes most altered by hypoxia were found to be 
involved in energy metabolism as part of glycolysis (12 genes mapped out of 45 reference 
genes as listed in Table 3-1 and listed in Appendix 3), gluconeogenesis (8 genes mapped out 
of 42 reference genes as listed in Table 3-1) and the pentose phosphate pathway (such as GPI, 
PFKP, PGM1 as highlighted in Appendix 5). We also observed the signatures of genes, 
which are often associated with malignant invasive tumour phenotype such as angiogenesis 
and chemotaxis (Kaplan, Riba et al. 2005, Sullivan and Graham 2007). Collectively, our gene 
expression data also suggest a reduced proliferation and invasive phenotype as previously 
described (Kang, Siegel et al. 2003, Muller, Stahmann et al. 2005, Jerby, Wolf et al. 2012). 
Using DAVID, we annotated the related genes based on their associated Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathway. Figure 3-3 shows the 
corresponding selected pathways and the number of genes mapped with Benjamini-Hochberg 






Table 3-1: Classification of the transcripts that were significantly altered in response to hypoxia into 
biological processes. The '# list' and '# ref' columns represent the number of matched genes in the input 
list and reference list for a given annotation. 
#. List 
 




Mapped Gene ID 
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98  3.79e-13 GO:0006006: glucose 


























18 290 2.35E-08 GO:0005975: 
carbohydrate 









17 341 1.54E-06 GO:0008285: negative 











... (continued on next page) 
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15 301 9.12E-06 GO:0042493: response 















3 5 5.838E-4 GO:0060754: positive 
regulation of mast cell 
chemotaxis  
VEGFA,VEGFB,VEGFC 














Figure 3-3: Significant annotated pathways that were altered in hypoxia and the number of genes 
supporting the significant changes. Benjamini-Hochberg factor of ≤ 0.05 was used to control the false 
discovery rate. The corresponding gene set in each annotated pathways are shown in Appendix 3, 
Appendix 4 and Appendix 5. 
 
3.2.3 Metabolomics profile of hypoxic MCF7 cells 
Based on the changes in GO and pathway enrichment demonstrated above, we evaluated 
whether these differences could translate into an alteration in cellular metabolism. We 
therefore first compared the steady-state metabolic profile of cells in normoxia and hypoxia 
as this provides an overview of the cellular metabolome. Using a 1H NMR metabolomics 
approach we obtained spectra that were used to conduct an unsupervised statistical analysis – 
a principal component analysis (PCA) - on the 1D proton spectra, averaged from 5 
experiments for each condition. 
 
The PCA results show a clear separation in the first principal component (PC1, Figure 3-4). 
This observation indicates that there are significant differences in the metabolite 
concentrations between these two groups. From the loadings plot of normoxic and hypoxic 
MCF7 cells, we identified 24 metabolites that are responsible for the separation between the 
two groups. Figure 3-5 shows the loadings plot of the metabolites contributing to the PC1 
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separation. To test for statistical significance for each metabolite, univariate statistic analyses 
were also conducted (Appendix 2). 
 
One disadvantage of PCA analysis is that it does not provide direct evidence of the metabolic 
pathways usage by the hypoxic cells. In order to try to understand how these changes in 
individual metabolites relate to individual metabolic pathways, the metabolites identities 
were mapped onto KEGG (Kanehisa and Goto 2000) pathway maps, and several potential 
pathways associated with metabolic profile alteration in hypoxia were identified (Figure 3-6 
and Table 3-2). 
 
Hypoxic MCF7 cells showed altered glucose metabolism. We were able to detect decreased 
glucose and increased lactate and alanine under hypoxic conditions. At the same time, in our 
experiments the concentration of some TCA cycle and associated metabolites such as 
glutamine and aspartate were found to be increased while the concentration of citrate, 
succinate and fumarate were not significantly changed in hypoxia.  
 
Higher concentrations of other ‘carbon backbone’ molecules such as acetate and formate 
were also detected in hypoxic MCF7 cells. The increase in the level of these metabolites 
could serve as the precursors of acetyl-CoA and fatty acids or ketone bodies. Furthermore, 







Figure 3-4: PCA scores plot of MCF7 cells in normoxia (+, n=5) and hypoxia (◊, n=5) after 48 hours. The 
normoxic and hypoxic samples displayed two clear clusters separated along PC1 which each could 







Figure 3-5: Loadings plot of principal component analysis of MCF7 cells with positive peaks representing 
metabolite which are higher concentration in hypoxia, and negative peaks corresponding to those 







Figure 3-6: Metabolites concentration identified using 1H-NMR spectroscopy for the polar extracts of 
MCF7 cells after exposure to normoxia or hypoxia for 48 hours. Each data ...(continued on next page)   
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point is the average ± SEM of five independent experiments. ‘*’ indicates results of a student’s unpaired 
two-tailed t-test (Appendix 2): *p <0.05; **p <0.01; ***p <0.001. ns = not significant. Abbreviations: 
acetyl-CoA (Ac-CoA), oxaloacetate (OAA) and alpha-ketoglutarate (α-KG). 
 
 
Table 3-2: A heatmap showing the log2 transformed fold changes of metabolites in hypoxia with respect 




3.2.4 Metabolomics flux analysis of hypoxic MCF7 cells 
From the metabolomics profile, we found that intracellular glucose concentrations were 
significantly reduced in hypoxia. The increased glucose usage and lactate production (Figure 
3-1) suggests a significant hypoxia-induced increase in glucose metabolism, in agreement 
with the literature (Wenger 2002, Semenza 2003, Kim, Hahn et al. 2004). We therefore used 
a stable isotope labelling strategy to more precisely investigate the fate of glucose in hypoxia, 
using NMR spectroscopy. To conduct this analysis, we incubated normoxic and hypoxic 
MCF7 cells with 10 mM [1,2-13C]glucose for between 1 to 24 hours, and subsequently 
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extracted the polar cellular metabolites. HSQC spectra were obtained from these extracts. An 
example of such spectrum, derived from a normoxic 3 hour extract, is shown in Figure 3-7. 
 
 
Figure 3-7: Example of a section of a HSQC spectrum obtained from normoxic MFC7 cells labelled for 3 
hours with [1,2-13C]glucose. 1H chemical shift (ppm) is on the horizontal axis and 13C chemical shift (ppm) 
in on the vertical axis.  
 
3.2.4.1 Global metabolic profiles of MCF7 cells from [1,2 -13C] glucose in hypoxia 
Despite earlier observations that hypoxic cells had mostly similar intracellular steady-state 
levels of metabolites to the normoxic cells, we noted an overall reduction in label 
incorporation from glucose into metabolites under these conditions. However, we observed 
enhanced labelling into lactate and alanine from [1,2-13C]glucose in hypoxia (assessed by 
incorporation of 13C into the C3 position of these metabolites, Figure 3-8), which is consistent 
with the steady-state metabolic and transcriptomic data suggesting increased glucose use. 
 
In normoxia, the incorporation of 13C into TCA cycle intermediates including succinate, 
glutamate, and aspartate, all of which showing increasing trends with time, indicates active 
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TCA cycle flux (Figure 3-8). However, in hypoxia, incorporation into metabolites in the TCA 
cycle was lower, indicating that in these conditions, flux from glucose into this pathway was 
reduced. This is also consistent with the transcriptomic data showing increased pyruvate 
dehydrogenase kinase 1 (PDK1) expression in Table 3-1, which inhibits pyruvate 
dehydrogenase (PDH) through phosphorylation, and thereby decreases pyruvate oxidative 
metabolism. 
 
Interestingly, label incorporation into metabolites related to the TCA cycle, such as glutamate 
and aspartate, was sustained in hypoxia suggesting the reduced activity the of TCA cycle 
could be compensated by additional anaplerotic metabolic reactions from glucose. In 
particular, when evaluating the carbon labelling in glutamate, the C4 labelling as an indicator 
of PDH activity was lower in hypoxia, but C2 and C3 labelling was maintained. This 
suggests that different metabolic pathway(s) which originate from glucose become more 
active, resulting in the sustained 13C labelling of aspartate and glutamate at C2 and C3 in 
hypoxia (Figure 3-8). Labelling into glutamine from the two conditions did not reach 






Figure 3-8: Glucose metabolism of MCF7 cells in normoxia and hypoxia using [1,2-13C]glucose as 
labelling source. The amount of 13C carbon incorporation at 1 hour, 3 hours, ... (continued on next page)  
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6 hours and 24 hours for each detected metabolites is plotted for both normoxia (denoted as Nor) and 
hypoxia (denoted as Hy). Each data point is the average ± SEM of three independent experiments. ‘*’ 
indicates results of a student’s unpaired two-tailed t-test comparing normoxia to hypoxia at each time 
point , *p <0.05; **p <0.01. Abbreviations: acetyl-CoA (Ac-CoA), oxaloacetate (OAA), and alpha-
ketoglutarate (α-KG). 
 
3.2.4.2 13C isotopomer distribution (CID) to determine 13C metabolic fluxes 
While the site specific 13C enrichment originates from the propagation of a labelled precursor, 
the isotopomer distribution provides information about the breakdown or formation of 13C to 
13C linkages in the metabolic network. These data are required for estimating the distribution 
of carbon fluxes in metabolic networks. Using [1,2-13C]glucose as substrate, the isotopomer 
distribution of lactate could be used as a readout of label distribution by glycolysis and 
recycling of 13C label via the non-oxidative PPP branch (Figure 1-11 and Figure 3-9). 
Detecting from the C3 multiplets of lactate in a HSQC spectrum, [1,2-13C]glucose 
metabolised though glycolysis would produce a 13C doublet - [2,3-13C]lactate, while if 
diverted through the PPP would yield a 13C singlet from [3-13C]lactate and [1,3-13C]lactate 
(Figure 1-9, Figure 1-10, Figure 1-11 and Figure 3-9). 
 
The 13C label arising from glucose gets incorporated into pyruvate and from there can be 
metabolised in the TCA cycle through either oxidative decarboxylation by the PDH to 
produce acetyl-CoA, or by carboxylation by via pyruvate carboxylase (PC) to produce 
oxaloacetate. Both the actions of PC and PDH can theoretically occur simultaneously, and 
thus the 13C labelled metabolites may reflect the combined effect of both pathways as 
demonstrated in Figure 3-10.  
 
From [1,2-13C]glucose the [2,3-13C]pyruvate produced by glycolysis would produce [4,5-
13C]glutamate if oxidised by PDH on the first pass whereas, if carboxylated by PC, the same 
pyruvate isotopomer would produce [2,3-13C]glutamate (Figure 1-12). The labelling patterns 
can then become more complex if the 13C labelled metabolites pass through several turns of 
the TCA cycle (Figure 3-10 to Figure 3-15). The two symmetrical TCA cycle molecules, 
succinate and fumarate further exacerbate the complexity of 13C labelling in the TCA cycle: 
asymmetric labelling is symmetrised on passing through those molecules and therefore 
doubles the potential isotopomers once the label passes back into an asymmetric molecule 
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such as malate. Despite the complexity of label distribution in mammalian systems, analysing 
individual multiplet signals can identify unique labelling fluxes arising from different 
pathways. As illustrated in Figure 3-10, if PC is active [2,3-13C]glutamate appears as early as 
the first round of the TCA cycle, whereas if PC is not active, [2,3-13C]  glutamate does not 
appear until the third round  (Cheng, Sudderth et al. 2011).  
 
Analysing CID of glutamate C4 could be used to follow the PDH activity. If [1,2-13C]glucose 
is metabolised via PDH (Figure 1-12), [2,3-13C]pyruvate forms [1,2-13C]acetyl-CoA (Ac-
CoA). Upon condensation of labelled acetyl-CoA with unlabelled oxaloacetate, [1,2-
13C]citrate is formed. This isotopomer of citrate once converted to glutamate through α-
ketoglutarate will always form a molecule labelled in the C4 and C5 positions. Hence, 
analysing the extent of [4,5-13C]JC4C5 glutamate multiplets at C4 glutamate can reveal PDH 
activity (Figure 3-10 to Figure 3-15).  
 
To deconvolute the various 13C isotopomers present in the complex multiplets from the 13C-
dimension of HSQC spectra, we carried out CID analysis.  For example, the analysis of the 
CID of glutamate C2 can be used to reveal PC activity when analysing the [2,3-13C]JC2C3 
glutamate signal. By following the time dependent evolution of unique isotopomer species of 
metabolites produced from 13C-glucose, we can probe the overall rate of the metabolic 
pathway(s) involved. We therefore resolved unique isotopomer patterns of downstream 
metabolites to determine distinctive isotopomer species at various time points to provide an 
‘isotopomer fingerprint’, characteristic of specific metabolic pathways.  
 
Multiplet analysis was performed using a quantum mechanical simulation of the indirect 
dimension of the HSQC spectrum. This is part of the 'hsqcMA' software developed by Dr 
Christian Ludwig (Ludwig and Gunther 2011). To obtain a reasonable simulation speed, the 
simulation was performed as a 1D 13C spectrum simulation. A spin-echo to account for J-
coupling evolution during the echo/anti-echo gradient was used to generate the py-gamma 
spectrum. This lead to the non-absorptive line shape observed in the experimental spectra. 
For the fitting to proceed, a user defined spin system was required. This pre-defined input file 
required information such as the possible isotopomers, chemical shift and J-coupling. A 
simplex algorithm was used to find the global optimum as the end point of the simulation. 
However, manual inspection is always recommended to ensure a good match between the 




The feasibility of using CID analysis to deconvolute various 13C isotopomers was 
demonstrated using glutamate C2 signals from a cell extract sample which was labelled with 
[1,2-13C]glucose for six hours (Figure 3-16). To obtain good results, the possible isotopomers 
and their respective chemical shifts as well as J-coupling constants have to be well defined. 
The possible isotopomers would be ≤ 4 (example for C2 of glutamate: 12C1-13C2-12C3-
12C4-12C5, 13C1-13C2-12C3-12C4-12C5, 12C1-13C2-13C3-12C4-12C5 and 13C1-13C2-
13C3-12C4-12C5) due to the 1J13C -13C coupling arising from a 13C-HSQC spectrum. The 
chemical shifts can usually be determined quite well through manual peaks picking as high 
resolution spectrum were acquired (1024 x 4096). Although a 16K data points 13C-HSQC 
spectrum can generate very well resolved peaks that help to ensure good quality fitting results 
through manual identification of individual isotopomers, it is not a feasible solution as the 
measurement time for each of these spectrum would be about 16 hours. Therefore a 16K data 
points spectrum for one of the sample was first used to conduct a simulation and obtain a 
good fitting results (i.e. all isotopomers can be clearly identified and adjusted to match with 
experimental spectrum). The resultant Jcc coupling constants were then chosen as subsequent 
fitting analysis which used the spectrum acquired at 4K data points. Comparing to the 16K 
spectrum, the 4K spectrum causes some signals to merge together (for example: [2.3-
13C]glutamate and [1,2-13C]glutamate were not resolved in Figure 3-16b). However, with a 
good initial pre-defined spin system (assisted by Jcc coupling constants obtained from the 
16K spectrum) the 4K data also generated very similar results compared to the 16K spectrum 
(for example: the fractions of isotopomers were similar between simulation using the 16K 
and 4K spectrum Figure 3-16). 
 
Depending on the signal-to-noise ratio, the fitting procedure could detect label multiplet 
components from about 0.5% contribution to the entire multiplet reliably, if the signal-to-
noise ratio of this multiplet component was at least 2:1. An example is shown in Figure 3-17 
where the [3-13C]lactate signal which is next to a much larger signal ([2,3-13C]lactate). This 
isotopomer can nevertheless be distinguished at a level as low as 0.5% (purple spectrum in 
Figure 3-17) with respect to the entire lactate C3 signals and therefore it is capable to detect 




Time series experiments were conduct for the MCF7 cells in normoxia and hypoxia. Since 
specific isotopomers can be used to follow the 13C metabolic flux of various metabolic 
pathways, simulations were conducted to determine the 13C % for these isotopomers. For a 
specific isotopomer, a plot was made for their 13C percentage at various time points. Such 
time series experiment typically has an analytical solution in the form of an exponential 
function. Although there are two variable parameters (a rate constant and a plateau value), 
these values can be obtained by numerically fitting data from the CID measurements. This is 
based on the assumption that the build-up follows a first order kinetics. When the resulting 
plots of labelled isotopomers versus time follow a single exponential saturation curve, the 
flux of their associated reaction can be estimated by multiplying the rate constant by the pool 







Figure 3-9: Labelling patterns from [1,2-13C]glucose resulting from the pentose phosphate pathway (PPP) 
and glycolysis activity. The circles symbolise the carbon backbone of the molecules numbered from left to 
right. Black circles mark the position of 13C labelled. Three molecules of [1,2-13C]glucose produce three 
molecules of [2,3-13C]lactate (through glycolysis), one molecule of [3-13C] lactate (through PPP) and one 





Figure 3-10: Labelling patterns from [1,2-13C]glucose resulting from pyruvate carboxylase and pyruvate 
dehydrogenase to derive labelled glutamate during several rounds of the ... (continued on next page)  
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TCA cycle. Examples for the derivation of labelled glutamate ((a)-(n)) are shown in Figure 3-11 to Figure 
3-15. Green filled circles mark the position of 13C labelled carbon derived from PC activity and orange 
filled circles indicate the position of 13C derived only from PDH activity. The carbons numbering of 






Figure 3-11: Detailed labelling schemes showing molecules (a) to (c) for labelled glutamate in Figure 3-10 
resulting from pyruvate carboxylase and pyruvate dehydrogenase when MCF7 cells are fed with [1,2-
13C]glucose. Green filled circles mark the position of 13C labelled carbon derived from PC activity and 
orange filled circles indicate the position of 13C derived only from PDH activity. The carbons numbering 





Figure 3-12: Detailed labelling schemes showing molecules (d) to (e) for labelled glutamate in Figure 3-10 
resulting from pyruvate carboxylase and pyruvate dehydrogenase when MCF7 cells are fed with [1,2-
13C]glucose. Green filled circles mark the position of 13C labelled carbon derived from PC activity and 
orange filled circles indicate the position of 13C derived only from PDH activity. The carbons numbering 






Figure 3-13: Detailed labelling schemes showing molecules (g) to (i) for labelled glutamate in Figure 3-10 
resulting from pyruvate carboxylase and pyruvate dehydrogenase when MCF7 cells are fed with [1,2-
13C]glucose. Green filled circles mark the position of 13C labelled carbon derived from PC activity and 
orange filled circles indicate the position of 13C derived only from PDH activity. The carbons numbering 







Figure 3-14: Detailed labelling schemes showing molecules (j) to (l) for labelled glutamate in Figure 3-10 
resulting from pyruvate carboxylase and pyruvate dehydrogenase when MCF7 cells are fed with [1,2-
13C]glucose. Green filled circles mark the position of 13C labelled carbon derived from PC activity and 
orange filled circles indicate the position of 13C derived only from PDH activity. The carbons numbering 







Figure 3-15: Detailed labelling schemes showing molecules (m) and (n) for labelled glutamate in Figure 
3-10 resulting from pyruvate carboxylase and pyruvate dehydrogenase when MCF7 cells are fed with 
[1,2-13C]glucose. Green filled circles mark the position of 13C labelled carbon derived from PC activity 
and orange filled circles indicate the position of 13C derived only from PDH activity. The carbons 
numbering of metabolites starts from left to right. Abbreviations: acetyl-CoA (Ac-CoA), oxaloacetate 




Figure 3-16: Examples of fitted isotopomers using a 16K (A) and a 4K (B) 13C-HSQC spectrum for an 
extract of cells exposed to [1,2-13C]glucose for 6 hours. The experimental spectrum is in blue and the 
fitted spectrum is in red. The simulation was first conducted using a 13C-HSQC spectra acquired with 
16384 increments in the indirect dimension (A) to determine the Jcc coupling constants. Using the same 
Jcc coupling constants, subsequent simulations were conducted using 13C-HSQC spectra acquired with 




Figure 3-17: Overlays of 13C slices of lactate C3 signals with different contributions of the faction of [3-
13C]lactate isotopomer showing that the fitting process can detect labelled multiplet components from 
about 0.5% contribution to the entire multiplet reliably. The 13C slices were projections from 13C-HSQC 





Figure 3-18: The concepts of CID analysis. At individual time points, depending on which branch point 
the labelled precursors has propagated, the proportion of various isotopomers varies. The drawing 
represent each time points symbolised various possible branch points for 13C label. The resultant plot is a 
build-up curve of a specific 13C% labelled isotopomer. The changes of 13C% labelled isotopomer usually 
is a first order kinetics that has few free parameters ( i.e. rate constant and plateau values). Since 
metabolic flux describes the rate of production of a metabolite in a biological system, that would be equal 
to the rate constant multiplied by the plateau.  
  
3.2.4.2.1 Estimating fluxes from lactate CID analysis for glycolysis activity 
As previously described, the kinetics of the evolution of [2,3-13C]JC2C3 lactate originating 
from [1,2- 13C]glucose can be used to directly probe glycolytic flux (Section 1.6.2 and Figure 
3-9). Figure 3-19 shows the time course for C2 of [2,3-13C]JC2C3 lactate label incorporation in 
MCF7 cells in normoxia and hypoxia derived from CID analysis. All fittings of the [2,3-
13C]JC2C3 isotopomer were conducted using  JC2C3 coupling constant of 36.7 Hz (determined 
from the 16K spectrum) at carbon 3 of lactate using a 13C-HSQC spectrum acquired at 1024 x 
4096 data points. The result of the CID analysis fitted using an exponential saturation model 










Figure 3-19: Time course of [2,3-13C]JC2C3 lactate label incorporation at C2 for MCF7 cells grown in 
normoxia and hypoxia in the presence of [1,2-13C]glucose with each time points consisting of 3 biological 
replicates. Each of the data points corresponds to the C2 of [2,3-13C]JC2C3 lactate fraction determined 
from the CID analysis and multiplied by the pool size of C2 (lactate C2 13C site specific labelling 
percentage). 
  























Table 3-3: Results for fitting an exponential saturation curve to the build-up of the C2 of [2,3-13C]JC2C3 
lactate reflects glycolytic flux in normoxia and hypoxia. The best fit of the data yields a plateau value and 
the rate constant k of glycolytic flux for each of the conditions.  
Model   Exponential saturation  
Y= Y0 +  
(Plateau-Y0)*(1 - exp(-k*(X-X0))) Normoxia  Hypoxia  
Best-fit values     
Y0 = 1.00 = 1.00 
Plateau (a) [13C-lactate %] 17.5 22.8 
k (b) [hr -1] 0.43 0.42 
Tau (or 1/k) [hr] 2.31 2.37 
Span (Plateau - Y0) [13C-lactate %] = -16.5 = -21.8 
Flux through [2,3-13C]JC2C3 lactate = 
(a*b) 
[13C % hr-1] 7.60 9.62 
   
Standard error     
Plateau 1.37 1.98 
k 0.11 0.12 
   
Goodness of fit     
R square 0.60 0.54 
 
 
3.2.4.2.2 Estimate fluxes from Lactate CID analysis for PPP activity 
As previously described in Figure 1-11 and Figure 3-9, recycling of carbon from non-
oxidative PPP flux can be inferred from the build-up rate of the [3-13C]singlet lactate signal that 
originates from [1,2-13C]glucose labelling (Lee, Boros et al. 1998). The most probable way to 
get enrichment from [1,2-13C]glucose into the [3-13C]singlet lactate is via PPP (Figure 3-9) and 
the time course evolution of the [3-13C]singlet lactate originating from [1,2-13C]glucose is 
shown in Figure 3-20. All fittings of the [3-13C] singlet lactate isotopomer were conducted 
using JC2C3 coupling constant of 36.7 Hz (determined from the 16K spectrum) at carbon 3 of 
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lactate using a 13C-HSQC spectrum acquired at 1024 x 4096 data points. Approximating the 
build-up data by a single exponential saturation model yields the rate constant for PPP as 
tabulated in Table 3-4. Comparing the best-fit values for both the rate constant k and plateau 
value in hypoxia and normoxia shows that PPP flux is higher in the (more malignant) 
hypoxic MCF7 cells.   
 
 
Figure 3-20: Time course evolution of the [3-13C]singlet lactate for MCF7 cells maintained in normoxia and 
hypoxia following the labelling of [1,2-13C]glucose with each time points consisting of 3 biological 
replicates. Each of the data points corresponds to the fraction of the [3-13C]singlet lactate determined from 
the CID analysis multiplied by the pool size of C3 (lactate C3 13C site specific labelling). 
  























Table 3-4: The analytical fitting solution for [3-13C]singlet lactate % reflects PPP flux. Values were obtained 
by approximating an exponential saturation binding model in normoxia and hypoxia. The best fit values 
of the rate constant k and the plateau value is indicative of the PPP flux for each of the conditions. 
Model  Exponential saturation  
Y= Y0 +  
(Plateau-Y0)*(1 - exp(-k*(X-X0))) Normoxia  Hypoxia  
Best-fit values   
Y0 0.53 1.37 
Plateau (a) [13C-lactate %] 1.28 3.19 
k (b) [hr -1] 0.077 0.12 
Tau (or 1/k) [hr] 12.9 8.00 
Span (Plateau - Y0) [13C-lactate %] -0.75 -1.81 
Flux through [3-13C]singlet lactate = (a*b) 
[13C% hr-1] 0.10 0.40 
   
Standard error     
Plateau  0.30 0.52 
k 0.080 0.12 
   
Goodness of fit     
R square 0.66 0.52 
 
 
3.2.4.2.3 Estimated fluxes from Glutamate CID analysis for PDH activity 
Metabolism of labelled glucose via the TCA cycle is depicted in Figure 3-10 to Figure 3-15. 
Metabolism of [1,2-13C]glucose to glutamate through PDH activity and transamination of α-
KG results in the production of  [4,5-13C]JC4C5 glutamate. As previously stated, this specific 
labelling pattern of glutamate allows the examination of PDH activity (Malloy, Sherry et al. 
1988, Zwingmann, Leibfritz et al. 2003). Figure 3-21 shows the time course of the C4 signal 
in [4,5-13C]JC4C5 glutamate in normoxia and hypoxia, by performing the CID analysis. All 
fittings of the [4,5-13C]JC4C5 isotopomer were conducted using JC4C5 coupling constant of 
52.5 Hz and JC2C3 coupling constant of 34.0 Hz (determined from the 16K spectrum) at 
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carbon 4 of glutamate using a 13C-HSQC spectrum acquired at 1024 x 4096 data points. 
Approximating the build-up data by a single-exponential saturation curve yields the time 
constant (k) and label incorporation (in %) when approaching the steady-state (plateau) for 
PDH (Table 3-5). Evaluating from the best-fit values for rate constant k and plateau value 




Figure 3-21: Time course evolution of C4 of [4,5-13C]JC4C5 glutamate % for MCF7 cells cultured in 
normoxia and hypoxia following labelling with [1,2-13C]glucose with each time points consisting of 3 
biological replicates. Each of the data points corresponds to the fraction of the C4 doublet of [4,5-13C]JC4C5 
glutamate determined from CID analysis multiplied by the pool size of C4 (glutamate  C4 13C site specific 
labelling). 
  

























Table 3-5: The analytical fitting solution for C4 of [4,5-13C]JC4C5 % glutamate reflects PDH flux by 
approximating a single exponential saturation binding model in normoxia and hypoxia. The resulting 
best-fit values of plateau value and k (rate constant) give the PDH flux for each of the condition. 
Model  Exponential saturation  
Y= Y0 +  
(Plateau-Y0)*(1 - exp(-k*(X-X0))) Normoxia  Hypoxia  
Best-fit values     
Y0 0.98 6.75e-013 
Plateau (a) [13C-glutamate %] 4.69 1.13 
k (b) [hr -1] 0.30 0.41 
Tau (or 1/k) [hr] 3.3 2.4 
Span (or Plateau - Y0) [13C-glutamate %] -3.71 -1.13 
Flux through [4,5-13C] JC4C5 glutamate  
= (a*b) [13C% hr-1] 1.44 0.46 
   
Standard error     
Plateau 0.51 0.19 
k 0.16 0.33 
   
Goodness of fit     
R square 0.71 0.52 
 
 
3.2.4.2.4 Estimated flux from glutamate CID analysis for PC activity 
As demonstrated in Figure 3-10, one of the major anaplerotic pathways for pyruvate entry 
into the TCA cycle is via PC (Malloy, Sherry et al. 1988).  The flux through PC can be 
estimated by the rate of formation of the [2,3-13C]JC2C3 glutamate doublet following [1,2-
13C]glucose labelling (Zwingmann, Leibfritz et al. 2003). CID analysis was carried out for the 
C2 signal of glutamate to reveal the population of molecules with the [2,3-13C]JC2C3 glutamate 
doublet. Figure 3-22 shows the time course for the generation of the C2 doublet of [2,3-
13C]JC2C3 glutamate in normoxia and hypoxia. All fittings of the [2,3-13C]JC3C3 isotopomer 
were conducted using JC2C3 coupling constant of 34.0 Hz and JC4C5 coupling constant of 51.5 
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Hz (determined from the 16K spectrum) at carbon 2 of glutamate using a 13C-HSQC 
spectrum acquired at 1025 x 4096 data points. Approximation of the reaction data by a single 
exponential saturation model yields the time constant and plateau for PC as tabulated in Table 
3-6. Evaluating from the best-fit values of rate constant k and plateau, the PC flux in 
normoxia is around one-third that under hypoxia. 
 
 
Figure 3-22: Time course evolution of the C2 doublet of [2,3-13C]JC2C3 glutamate % for MCF7 cells 
cultured in normoxia and hypoxia following the labelling of [1,2-13C]glucose with each time points 
consisting of 3 biological replicates. Each of the data points corresponds to the fraction of the C2 of [2,3-
13C]JC2C3 glutamate determined from CID analysis multiplied by the pool size of C2 (glutamate  C2 13C 
site specific labelling). 
  


























Table 3-6: The analytical fitting solution for C2 of [2,3-13C]JC2C3 glutamate % reflects PC flux by 
approximating a single exponential saturation binding model in normoxia and hypoxia. The best-fit 
values of plateau value and k (rate constant) give the PC flux for each of the two conditions. 
Model  Single exponential saturation  
Y= Y0 +  
(Plateau-Y0)*(1 - exp(-K*(X-X0))) Normoxia  Hypoxia  
Best-fit values   
Y0 1.31e-016 0.067 
Plateau (a) [13C %] 0.71 1.88 
k (b) [hr -1] 0.30 0.37 
Tau (or 1/k) [hr] 3.38 2.67 
Span (or Plateau - Y0) [13C-glutamate%]  -0.71 -1.81 
Flux through [2,3-13C]JC2C3  glutamate  
= (a*b) [13C% hr-1] 0.21 0.70 
   
Standard error     
Plateau 0.05 0.20 
k 0.10 0.22 
   
Goodness of fit     
R square 0.87 0.57 
 
 
3.2.5 Integrating metabolomics flux data and gene expression  
Glycolysis and PPP appeared to be significantly altered at the level of both gene expression 
analysis and metabolomics flux analysis (Section 3.2.2 and Section 3.2.4). We therefore 
attempted to match our results from both sections. A numerical correlations between the two 
platforms were not available, therefore we manually compared the genes expression that were 
significantly changed to the 13C metabolic flux results with reference to KEGG annotated 
metabolic pathways. Comparison of the mapped pathways from transcription analysis 
coincided with the differences in metabolomic flux pathways (Appendix 3, Appendix 4 and 
Appendix 5). The gene expression changes were associated with upregulation in glycolysis 
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and PPP are correlated with the MFA results (Figure 3-23). Thus, gene expression data 
supported the significant changes in glycolysis and PPP in hypoxia, as was suggested by the 
metabolomics flux analyses. Even though we detected the upregulation only of PDK1 mRNA 
expression in hypoxia, in agreement with flux results we found a decrease in PDH expression 
in hypoxia. The alternate carbon flux in the TCA cycle was detected by PC flux in hypoxia 
although the gene expression of PC was not significantly changed in hypoxia. 
 
 
Figure 3-23: Differential gene expression data correlates with metabolomic flux changes associated with 
glycolysis and PPP for MCF7 cells under (A) normoxic and (B) hypoxic conditions. Gene names 
highlighted in red boxes had significantly increased values in gene expression. Conversely, the 
significantly decreased levels are highlighted in yellow boxes and the not significantly changed values are 
in grey boxes. The green coloured areas represent metabolic fluxes in normoxia and hypoxia. The size of 




3.2.6 Attempting to understand flux results from biochemical analysis 
With a lower proliferation rate of MCF7 cells in hypoxia we sought to understand the higher 
PPP flux of MCF7 cells in hypoxia. In contrast to the metabolic tracer analysis, the gene 
expression data showed significantly lower G6PD (glucose 6 phosphate dehydrogenase) 
expression in hypoxia (Figure 3-23). G6PD is a rate limiting enzyme for the PPP pathway 
which is responsible for oxidising glucose 6-phosphate into 6-phosphogluconolactone and 
producing reduced nicotinamide adenine dinucleotide (NADPH) (Eggleston and Krebs 1974). 
NADPH negatively modulates the activity of G6PD. Depending on the cell requirements, 
NADPH can be utilised for anabolic reactions as well as maintaining cellular redox 
homeostasis. In highly NADPH-consuming cells such as cancer cells, G6PD has previously 
been shown to be overexpressed (Jonas, Benedetto et al. 1992, Wang, Yuan et al. 2012, 
Tsouko, Khan et al. 2014). Moreover, because of the need to adapt to a stressful environment 
such as hypoxia, the pentose phosphate pathway has been suggested to promote cancer 
progression and therapy resistance (Boros, Brandes et al. 1998, Ramos-Montoya, Lee et al. 
2006).  
 
In the experiments described here, the protein levels of G6PD in normoxia and hypoxia were 
similar according to western blots (Figure 3-24). We therefore postulated that post-
translational regulation of G6PD might contribute to the higher PPP flux in hypoxia. We used 
microscopy to explore potential differences in enzyme localisation that might explain the 
higher activity of the PPP but lower gene expression of G6PD in hypoxia. Interestingly, by 
electron microscopy it has been shown that G6PD is localised to the ribosomes of the 
granular endoplasmic reticulum, at the periphery of peroxisomes, in the cytoplasm and in the 
matrix of mitochondria (Frederiks and Vreeling-Sindelarova 2001, Mailloux and Harper 
2010). Since hypoxia often modulates mitochondrial oxidative metabolism, we stained the 
mitochondria of MCF7 cells with MitoTracker Orange for immunofluorescence analysis 
(Figure 3-25). These experiments suggested that G6PD could be localised to both 
mitochondria and cytoplasm in normoxia and hypoxia. However further confirmation with 
electron microscopy is required to better resolve the morphology of mitochondria and cellular 
localisation of G6PD. 
 
We also confirmed the localisation of a pool of G6PD as mitochondrial by western blotting in 
normoxia. We isolated the mitochondria by differential centrifugation and extracted proteins 
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from this compartment and the cytosol. Immunoblotting for G6PD revealed that it was 
observed in both the mitochondria and cytosol (Figure 3-26A). The isolated mitochondrial 
samples were also validated by the mitochondrial marker - VDAC (voltage-dependent anion 
channels) (Figure 3-26B) and cytosolic marker – AKT (Figure 3-26C). In order to assess 
whether G6PD was only associated with the outer leaflet of the mitochondria, or was an 
integral part of the mitochondrial membrane or matrix we disrupted the mitochondrial 
membrane stability by alkaline wash (Fujiki, Hubbard et al. 1982) to separate the 
mitochondrial matrix (including potential integrated membrane proteins) from the 
mitochondrial outer membrane. Blotting for G6PD showed that G6PD was not loosely 
associated with the mitochondrial outer membrane, but was either in the mitochondrial matrix 
or an integral part of one of the membranes (Figure 3-26B), consistent with recent work 
suggesting that cells rely on G6PD within the mitochondrial matrix under high glucose 
environment (Mailloux and Harper 2010).  
 
The isolation of mitochondria was performed under normoxia but corresponding data 
obtained under hypoxia are not available at the present moment. This is due to the inability to 
house a homogeniser in a hypoxic station for isolating the mitochondria. Nevertheless, from 
the immunofluorescence microscopic analysis (Figure 3-25), the G6PD localisation in 
hypoxic MCF7 cells appeared similar to that of normoxic cells and a subset of G6PD was 
again localised to the mitochondria. It is important to note that other enzymes in addition to 
G6PD are also required for PPP. Some of these additional enzymes may also be localised in 
the mitochondrial matrix. We therefore conducted native PAGE analysis of isolated 
mitochondria aiming to resolve native proteins or protein complexes that were acting in 
parallel as G6PD in the mitochondria.  
 
To identify other associated enzymes we first resolved the protein complexes in the 
mitochondrial membrane by native PAGE gel. The protein complexes can be visualised from 
the separated bands of native PAGE gel in Figure 3-27. To identify the protein complexes 
linked to G6PD, we cut the resolved protein complexes from a single lane of the native 
PAGE gel, denatured them in lithium dodecyl sulfate (LDS) sample loading buffer under 
reducing conditions before resolving the protein complexes by reducing denaturing gel 
electrophoresis. Once again, we immuno-blotted for G6PD to identify the protein complex 
that also contained G6PD. As shown in Figure 3-27, the most probable protein complex that 
contained G6PD had a molecular mass of ~440kDa. In parallel, the complex of interest 
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(440kDa) was excised from a Native PAGE for mass spectrometry analysis to identify G6PD 
bound protein complexes that were localised in mitochondria. However, the initial mass 
spectrometry analysis was not successful, as G6PD could not be identified from the excised 
band (data not shown here). Further detailed analysis of protein association is essential to 
characterise the novel G6PD associated supermolecular complex in the mitochondrial matrix. 
 
 
Figure 3-24: Expression of G6PD of MCF7 cells in hypoxia and normoxia with each conditions consist of 








Figure 3-25: Immunofluorescent colocalisation of G6PD in mitochondria for fixed MCF7 cells in 
normoxia and hypoxia with each conditions consist of 2 biological replicates. The normoxic and hypoxic 
MCF7 cells were stained with MitoTracker probe (rosamine based MitoTracker probes) and rabbit anti-
G6PD antibody, followed by anti-rabbit AlexaFluor 488 conjugated secondary antibody. Green 








Figure 3-26: Colocalisation of G6PD of MCF7 cells by western blotting in normoxia with each conditions 
consist of 2 biological replicates. (A) Immunoblot analysis of G6PD, VDAC and AKT level in cytosol and 
mitochondria. (B) Mitochondria disrupted by alkaline wash (0.1M Na2CO3 pH 11.5)  for separating 
mitochondrial outer membrane and mitochondrial matrix was immuno-blotted for G6PD. Each protein 






Figure 3-27: Native PAGE gel of isolated mitochondria of normoxic MCf7 cells consist of G6PD-
containing protein complex. (A) Resolved protein complexes from isolated mitochondria on 4-16% Native 
PAGE gel stained with Coomassie R-250 using 200 μg protein loading. (B)Western blot of isolated 
mitochondria of MCF7 cells after resolving with Native PAGE. G6PD western blot for an isolated 
mitochondrial lane from Native PAGE. The arrowhead indicates the most probable G6PD-containning 
protein complex and corresponds to a complex of molecular weight ~440kDa. The native PAGE gel and 
the protein target were conducted with two independent experiments and showed similar results (one set 







A metabolomic study of a hypoxic luminal breast cancer cell line was carried out by 
integrating information obtained from gene expression, metabolite steady-state levels and 
metabolomics flux analysis. By exposing the MCF7 cells to hypoxic conditions, the luminal 
breast cancer cells displayed the key metabolic features of hypoxia in terms of energy source 
usage. Under hypoxia, the MCF7 cells increased the uptake of glucose and produced higher 
levels of lactate (Figure 3-1). This phenomenon is ubiquitous in hypoxia (Semenza, Roth et 
al. 1994, Iyer, Kotch et al. 1998), and was first observed by Louis Pasteur who demonstrated 
that glucose flux was reduced in the presence of oxygen (Krebs 1972, Nelson 2008). In our 
present model, the reduced oxygen level of hypoxia did not affect the consumption of 
glutamine. This is in contrast to ER-negative and basal-like breast cancer tumour studies, 
which have reported the accumulation of 2-hydroxyglutarate and reduced levels of glutamine 
(Terunuma, Putluri et al. 2014). However, our findings are consistent with studies on luminal 
subtype breast cancer cell lines which are independent of glutamine for survival (Kung, 
Marks et al. 2011). 
 
The distinct metabolic differences of hypoxic versus normoxic MCF7 cells are well reflected 
in gene expression analysis. Thus, when we overlaid the significantly increased genes 
expressed in hypoxic MCF7 cells on KEGG pathways, we found that glycolysis, fructose 
metabolism and PPP as part of the glucose metabolism were again identified as significantly 
upregulated (Figure 3-3). Moreover, the significantly changed biological processes from the 
gene ontology analysis are mostly related to glycolysis, anti-apoptosis, anti-proliferation and 
chemotaxis (Table 3-1). The genome level analysis again reinforces the importance of 
glucose metabolism in hypoxia and its lower proliferative phenotype. The transformation of 
MCF7 cells in hypoxia can be explained by a subtype independent 'go or grow' model, where 
tumour cells decrease their proliferation rates as they increase their metastatic capability 
(Hatzikirou, Basanta et al. 2010, Jerby, Wolf et al. 2012). By simply switching into hypoxia 
metabolism, the MCF7 cells decrease their proliferation rate in order to exploit the enhanced 




Steady-state levels of 24 metabolites measured by NMR clearly separated the normoxic and 
hypoxic MCF7 cells using an unsupervised multivariate statistical analysis (PCA). Following 
varied chemical shifts under hypoxic and normoxic conditions, we observed a switch from 
oxidative to glycolytic metabolism under hypoxic conditions.  Steady-state metabolomics and 
gene expression data suggest that hypoxic MCF7 cells reprogram glucose metabolism 
through the activation of LDHA and PDK1 (pyruvate dehydrogenase kinase 1) thereby 
producing higher levels of lactate while inhibiting the oxidation of pyruvate to acetyl-CoA 
for entry into the TCA cycle.  
 
We did not observe significant changes in the concentration of TCA cycle metabolites but 
observed significantly increased levels of intracellular glutamine (Figure 3-6). The higher 
concentration of intracellular glutamine in hypoxia could be due to an increase in glutamine 
production, increased glutamine uptake or the decrease in glutamine usage by hypoxic cells. 
Interestingly, we observed higher concentrations of aspartate in hypoxic MFC7 cells - a 
readout of oxaloacetate concentration for pyruvate carboxylation (Merritt, Harrison et al. 
2011). Also, there were increased intracellular levels of essential amino acids suggesting 
either a higher degree of protein degradation under hypoxic conditions which could be an 
outcome of hypoxia induced autophagy - a possible mechanism to trigger cell survival 
(Bellot, Garcia-Medina et al. 2009), or an increased uptake of amino acids from the 
intracellular environment. Interestingly, the concentration of taurine and glutathione were 
increased in hypoxia, potentially as an adaptive response to have higher concentration of 
these molecules to cope with the hypoxic and higher ROS microenvironment (Amano, 
Maruyama et al. 2003, Oh, Dong et al. 2008). Previous studies have shown that taurine and 
glutathione could both serve as osmoregulators and antioxidants (Jong, Azuma et al. 2012).   
 
Knowing that glucose metabolism is upregulated in hypoxic MCF7 cells, we continued our 
quest to identify metabolic adaptation by performing [1,2-13C]glucose flux analysis. Probing 
build-up rates of [2,3-13C]JC2C3 lactate, we found a higher glycolytic flux in hypoxic MCF7 
cells. By following the evolution of [3-13C]lactate, we unexpectedly found higher flux of PPP 
through measuring flux of this isotopomer at carbon 3 of lactate (Figure 3-20). We 
hypothesised that the hypoxic MCF7 cells may have shifted the function of the oxidative PPP 
from production of ribose for proliferation to the production of redox equivalents in the form 
of NADPH through the recycling of ribose 5-phosphate back into the glycolysis pathway. A 
similar observation was reported in drug resistant BCR-ABL transformed cells where the 
112 
 
imatinib-resistant chronic myeloid leukemia cells also have an increased rate of glycolysis, 
higher expression of non-oxidative PPP enzyme but a decreased rate of proliferation (Zhao, 
Mancuso et al. 2010). This seemingly wasteful process could be a beneficial mechanism for 
MCF7 cells to survive in a hypoxic microenvironment. F6P, the downstream product of PPP, 
could regenerate by isomerisation into G6P, and subsequently re-enter the PPP to produce 
more NADPH. The higher NADPH could serve to scavenge ROS, enhancing the ability of 
MCF7 cells to survive in their pro-oxidant environment, as has also been demonstrated in 
multiple studies (Abid, Kachra et al. 2000, Anastasiou, Poulogiannis et al. 2011). At the same 
time, the non-oxidative arm of the PPP could channel the end products (F6P and G3P) back 
into glycolysis and still permit some ATP generation. By increasing glucose degradation and 
suppressing proliferation in hypoxia, the net effect could be to adjust the cellular demand 
under stress and generate additional NADPH. But, whether the high flux through glycolysis 
and non-oxidative PPP is specific to MCF7 cells or is a common phenomena for early 
carcinoma stage breast cancer in hypoxia remains to be elucidated. [1,2-13C]glucose flux 
analysis using other breast cancer cells lines representing stages of human breast cancers 
would help to understand the metabolic pathways alteration of human breast cancer in 
hypoxia. 
 
Another role of hypoxic metabolic reprogramming is to divert glucose metabolism away from 
mitochondrial oxidative metabolism (Figure 3-21, (Kim, Tchernyshyov et al. 2006, 
Pouyssegur, Dayan et al. 2006)). We detected a lower flux of PDH derived glutamate in 
hypoxia corroborated by a significantly higher gene expression of PDK1 (Figure 3-23).  
Moreover, flux analysis also uncovered a higher flux though the anaplerotic PC pathway in 
hypoxia, although PC gene expression was not significantly altered. In mitochondria, PC 
fixes CO2 by carboxylating pyruvate to produce OAA with the consumption of ATP. 
Increased PC levels have been identified in some cancer models (Liu, Kleps et al. 1991, Fan, 
Lane et al. 2009, Cheng, Sudderth et al. 2011, Sellers, Fox et al. 2015), but the understanding 
of the mechanistic function of PC is limited. Unexpectedly, we found that the hypoxic MCF7 
cells redirect glucose carbon flux into mitochondria via PC (Figure 3-22). We therefore 
hypothesised that hypoxia could trigger the PC pathway in early breast cancer carcinoma, 
introducing glucose carbon back to mitochondria and replenishing OAA under a lower TCA 




Finally, the evidence for higher PPP flux in hypoxia suggested that there may be a role for 
substrate channelling through enzyme compartmentalisation, a concept which remains 
controversial (Elcock, Huber et al. 1997, Ovadi and Saks 2004). However, it has been 
previously demonstrated for a few enzyme systems such as the binding of hexokinase II to 
the outer mitochondrial membrane via the voltage-dependent anion channel (VDAC) 
(Nakashima, Mangan et al. 1986, Colombini 2004, Mathupala, Ko et al. 2006). A 
mitochondrial G6PD-containing complex producing NADPH is an elegant solution to the 
increased redox stress that the mitochondria are exposed to under hypoxia. Under the limiting 
availability of oxygen in hypoxia, NADPH becomes an important co-factor to maintain a 
number of cellular processes such as anti-oxidative defence and some anabolic reactions that 
require reducing power. It is plausible that G6PD is part of a number of supermolecular 
complexes localised in various cellular compartments with multiple activities in normoxia 
and hypoxia, thereby providing metabolic flexibility for the cells to cope with 
microenvironment stresses. In our analysis, it is possible that a G6PD-containing 
supremolecular complex (at least in normoxia) is localised on the mitochondrial membrane 
(Figure 3-27). However, our analysis was not statistically significant as only two sets of 
independent experiments have been conducted. Nevertheless, the analysis highlighted the 
potential role of specific enzyme localisation to meet the need for the cellular homeostasis. 
Since there is no NADPH transporter across the mitochondrial membrane (Hanukoglu and 
Rapoport 1995), it could be that the mitochondrial NADPH pool is distinct from that in the 





By integrating data from gene expression, steady-state metabolite concentrations and 
metabolic fluxes, it was possible to identify a hypoxia-induced global reprogramming 
through alteration of glucose consuming pathways. Without this multi-platform approach, it 
is possible that some important findings would have been missed. For instance, G6PD and PC 
gene expression had not shown higher expression in hypoxia but the flux analysis suggested 




In summary, data from the gene expression and 13C metabolic flux analysis were compared 
for a early carcinoma stage breast cancer cell line. The analysis on MCF7 cells from multiple 
platforms showed that the hypoxic MCF7 primarily consumed more glucose via a higher 
glycolytic flux. At the same time, the higher glycolytic flux could allow for higher rates of 
PPP and for increased production of NADPH. MCF7 cells in hypoxia also displayed the 
flexibility to shift glucose carbon from usage in mitochondria when O2 is limited by diverting 
to the anaplerotic entry into the TCA cycle via PC. Together, these metabolic pathway 
alterations could provide a solution to provide for the needs of both macromolecules and co-
factors for the MCF7 cells in hypoxia. These metabolic pathways changes may be 







4. Targeting Pyruvate Carboxylase to Suppress Cell 





It is clear that hypoxia plays a central role in the progression of tumour malignancy and the  
clinical outcome of various human cancers (Höckel and Vaupel 2001). Immunohistochemical 
analyses of several cancers have shown that over-expression of HIF1α is associated with 
higher patient mortality (Zhong, De Marzo et al. 1999, Harris 2002). In clinical studies, 
HIF1α over-expression and patient mortality were shown to be strongly correlated in cancers 
of the brain (oligodendroglioma), breast, cervix, oropharynx, ovary and uterus (Birner, 
Schindl et al. 2001, Semenza 2003, Vaupel and Mayer 2007). As a key regulator in cancer, 
hypoxia is known to influence the progression and metastasis of tumours. Studies have shown 
that various steps of the metastatic process are correlated to hypoxia (Dachs and Tozer 2000, 
Peinado and Cano 2008), demonstrating a critical roles of hypoxia in cancer progression.  
 
The hypoxic microenvironment is hostile and dynamic. The regions of a tumour that 
experience inadequate oxygenation due to abnormal vascularisation exhibit compromised 
biological function (Vaupel, Kallinowski et al. 1989). To continuously support deregulated 
cell growth in a hypoxic environment, tumour cells commit to significant metabolic 
reprogramming (as discussed in Section 1.4.2).  
 
Some studies have highlighted the roles of additional pathways through glutaminase (GLS) in 
maintaining the NADPH: NADP+ ratio in some transformed cell lines. For instance, in some 
cells, glutamine can be converted into lactate and excreted from the cell (DeBerardinis, 
Mancuso et al. 2007). Although seemingly wasteful, this metabolism of glutamine is coupled 
to the activity of malic enzyme, which decarboxylates malate to produce pyruvate and 
reduces NADP+ to NADPH. NADPH, a source of reducing equivalents, is required for 
nucleotide and fatty acid synthesis (DeBerardinis, Mancuso et al. 2007). Moreover, several 
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reports have further demonstrated the role of glutaminolyisis induced by the activation of 
Myc signalling pathway (Wise, DeBerardinis et al. 2008, Gao, Tchernyshyov et al. 2009).  
 
The other most common route of TCA cycle anaplerosis is pyruvate carboxylation. Pyruvate 
carboxylase (PC) carboxylates pyruvate to form OAA in an ATP-dependent manner (Utter 
and Keech 1960). Data from a number of studies have demonstrated the vital roles of PC in 
liver, brain, adipose tissue and pancreatic islets which utilize OAA (i) as the precursor for 
gluconeogenesis (Robinson 1971), (ii) as a precursor for glutamate production (Hertz, Peng et 
al. 2007), (iii) as a citrate precursor for de novo fatty acid synthesis (Reshef, Olswang et al. 
2003), and (iv) in pyruvate cycling to generate more NADPH (MacDonald 1995). The PC 
activity directly replenishes OAA without transfer though the multiple steps of the TCA 
cycle. PC therefore is an important element of anaplerotic reaction for numerous biological 
processes and particularly relevant for tumour cells which are under microenvironmental 
stress. 
 
Less is known regarding the role of PC activity in cancer. In gliomas (Brand, Engelmann et 
al. 1992) and hepatomas (Hammond and Balinsky 1978) PC activity was reported to be 
comparable to that in normal primary cell lines. However, PC activity was found to be 
enhanced in both mitogen-stimulated lymphocytes (Curi, Newsholme et al. 1988) and liver 
tumour-bearing rats using a 13C-alanine perfusion model (Liu, Kleps et al. 1991). Recently, 
through the infusion of 13C-glucose into lung cancer patients prior to surgery, Fan et al. 
highlighted the accumulation of metabolite isotopomers characteristic of PC activity in lung 
tumour tissues (Fan, Lane et al. 2009, Sellers, Fox et al. 2015). Interestingly, a recent 
association between PC expression and Wnt signalling in breast and colon cancer (Lee, Jeon 
et al. 2012) suggested that PC activity plays a role in the activation of this signalling pathway 
to support tumour growth.  
 
The therapeutic potential of targeting glucose and glutamine metabolism in cancer has been 
emphasised in recent studies (Pelicano, Martin et al. 2006, Seltzer, Bennett et al. 2010, 
Cardaci, Rizza et al. 2012, Wang, Beaumont et al. 2014). It is therefore reasonable to 
postulate that PC has a prominent role in breast cancer tumourgenesis as it represents a 
significant means of supporting the biosynthetic demands of a tumour to sustain proliferation. 
This is reflected in the fact that the vast majority of cancer cells consume glucose more 
rapidly than any other nutrient, providing a major source of pyruvate for carboxylation. 
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However, it appears that there might be functional redundancy between PC and GLS activity 
in some cell lines, as PC activity was able to compensate for glutamine deprivation in cells 
with high GLS expression (Cheng, Sudderth et al. 2011), suggesting that PC activity could 
render tumours resistant to therapies targeting glutaminolysis (Cheng, Sudderth et al. 2011).   
 
As suggested earlier (Chapter 3), PC plays a significant role in mediating the constant influx 
of macromolecular precursors into the mitochondrial TCA cycle. The importance of PC in 
cancer metabolism has been implicated in a number of systems. However, the detailed role of 
PC in cancer metabolism is understudied. We hypothesised that PC activity may serve as a 
means of preserving TCA cycle functionality under hypoxia. Therefore, in this chapter we 
aimed to use 13C stable isotope labelling, 13C flux analysis and biochemical assays to 





4.2.1 NMR analysis shows that hypoxia triggers oxidative metabolic adaptation in 
MCF7 cells 
We (in Chapter 3: Figure 3-6, Figure 3-3) and others have demonstrated that MCF7 cells 
display distinct profiles at the transcriptome and metabolome levels in hypoxia. We have 
observed high glucose consumption in hypoxia and elevation of the gene expression for a 
vast majority of glycolytic enzymes, presumably to support and facilitate the glycolysis flux 
(Table 3-1). At the same time, both from the gene expression and metabolomics flux data, we 
found alterations in mitochondrial metabolism with a significant increase in PDK1 mRNA 
expression in hypoxia (Figure 4-1) and almost a 3-fold reduced flow of carbon from glucose 
through PDH into glutamate in hypoxia (Figure 3-21). 
 
To study the effects of hypoxia on the metabolism of MCF7 cells in more detail, the 13C 
labelling of metabolites in the central carbon metabolism in cell extracts using [1,2-13C] 
glucose and [3-13C] glutamine labelling was analysed using NMR 13C-HSQC spectroscopy. 
From the 13C-HSQC spectrum, information such as positional incorporation percentage and 
isotopomer distribution can be obtained. The 13C positional incorporation percentage 
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provides a global view of where the 13C atoms have been incorporated into various NMR 
detected metabolites whereas the isotopomer distribution allows the deduction of metabolic 
pathways that contribute to a particular isotopomer distribution. Pseudo 3D experiments such 
as TILT TOCSY-HSQC and TILT HCCH-TCOSY experiments were also conducted. These 
more complex NMR experiments were conducted to detect long-range multisite-labelled 
isotopomers. They were used to confirm that the isotopomers detected in the HSQC spectrum 
are the markers of PC activity (i.e.: the [2,3-13C] glutamate or aspartate) and not due to other 
multisite 13C labelled species (such as [2,3,5 -13C]glutamate) that also have the same 1J 




Figure 4-1: PDH mRNA expression is suppressed by the high expression of PDK1 in hypoxia. mRNA 
level of PDK1 of MCF7 cells in normoxia and hypoxia were assessed with RNA sequencing. Each data 
point is the average ± SEM of three independent experiments. ***p <0.001.  
 
4.2.1.1 NMR 13C positional incorporation percentage shows that hypoxia triggers 
metabolic alterations 
The 13C positional incorporation percentage was measured using a pair of samples that either 
had been exposed to a 13C enriched nutrient or a non-13C enriched nutrient. By dividing the 
peak intensity for the 13C enriched sample by that of  the non-13C enriched sample, the 13C 























In hypoxia, cells labelled with  [1,2-13C] glucose (Figure 4-2) showed a higher trend for the 
incorporation in lactate, while metabolites related to the oxidative metabolism of pyruvate 
such as C4 position of glutamate and C2 or C3 of succinate (indistinguishable in a HSQC 
spectrum) had relatively lower 13C incorporation. This is consistent with the idea of a 
metabolic hypoxic signature (Favaro, Lord et al. 2011), which is characterised by MCF7 cells 
increasing their glycolytic rate and reducing mitochondrial metabolism of glucose-derived 
carbons.  
 
Due to the low intensity of citrate in the non-13C enrich samples, the 13C positional 
incorporation percentage for this metabolite cannot be reliably calculated. However, the 
extent of 13C position labelling can be obtained from the 13C intensity of citrate normalised to 
their cell numbers. As shown in Figure 4-3, the 13C relative intensity of citrate at the CH2 
positions (either C2 or C4) which can be derived from both PC and PDH was significantly 
lower in hypoxia. In contrast, the label incorporation in carbon positions consistent with PC 
activity, such as C2-aspartate, C3-asparate, C2-glutamate and C3-glutamate, was comparable 
in both normoxia and hypoxia (Figure 4-2). The lower levels of 13C positional incorporation 
for the 13C sites that could arise from PDH pathway (i.e.: [4-13C]glutamate and C2 or C3 of 
succinate in Figure 4-2) but similar levels of 13C positional incorporation for the 13C sites that 
derived from PC (i.e.: C2-aspartate, C3-asparate, C2-glutamate and C3-glutamate in Figure 
4-2) suggested that PC may be able to compensate for a loss of PDH activity by supplying 
carbons for TCA cycle activity in hypoxia.  
 
Aside from glucose, glutamine is another important substrate for energy metabolism in both 
normal and tumour cells (Sauer and Dauchy 1983, Medina, Sanchez-Jimenez et al. 1992). 
Using [3-13C] glutamine as precursor, we traced the use of glutamine carbons in hypoxic 
MCF7 cells (Figure 4-4). 13C label was mainly observed in TCA cycle-associated metabolites 
such as glutamate, succinate, fumarate and aspartate, demonstrating the active usage of 
glutamine in both normoxia and hypoxia. At the same time, we noted a lower amount of label 
incorporation into citrate, assessed from the 13C relative intensity of citrate at CH2 positions 
(either C2 or C4) (Figure 4-5). From the [3-13C]glutamine positional incorporation results, the 
MCF7 cells did not show higher use for glutamine as a substrate for TCA cycle-associated 
metabolites or citrate as a potential fatty acid synthesis precursor. This is in line with previous 
findings that demonstrated that luminal breast cancer cell lines such as MCF7 cells were 
generally independent of glutamine for survival and proliferation (Kung, Marks et al. 2011). 
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This is however in contrast to some other brain cancer cell lines studied under hypoxic 
conditions that underwent reductive carboxylation of glutamine to citrate as a means of 






Figure 4-2: [1,2-13C]glucose tracer analysis of MCF7 cells in normoxia and hypoxia indicates 13C atoms 
flow through PDH and PC in normoxia and hypoxia.  The amount of 13C  ... (continued on next page)  
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incorporation at 3 hours is plotted for both normoxia (21%) and hypoxia (1%). Orange filled circles 
mark the 13C-labelled positions of metabolites derived from PC activity and green filled circles indicate 
13C-labelled positions derived only from PDH activity. Each data point is the average ± SEM of three 
independent experiments. The same data set as Chapter 3 was used to calculate the metabolites 
percentage labelling. The carbons numbering of metabolites starts from left to right. α-KG, α-




Figure 4-3: 13C intensity of citrate for MCF7 cells in normoxia (21% O2, green) and hypoxia (1% O2, 
blue) from the [1,2-13C]glucose labelling experiment after 3 hours. Due to the chiral CH2 group of citrate, 
the C2 and C4 signals of citrate are identical in HSQC spectrum. The 13C intensity was normalised to the 
number of cells. The cells count was obtained from a dummy plate (an extra tissue culture plate for cell 
counting purpose) at each condition. Each data point is the average ± SEM of three independent 
experiments. The carbons numbering of metabolites starts from left to right. The same data set as 






















Figure 4-4: [3-13C]glutamine tracer analysis of MCF7 cells in normoxia and hypoxia showing the active 
use of glutamine-derived carbons in the TCA cycle in both normoxia and ... (continued on next page)  
hypoxia. The amount of 13C position incorporation at 6 hours is plotted for each detected metabolite at 
oxygen concentrations of 21% O2, green and 1% O2, blue. The possible isotopomers arising from [3-
13C]glutamine into TCA cycle for the 1st, 2nd and 3rd round of TCA cycles were considered. Each data 
point is the average ± SEM of three independent experiments. The carbons numbering of metabolites 
starts from left to right. The same data set as Chapter 3 was used to calculate the metabolites percentage 






Figure 4-5: 13C intensity of citrate for MCF7 cells in normoxia (21% O2, green) and hypoxia (1% O2, 
blue) from [3-13C]glutamine labelling for 6 hours. Due to the chiral CH2 group of citrate, the C2 and C4 
signals of citrate are identical in HSQC spectrum. The 13C intensity was normalised to the number of 
cells. The cells count was obtained from a dummy plate (an extra tissue culture plate for cell counting 
purpose) at each condition. Each data point is the average ± SEM of three independent experiments. The 
same data set as Chapter 3 was used to calculate the metabolites percentage labelling.  *p <0.05. 
 
4.2.1.2 Hyperfine 13C-HSQC multiplets and CID analysis detect pyruvate carboxylase 
derived metabolites in hypoxia 
One of the main advantages of conducting metabolic analyses using NMR spectroscopy is the 
simplicity with which it can be used to determine structural information. Apart from 
quantifying the site-specific labelling, multiple adjacent carbon atoms of certain metabolites 
form a unique multiplet pattern in the spectra depending on the combination and degree of 
13C labelling of their respective neighbouring carbon atoms. In the 13C-HSQC spectrum 
acquired for MCF7 cells in normoxia and hypoxia, this effect is clearly shown from 13C 
incorporation distribution of various metabolites. In hypoxia (Figure 4-2), we detected the 
incorporation of 13C into C2 and C3 of aspartate. However, labelling incorporation into the 
C4 position of glutamate (representing activity through PDH pathway) was low in hypoxia. 
This labelling pattern could arise from PC activity due to the effect of carboxylating, rather 
















position of aspartate can provide the metabolic pathway information. The presence of large 
population of [2,3-13C]JC2C3 aspartate would be expected if PC was the predominant reaction. 
However, if PDH activity resulted in aspartate label incorporation, one would expect to 
observe label in both C2 and C1 positions (or C3 and C4) within the same molecule. The two 
metabolic activity can be distinguished from the couplings observed in 13C spectra. As shown 
in Figure 4-6, the scalar coupling of C2 observed in hypoxia was 41.2 Hz, indicative of an 
alkyl group coupling (i.e. C2-C3 aspartate as the marker for PC activity) whereas in normoxia 
the scalar coupling is 58.9 Hz, which indicates a carboxyl group coupling (i.e. C2-C1 
aspartate as the marker for PDH activity). A similar scenario is confirmed from the hyperfine 
multiplet of C2 glutamate in hypoxia, which shows the [2,3-13C]JC2C3 glutamate isotopomer 
(i.e. 41.2 Hz in Figure 4-7b) is a dominant species. 
 
PC and PDH activity often occur simultaneously, and thus the observed 13C labelling pattern  
represents the combined effect of both pathways. The hyperfine 13C HSQC spectra clearly 
distinguish the dominant isotopomer as shown in Figure 4-6 and Figure 4-7.  In order to more 
quantitatively assess the activity of PC in normoxia and hypoxia, we conducted CID analysis. 
The populations of C2 of [2,3-13C]  JC2C3 aspartate and C2 of [2,3-13C]JC2C3 glutamate were 
determined from CID analysis and the resulting PC flux can be estimated as C2 of [2,3-
13C]JC2C3 aspartate or C2 of [2,3-13C]JC2C3 glutamate population multiplied by the labelled 
metabolite pool size. As tabulated in Figure 4-8 (a and b), the flux through PC determined 
from C2-aspartate and C2-glutamate was significantly higher in hypoxia. Interestingly, the 
PDH flux assessed from the C4 of [4,5-13C]glutamate was significantly lower in hypoxia 
(Figure 4-8c). However, the ratio of PC to PDH activity was around two times higher in 
hypoxia again indicating that PC activity was an important source of carbon into TCA cycle 






Figure 4-6: Hyperfine HSQC multiplet of C2-aspartate after labelling with [1,2-13C]glucose for 3 hours. 
(a) In normoxia the C2 aspartate is predominantly [1,2-13C]JC1C2 with coupling constant of 59 Hz 
(measured from HSQC spectrum). (b) In hypoxia the C2 aspartate is predominantly  [2,3-13C]JC2C3  with 
coupling constant of 41 Hz (measured from HSQC). These coupling constants are obtained by peaks 
picking. The predicted chemical shifts were marked in black crosses and the picked peaks were marked 
in red crosses. The peaks picking are obtained by manually select the region of each peak. The data 




Figure 4-7: Hyperfine HSQC multiplet of C2-glutamate after labelling with [1,2-13C]glucose for 3 hours. 
(a) In normoxia the C2 glutamate is predominantly [1,2-13C]JC1C2 with coupling constant of 59 Hz. 
(measured from HSQC) (b) In hypoxia the C2 glutamate is predominantly  [2,3-13C]JC2C3 with coupling 
constant of 41 Hz (measured from HSQC). These coupling constants are obtained by peaks picking. The 
predicted chemical shifts were marked in black crosses and the picked peaks were marked in red crosses. 
The peaks picking are obtained by manually select the region of each peak. The data processing software 






Figure 4-8: Pyruvate carboxylation and pyruvate dehydrogenase fluxes after labelling with [1,2-13C] 
glucose for 3 hours in normoxia (21% O2) and hypoxia (1% O2) determined from the CID of (a) C2-
aspartate, (b) C2-glutamate and (c) C4-glutamate. The higher [2,3-13C]aspartate% and higher [2,3-
13C]glutamate % in hypoxia showing higher PC activity in hypoxia, while the lower [4,5-13C]glutamate in 
hypoxia showing lower PDH activity in hypoxia. (d) Relative PC to PDH flux assessed from the ratio of 
C2 of [2,3-13C]glutamate % to C4 of [4,5-13C]glutamate %. Each data point is the average ± SEM of three 
independent experiments. *p <0.05; **p <0.01; ***p <0.001.  
 
4.2.1.3 TILT TOCSY-HSQC experiments confirm pyruvate carboxylase derived 
metabolites in hypoxia 
As discussed in Section 3.2.4.2, the C2 of [2,3-13C]glutamate and C2 of [2,3-13C]aspartate are 
good reporters for PC activity for cells grown with [1,2-13C]glucose as a precursor. Although 
there is a small probability that the [2,3-13C]glutamate signals observed could be derived after 
multiple rounds of recycling in TCA cycles from PDH activity, those would not appear 
before the 3rd round of the TCA cycle (Figure 3-10 to Figure 3-15) which makes it highly 
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unlikely. Two types of TILT experiments - TILT TOCSY-HSQC and TILT HCCH-TOCSY 
used in this work provide complementary information to reveal multisite 13C-labelled 
isotopomers. The TILT TOCSY-HSQC spectrum reveals the possible isotopic isomers 
present for a given metabolite while the TILT HCCH-TOCSY confirms the 13C site-specific 
labelling of atoms.  
 
The TILT TOCSY-HSQC and TILT HCCH-TOCSY experiments confirmed that the C2 
multiplet (doublet in this case) of glutamate arising from the JC2C3  coupling in hypoxia was 
indeed associated with [2,3-13C]glutamate and not the [2,3,4,5-13C]glutamate isotopomer. 
This was evidenced by label incorporation into glutamate in positions C2 and C4 and C3 and 
C4 from TILT TOCSY-HSQC and TILT-HCCH-TOCSY experiments (Figure 4-9 and 
Appendix 7). Importantly, the glutamate C2&C4 and C3&C4 cross peaks from these pseudo 
3D experiments are apparent in normoxia, providing a positive control for these experiments 
(Figure 4-9). In contrast, under hypoxic condition, negligible labelling was observed in 
glutamate C2 and C4 and C3 and C4 in the TILT TOCSY-HSQC spectrum (Appendix 6). 
These cross peaks in the two pseudo 3D experiments could only be observed if there was a 
significant population of [2,3,4-13C] or [2,3,4,5-13C] glutamate. The lack of [2,3,4-13C] or 
[2,3,4,5-13C]glutamate labelling in hypoxia is consistent with the reduction in PDH activity 
apparent from the [4-13C]glutamate labelling percentage derived from the HSQC experiment 
(Figure 4-2).  
 
The results of the multidimensional NMR experiments have important implications. First, 
they confirm under hypoxic conditions the presence of [2,3-13C]glutamate from the C2-C3 
cross peak in the TILT TOCSY-HSQC spectrum. This signal is indicative of PC activity. 
Secondly, the 'triple' or 'quadruple' position labelled species; [2,3,4-13C] and [2,3,4,5-
13C]glutamate, that are indicative of labelling arising from multiple rounds of the TCA cycle 






Figure 4-9: Schematic representation for the two variants of TILT TOCSY-HSQC and TILT HCCH-
TOCSY experiments for MCF7 cells grown under normoxia with 3 hours labelling using [1,2-13C]glucose 
as precursor. The multisite cross peak labelling in the TILT TOCSY-HSQC experiment was obtained by 
dividing the peak intensity for individual isotopomer in the double edited TILT TOCSY-HSQC 
experiment by that in the single edited TILT TOCSY-HSQC experiment. The 3 hours normoxic sample 
shows cross-peaks between carbons 2 and 4 and between carbons 3 and 4 suggesting the presence of 
multiple rounds of the TCA cycle. The percentage values of the diagonal peaks in TILT-TOCSY-HSQC 
spectrum are symmetrical pairs, therefore only one of the percentage values is indicated. 
 
4.2.2 PC activity in different breast cancer cell lines 
 
Two other breast cancer cell lines, non-transformed (MCF10A) and metastatic (MDA-MB-
231), were investigated to examine PC activity in both normoxic and hypoxic conditions. For 
each of these cell lines, the cells were cultured with [1,2-13C]glucose for 3 hours and the 
resulting NMR spectra were assessed. As before, we used the splitting of the C2 of aspartate 
due to the neighbouring C3 carbon with a J-coupling constant of <50 Hz to detect the PC 
activity. In the non-transformed breast epithelial cell line MCF10A, no glucose-derived 
aspartate was detectable in normoxia but significant PC-derived aspartate was present in 
hypoxia (Figure 4-10). However, the MDA-MB-231 triple-negative breast cancer cell line 
exhibited detectable, significant PC activity in both normoxia and hypoxia (Figure 4-10). 








Normoxia - C2 aspartate 
 




Normoxia - C2 aspartate 
 
Hypoxia - C2 aspartate 
 
Figure 4-10: Comparison of hyperfine HSQC multiplets of C2-aspartate in normoxia and hypoxia 
labelling with [1,2-13C]glucose for 3 hours for MCF10A and MDA-MB-231 cell lines with 1H chemical 
shift (ppm) at the horizontal axis, 13C chemical shift (ppm) at the vertical axis and the JCC coupling 
constant annotated for each of the peaks. The predicted chemical shifts were marked in black crosses and 
the picked peaks were marked in red crosses. 
 
4.2.3 The role of PC activity in hypoxic metabolism 
 
As shown in the previous section, MCF10A, MCF7 and MDA-MB-231 cells exhibited PC 
activity in hypoxia, with MDA-MB-231 also demonstrating substantial PC activity in 
normoxia. To test whether this PC activity is crucial for metabolic adaptation in hypoxia, we 
attempted to knockdown PC expression in both MCF7 and MDA-MB-231 cell lines. We first 
tried to do this by transfecting the cells with doxycycline (dox) inducible shRNA (short 
hairpin RNA) constructs targeting PC, but this approach proved unsuccessful in MCF7 cells. 
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We therefore used a siRNA (small interfering RNA) knockdown approach in the MCF7 cell 
line. We also used a chemical inhibitor of PC, oxamate, to investigate the effect of inhibiting 
PC activity by quantifying with NMR the 13C positional incorporation percentage and 
isotopomer analysis. 
 
4.2.4 Knockdown of PC in MCF7 cells by siRNA and MDA-MB-231 by shRNA 
In order to analyse the role of PC in hypoxic MCF7 cells, we reduced PC expression by 
siRNA  in MCF7 cells and shRNA in MDA-MB-231 cells. The silencing was validated by 
quantitative real time PCR analysis of mRNA extracts from MCF7 cells transfected with non-
targeted siRNA (control group was transfected using ON-TARGETplus non-targeting 
siRNA, Dharmacon) or siPC (short interfering RNA specific to PC gene). A significant 
knockdown of PC mRNA expression was observed after 3 days of transfection (Figure 4-11) 
with no significant differences in terms of cell viability and cell morphology between the 
siPC knockdown and control cells. The siRNA silencing was further validated by PC western 
blot (Figure 4-12). As with the mRNA analysis, significant reduction of PC expression was 
observed in cells transfected with siPC after 3 days compared to the non-targeted control in 
both normoxia and hypoxia. A significant knockdown of PC mRNA expression was also 
observed after 3 days of doxycycline-induced induction of the shPC (short hairpin RNA 
specific to PC gene) construct in MDA-MB-231 cells (Figure 4-13). The shRNA silencing 









Figure 4-11: Knockdown of PC mRNA by siRNA. PC mRNA analysis by real time RT-PCR from MCF7 
cells transfected with non targeted siRNA (control) and siRNA targeting PC gene for 48 and 72 hours, 




Figure 4-12: Knockdown of PC protein expression by siRNA. PC protein expression analysis  by western 











































Figure 4-13: Silencing of PC mRNA by shRNA. PC mRNA analysis by real-time RT-PCR from MDA-
MB-231 cells transfected with sh non specific (control) and shPC induced by 1ug/mL doxycycline for 72 
hours, n=3, bars represent mean ± SEM. ***p <0.001.  
 
 
Figure 4-14: Knockdown of PC protein expression by shRNA. PC protein expression analysis by western 
blot from MDA-MB-231 cells transfected with sh control and shPC after 3 days treatment with 1μg/mL 
doxycycline induction. 
 
4.2.5 Knockdown of PC in MCF7 and MDA-MB-231 cells assessed by NMR 
spectroscopy 
We examined the effect of PC silencing on 13C labelling metabolic profiles in normoxia and 
hypoxia using NMR 13C-HSQC spectroscopy and 1H heteronuclear spin echo experiments (a 
type of 1D proton 13C-edited experiment). Incorporation of 13C into metabolites after 
incubation of MCF7 cells with [1,2-13C] glucose for 3 hours yielded NMR spectra with 


























heteronuclear spin echo spectrum in Figure 4-15. This suggests that the silencing of PC does 
not drastically alter the fate of glucose in MCF7 cells. Moreover from the isotopomer 
analysis, no change in lactate label incorporation derived from glycolysis was found by 
analysing the C2 of [2,3-13C]lactate using CID analysis (Figure 4-16). We also examined 
specifically the previously outlined metabolic markers of PC activity, namely [2,3-
13C]glutamate. Analysis of the HSQC spectra focusing on this isotopomer revealed that the 
overall PC relative flux showed trends corresponding to a reduction after the siRNA 
knockdown; however, the decrements were not statistically significant (Figure 4-17). In 
hypoxia, after the siPC transfection, PC activity may fall by ~20% in cells with reduced PC 
expression while a fall of around 15% was observed in normoxia (Figure 4-17).   
 
As observed from the 13C-HSQC hyperfine splitting of aspartate in the triple negative breast 
cancer cell line, MDA-MB-231 (Figure 4-10), the [2,3-13C] doublet arising from the JC2C3 
coupling indicative of PC activity was apparent in normoxia. This high PC activity in the 
triple negative breast cancer cell line was not dependent on oxygen availability. We also 
examined whether inducible knockdown of PC resulted in a change in isotopomer 
distribution of label in glutamate. We found that we could induce effective knockdown of PC 
in these cells after treatment with doxycycline and this resulted in significant (around 50%) 
reduction of PC relative flux in normoxia but only falling to a lower reduction trend of PC 





Figure 4-15: Example of 1H heteronuclear spin echo spectrum using NMR experiments as described in 
section 2.6.3.2 in for MFC7 cells transfected with si-non targeted (control) and siPC which were labelled 
with [1,2-13C]glucose for 3 hours. The spin echo spectrum (Section 2.6.3.2) showing the global 13C 
labelling profiles of MCF7 cells at the two conditions have similar 13C labelling in metabolites such as 





Figure 4-16: PC silencing has no effect on glycolysis-derived lactate, as assessed using [2,3-13C] lactate 
fraction. The data was generated using the CID analysis from MCF7 cells transfected with si non-
targeting (control) and siPC for 72 hours and labelled with [1,2-13C] glucose for 3 hours. n=3 independent 





Figure 4-17: Reduced PC expression decreases relative flux through pyruvate carboxylation by 
comparing [2,3-13C]glutamate fraction. The data were generated using the CID analysis from MCF7 cells 
transfected with si non specific (control) and siPC for 72 hours. The cells were labelled with [1,2-13C] 
glucose for 3 hours, n=3 independent experiments, bars represent mean ± SEM in normoxia (21% O2) 



























































Figure 4-18: PC shRNA silencing decreases relative flux through pyruvate carboxylation. The data were 
generated using the CID (13C isotopomer distribution) analysis from MDA-MB-231 transfected with 
doxycycline-inducible shRNA non specific (control) and PC shRNA. The cells were labelled with [1,2-
13C]glucose for 3 hours, n=3, bars represent mean ± SEM in normoxia (21% O2) and hypoxia (1% O2). 
*p <0.05. 
 
4.2.6 Inhibition of PC in MCF7 cells by oxamate and assessed by NMR spectroscopy 
To verify the reduction of relative PC flux, we repeated the experiments with the pyruvate 
carboxylation inhibitor oxamate (OX). 40 mM of oxamate was used in this analysis based on 
the effective concentration of oxamate in mammalian cells reported by Thornburg et al. 
(Thornburg, Nelson et al. 2008). As an analogue of pyruvate, oxamate (Figure 4-19) is known 
as a non-competitive or uncompetitive inhibitor of PC with respect to pyruvate (Zeczycki, St 
Maurice et al. 2009, Marlier, Cleland et al. 2013). Indeed, inhibiting PC by using oxamate 
significantly reduced PC flux (>50% reduction), as shown by the decrease in label 
incorporation into [2,3-13C]glutamate (Figure 4-20). These data therefore suggest that PC is 
likely the mechanism by which glycolytic carbon enters the TCA cycle in hypoxia in MCF7 
cells. However, knockdown of PC expression using shRNA by >80% does not reduce 
enzymatic activity sufficiently to extinguish overall flux through PC. This indicates that PC is 





















































engineered knockdown system (such as siRNAs) whereas a pharmacological inhibitor could 
achieve a complete inhibition and altered the PC relative flux of MCF7 cells in both 
normoxia and hypoxia. Moreover, the decrease in the [2,3-13C]glutamate isotopomer after the 
treatment of oxamate was more pronounced in hypoxia (Figure 4-20) suggesting a higher 
reliance of PC in hypoxia. 
 
By examining the 13C labelling profile arising from [1,2-13C]glucose as a labelled precursor 
under oxamate treatment, we observed some significant changes in 13C labelling in normoxia 
and hypoxia. After the treatment with oxamate, the 13C label incorporation into the CH2 
groups of succinate was significantly reduced both in normoxia and hypoxia. In addition, the 
C2 and C3 glutamate label incorporation percentages dropped to lower trends in hypoxia 
(Figure 4-21). Remarkably, the inhibition of PC via oxamate did not change the labelling 
percentage of aspartate in normoxia but reduced aspartate to below the detection level of 
HSQC NMR in hypoxia (Figure 4-21), suggesting that the effective inhibition of PC reduced 
the concentration of OAA and thus the level of aspartate.  
 
Next, glutamine labelling experiments with or without oxamate were conducted for MCF7 
cells in normoxia and hypoxia. Studies have shown that cell lines with high PC activity were 
resistant to glutaminase silencing and were no longer sensitive to cell death under glutamine 
depletion conditions (Cheng, Sudderth et al. 2011). We therefore also tested the labelling 
patterns that are due to 13C glutamine labelling when PC was inhibited. Using [3-
13C]glutamine as the labelling precursor, the inhibition of PC by oxamate in normoxia 
showed a lower trend of 13C labelling in fumarate and aspartate, but the reductions were not 
statistically significant (Figure 4-22). Moreover, in hypoxia the labelling into fumarate, 
malate and aspartate was significantly lower after the oxamate treatment. It is possible that 
the reduction of 13C labelling in aspartate and malate could be due to the reduced level of 
OAA after the treatment with oxamate. However, it is also possible that the incorporation 
from [3-13C]glutamine labelling that we detected was driven by another pathway inhibited by 
oxamate since the reduction of 13C labelling in metabolites such as fumarate, malate and 
aspartate was not limited only in hypoxia (Figure 4-22). Such off-target effects could be due 









Figure 4-20: PC inhibition with 40mM oxamate decreases relative flux through pyruvate carboxylase. 
The data was generated using the CID analysis from MCF7 cells treated with oxamate (Ox) or without 
oxamate (Control) for 3 hours and labelled with [1,2-13C]glucose for 3 hours in 21% or 1% oxygen. n=3-4, 













































Figure 4-21: [1,2-13C]glucose tracer analysis of MCF7 cells with or without addition of oxamate (40mM) 
in normoxia and hypoxia. The data shows the inhibition of PC reduced 13C labelling in TCA cycle 
associated metabolites. The amount 13C carbon incorporation at 3 hours for each detected metabolite at 
both oxygen tensions is plotted. Each data point is the average ± SEM of three independent experiments. 
*p <0.05. Abbreviations: α-KG, α-ketoglutarate; Ac-CoA, acetyl-CoA; OAA, oxaloacetate; n.s., not 




Figure 4-22: [3-13C]glutamine tracer analysis of MCF7 cells with or without addition of oxamate (40 mM) 
in normoxia and hypoxia. The amount of 13C carbon incorporation at 6 hours for each detected 
metabolite at both oxygen tensions is plotted. Each data point is the average ± SEM of three independent 




4.2.7 Loss of PC suppresses cell growth under hypoxia 
We hypothesised that PC activity in hypoxia in MCF7 cells provides important anabolic 
precursors for cell repair and proliferation, particularly through the production of vital 
macromolecular precursors, aspartate and glutamate. We therefore tested whether inhibition 
of PC activity affects cell growth in hypoxic conditions. We evaluated the relative viability of 
MCF7 cells transfected with non-targeting siRNA (control) or siRNA against PC in normoxia 
and hypoxia. The relative viability in normoxia and hypoxia after the transfection were 
measured (Figure 4-23) after 3 days of transfection. This time point (3 days) was chosen 
considered that the knockdown was effective after 3 days of transfection and cells still grow 
normally in each condition. Although cell viability using a longer time point (more than 3 
days) would be lower, such condition might induce excessive cell death. After 3 days of 
transfection, the reduction in PC expression in MCF7 cells resulted in a small but significant 
decrease in cell number in hypoxia but not in normoxia. We observed a more severe 
suppression of cell growth when inhibiting PC with oxamate in hypoxia (Figure 4-24) 
demonstrating the potential usefulness of this compound to selectively inhibit cell growth in 
hypoxia. Interestingly, the reduction of PC expression in MDA-MB-231 cells did not lead to 
a significant reduction in cell number in either normoxia or hypoxia. 
 
 
Figure 4-23: Cell numbers as assessed using the sulforhodamine B (SRB) stain relative to control of PC 
knockdown with siRNA in normoxia and hypoxia after 72 hours of transfection. Compared to the relative 
viability in normoxia, under hypoxia, there was a small, but significant reduction in cell number.  n=3, 





























Figure 4-24: Relative viability of MCF7 cells in normoxia and hypoxia after inhibiting PC with 40 mM 
oxamate for 72 hours was measured with sulforhodamine B (SRB) assay. n=3, bars represent mean ± 





Figure 4-25: Relative viability after PC knockdown with shRNA in MDA-MB-231 cells in 21% 
(normoxia) or 1% O2 (hypoxia) for 48 hours after 3 days of transduction was measured with 























































The present work aimed to identify the metabolic relevance of the anaplerotic PC activity in 
hypoxia in terms of the associated metabolic pathways and cellular transformation potential. 
Several groups have linked PC activity to a malignant phenotype in various cancer models 
(Curi, Newsholme et al. 1988, Liu, Kleps et al. 1991, Richardson, Yang et al. 2008, Fan, 
Lane et al. 2009, Sellers, Fox et al. 2015). Using a 13C labelled glucose as a metabolic 
precursor in MCF7 cells, we observed an induction of PC activity caused by hypoxia. We 
therefore asked whether hypoxia-induced PC activity was a phenotype of breast cancer cells 
at all points in the malignant transformation process. We compared the hypoxia-induced PC 
activity in three cell lines: MCF-10A (non-transformed cells), MCF7 (early carcinoma, 
luminal type) and MDA-MB-231 (metastatic origin). Under normal oxygen tension, PC 
activity was observed only in the late carcinoma breast cancer cell line - MDA-MB-231, 
whereas in hypoxia we observed the induction of PC across MCF10A, MCF7 and MDA-MB-
231 cells (Figure 4-10). Therefore, our results suggest that PC activity could be a marker for 
hypoxic early carcinogenesis, or late malignant transformation of breast cancer. 
  
By analysing the JC2C3 scalar coupling constant for aspartate and glutamate, it was possible to 
gain insights into the extent of PC in each condition. Since both PC and PDH are possible 
routes for carbon entry into the TCA cycle, they could both contribute to the observed 
splitting patterns for aspartate and glutamate in the indirect dimension of a 13C-HSQC 
spectrum of cells labelled with [1,2-13C]glucose. To more accurately compare the PC 
contribution, we conducted an NMR-based isotopomer analysis. We used CID to assess the 
contribution of isotopomers arising from PC activity in various cellular models. We 
concentrated our CID analysis on delineating label incorporation into glutamate instead of 
aspartate because the greatly reduced intensity of aspartate after PC inhibition leads to 
significant errors in quantification. From the CID analysis, we observed a highly significant 
increase of PC activity as well as significantly decreased PDH activity in hypoxia (Figure 
4-8). Also, the ratio of PC to PDH activity was significantly higher in hypoxia thereby 
demonstrating the importance of PC in hypoxic MCF7 cells. 
 
Using the isotopomer analysis, we analysed the metabolic effect of PC knockdown using both 
siRNA and shRNA models. We were able to achieve >80% reduction in expression of PC 
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using both models. However, this reduction appeared insufficient to completely eliminate the 
PC flux. The remaining low level of PC expression could still produce significant PC flux. 
This finding is in accordance with that of Minet et al. who demonstrated that the presence of 
a low protein expression of PC in skeletal muscle could still produce significant biological 
activity (Minet and Gaster 2010). The trend of a reduction in PC activity after siPC 
knockdown in MCF7 cells was however consistent with significantly reduced cell growth in 
hypoxia (Figure 4-17 and Figure 4-23). More reduction of PC activity might be achieved with 
longer transfection (longer than 3 days) due to the long half life of this protein (1 to 2 days) 
(Chandler and Ballard 1988). However the viability of cells after a long term transfection 
might not to be biological justified. The long half life of PC was also suggested by Sellers et 
al., in which the authors demonstrated a significant reduction of PC activity in non-small-cell 
lung cancer cell lines after 10 days of shPC transfection (Sellers, Fox et al. 2015). 
 
We were particularly interested in understanding the role of PC in hypoxia. As our mRNA 
knockdown had only a limited effect on PC activity, a more effective pharmacological 
approach was used to examine the associated metabolic contributors of PC activity in 
hypoxia. There are a number of compounds which have been used to inhibit PC ranging from 
proteins such as avidin (Duggleby, Attwood et al. 1982) and prohibitin (Vessal, Mishra et al. 
2006) to TCA cycle intermediates such as acetyl-CoA, αKG and glutamate (Scrutton and 
White 1974, Zeczycki, Menefee et al. 2011). Here, oxamate - an analogue of pyruvate - was 
used. Oxamate has been used before to examine the biotin carboxylase and carboxyl 
transferase domains of PC (Attwood and Graneri 1991, Attwood and Graneri 1992, Zeczycki, 
St Maurice et al. 2009, Marlier, Cleland et al. 2013). Furthermore, it has been demonstrated 
by Atwood and co-workers that at 20 mM concentration, oxamate reduced the rate of PC 
catalysed ATP cleavage by 98% (Attwood and Graneri 1992). However, as an analogue of 
pyruvate, it is very likely that oxamate can also inhibit other enzymes that have functions 
related to pyruvate utilisation. It had been previously shown that oxamate could also be used 
as a lactate dehydrogenase inhibitor (Wilkinson and Walter 1972). However, to our surprise 
the addition of oxamate had little effect on lactate labelling in our experiments (Figure 4-21). 
A similar finding was also reported in a study of oxamate applied to MDA-MB-231 by 
Thornburg et al. (Thornburg, Nelson et al. 2008). Although oxamate did not appear to inhibit 
the lactate labelling from [1,2-13C]glucose labelling experiment in our case, it is likely that 





To examine the contribution of PC activity to hypoxic metabolism, we used labelled 
nutrients:  [1,2-13C]glucose and [3-13C]glutamine. We found that for cells labelled with [1,2-
13C]glucose, oxamate treatment of MCF cells dramatically diminished the labelling of 
aspartate only in hypoxia (Figure 4-21) consistent with its role as a PC inhibitor to inhibit the 
carboxylation of pyruvate into OAA. Aspartate labelling is a surrogate readout for OAA and 
has been adopted in multiple studies (Danne, Gornik et al. 2013, Eoh and Rhee 2013, Yang, 
Ko et al. 2014) since the OAA intracellular level is below the detection limit of NMR and 
MS. Besides the effect on aspartate labelling, 13C incorporation into succinate was also 
decreased when cells were treated with oxamate. However, this reduction of 13C succinate 
labelling was not specific to hypoxia (Figure 4-21).  
 
We examined whether carbons derived from glutamine may be important to compensate for 
the decrease in 13C aspartate labelling from glucose-derived carbon. This approach would 
also test whether oxamate acts at the point of carbon entry into the TCA cycle from 
glycolysis. From the labelling experiments with [3-13C]glutamine, we observed a reduction of 
label incorporation into aspartate and malate for cells treated with oxamate at both 1% and 
21% O2 (Figure 4-22). This suggested that to some degree the reduction of aspartate under 
steady-state conditions (and 13C incorporation from glucose) to an undetectable level after PC 
inhibition by oxamate could be compensated by possible off-target effects of oxamate. One of 
the potential off-target effects of oxamate could be to also inhibit the aspartate amino 
transferase (AAT, which inter-converts aspartate and αKG to OAA and glutamate 
respectively) (Rej 1979, Thornburg, Nelson et al. 2008). However, the reductions of labelling 
in aspartate, malate and fumarate were not only limited to hypoxia suggesting that this off-
target effect is likely not specific to hypoxia.  
 
The glutamate CID analysis is a more specific method to assess PC activity by analysing the 
isotopomers that would most likely be formed as a result of PC activity (i.e. from the C2 
signal of [2,3-13C]JC2C3 glutamate signal as described in Section 3.2.4.2). From the CID 
analysis of the C2 of [2,3-13C]JC2C3 glutamate, PC inhibition by oxamate did indeed 
significantly reduce PC flux in both normoxia and hypoxia with a greater reduction in 
hypoxia (Figure 4-20), suggesting the utility of this inhibitor in suppressing the PC activity in 
hypoxia. Although our results clearly showed that oxamate significantly reduced the PC flux 
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into mitochondria and suppressed cancer cell growth in hypoxia, we cannot rule out that the 
inhibitor have alternative inhibitory effects, as discussed above. 
 
The massively reduced 13C aspartate labelling derived from [1,2-13C]glucose in hypoxia 
prompted us to examine further the role of aspartate from a high flux of PC in hypoxia. We 
therefore initiated a 13C aspartate labelling experiment by supplementing cell culture media 
with [2-13C]aspartate in normoxia and hypoxia for 24 hours. Due to the relatively high 
concentration of endogenous non labelled aspartate, the long duration of 13C labelling 
experiments were conducted (24 hours [2-13C]aspartate labelling). However, [2-13C]aspartate 
was not highly taken up by the cells and only showed higher labelling of [3-13C] aspartate in 
hypoxia (Appendix 8) after 24 hours of the labelling experiment. Nevertheless, the higher 
labelling in [3-13C] aspartate from [2-13C]aspartate in hypoxia suggests a higher requirement 
of extracellular aspartate for hypoxic MCF7 cells. Also, for the cells to get labelled in [3-
13C]aspartate, a symmetrisation at fumarate would have been required. Hence, higher 
labelling of [3-13C]aspartate in hypoxia also suggests an enhanced usage of aspartate for 
mitochondrial TCA cycle intermediates in hypoxia. 
 
Using the late carcinoma MDA-MB-231 cells, the suppression of PC with shRNA did not 
reach significant levels in hypoxia (Figure 4-25). This could be attributed to the increased 
metabolic plasticity of this more malignant cell line and escape from cell viability in hypoxia. 
However, we established the requirements of the MCF7 cell line (representative of early 
carcinomas) for PC activity in using both PC-specific siRNA (Figure 4-23) and oxamate 
mediated inhibition (Figure 4-24). We speculate that PC is important to sustain proliferation 
in hypoxia owing to the requirement for PC to replenish TCA cycle-related intermediates 
such as OAA and aspartate. Therefore we suggest that PC could be essential to provide cells 
with building blocks for nucleotide synthesis, such as aspartate, due to the significant 
increase in de novo aspartate synthesis (from [1,2-13C]glucose labelling experiment - Figure 
4-8) and extracellular aspartate uptake (from [2-13C]aspartate labelling experiment in 
Appendix 8) in hypoxia. Further labelling experiments with longer labelling incubation (48-
72 hours) label using 15N-aspartate or 15N-glutamine to trace the 15N incorporation in 








Taken together, our data indicate that PC could be an important factor to sustain cell growth 
for MCF7 cells in hypoxia. This is because in MCF7 cells, the activation of PC is only found 
in hypoxia and the knockdown or inhibition of PC significantly reduces cancer cell growth 
through a pathway that requires aspartate, possibly as a precursor for pathways such as 
nucleotide synthesis. However, the activation of PC is not selective to hypoxia for the MDA-
MB-231 (metastatic origin) cells. Our observations support the role of PC in sustaining 
hypoxic tumour metabolism in early carcinoma stage breast cancer based on the analysis on 
MCF7 cells. Also, our results were offset by the off-target effect of oxamate. Therefore, other 
PC inhibitor would be needed to confirm our findings. In addition, it might be challenging to 
employ a potent PC inhibitor as an anti-breast cancer agent in hypoxic breast cancer cells due 




5. Stable Isotope Tracer Investigation Using a Breast 





At present, the methodology of using stable isotope tracers in animal models as a tool to 
investigate the metabolism in vivo is an emerging area. At this point, there is no systematic 
comparison between different methods to introduce stable isotope labelled tracers in animal 
models. Stable isotopes are ideal tools for the dynamic assessment of in vivo metabolism.  
Following dosing of the animal, the fate of the tracer can be assessed both qualitatively and 
quantitatively by measuring the relative abundance of tracer and isotopomer distribution 
(Sauer 2006).  This information is valuable for measuring metabolic pathway alterations and 
quantifying fluxes in cell, tissues and organisms.  
 
One of the pioneering in vivo 13C labelling studies has been carried out by Fan et al. who use 
stable isotope in vivo metabolomics to investigate lung cancer in xenograft mouse model 
(Fan, A. Lane et al. 2011). In this study, mice received a bolus injection of [U-13C]glucose 
followed by metabolite extraction from lung tissue to compare the metabolite composition of 
normal lung and lung tumour tissue. More recently, Marin et al. studied glioblastoma (GBM) 
by 13C tracer-based in vivo metabolomics. In these experiments, mice underwent a bolus 
injection followed by a continuous infusion of tracers such as 13C-glucose and 13C-glutamine 
(Maher, Marin-Valencia et al. 2012, Marin-Valencia, Yang et al. 2012). 
 
Existing protocols used an initial administration of tracers via intravenous (IV) or 
intraperitoneal (IP) injection at the beginning of the flux experiment (Fan, A. Lane et al. 
2011, Yuneva, Fan et al. 2012, Fendt, Bell et al. 2013). A modification of this protocol was to 
load the stable isotope tracer through a number of consecutive injections (either IP or IV) or 
by continuous infusion. For some protocols, especially where the label is loaded through 
infusion over a long period, the animals had to be anaesthetised, which could already affect 
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their physiology (Brown, Umino et al. 2005, Tanaka, Kawano et al. 2009). To circumvent the 
need for anaesthesia, some groups have implanted a venous catheter and restrained the 
animals to allow the labelled precursors to be infused into the animals over a longer time 
period (Fitzpatrick, Hetherington et al. 1990, Bandsma, Grefhorst et al. 2004, Vogt, 
Hunzinger et al. 2005, Meissner, Herrema et al. 2011, Marin-Valencia, Cho et al. 2012, 
Sancheti, Kanamori et al. 2014). However, animal physiological changes would also be 
expected due to the induction of stress responses, such as the release of adrenaline into the 
systemic circulation. There is therefore no universally accepted technique to study stable 
isotope labelling in whole model organisms. 
 
Here, we studied the metabolism of the mouse mammary tumour virus - polyoma middle T 
antigen (MMTV-PyMT) transgene-expressing model of breast cancer using infusion of 13C 
labelled glucose. The MMTV-PyMT model is created by overexpression of the PyMT 
oncogene under the control of promoter elements from mouse mammary tumour virus - Long 
terminal repeats (MMTV-LTR) in the mammary epithelium (Guy, Cardiff et al. 1992). 
MMTV is a well-established animal model and shares similarities with luminal-type human 
breast cancer (Herschkowitz, Simin et al. 2007). As a membrane scaffold protein, PyMT 
activates signalling pathways such as the Ras/ Raf/MEK and PI3K/Akt that are commonly 
found to be altered in human breast cancer (Rodriguez-Viciana, Collins et al. 2006). As the 
mice grow older, they progress to more advanced stages of breast cancer and they also exhibit 
histological and molecular markers that are correlated to human breast cancer progression 
(Maglione, Moghanaki et al. 2001). 
 
The tumour progression induced by MMTV-PyMT can be characterised by four stages: 
hyperplasia, adenomas, early and late carcinomas stage. At 4-6 weeks, most of the lesions are 
premalignant and are categorised as hyperplastic. By 8-9 weeks, the majority of the MMTV 
mice progress to adenoma in which the tumour is still bound to the basement membrane. By 
the age of 7-12 weeks, an early carcinoma is usually present. The early carcinoma stage is 
usually defined by increasing pleomorphic appearance (Guy, Cardiff et al. 1992, Lin, Nguyen 
et al. 2001). As the mice become older, they eventually progress to the late carcinoma stage 
where solid sheets of epithelial cells are visible in the tumour (Lin, Jones et al. 2003). In 
addition, these mice also develop secondary tumours in lung, liver and bone at 14 weeks of 
age (Lin, Jones et al. 2003). Moreover, similar to human breast cancers, expression of the 
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hormonal receptors ER (estrogen) PR (progesterone) and β1-integrin were found to decrease 
as the mice enter late stage disease (Fantozzi and Christofori 2006). 
 
The MMTV-PyMT model provides a unique opportunity to study the metabolic phenotype of 
progressing stages of breast cancer under the conditions most relevant to local tumour 
microenvironments. Our goals were threefold: first to optimise the use of a [1,2-13C]glucose 
administration protocol in the MMTV-PyMT mouse model that allows to carry out metabolic 
flux experiments; second to identify metabolic fates of glucose consumed by the tumour-
bearing mice; and lastly to identify metabolic pathway differences between early and 





5.2.1 Distinct metabolomics profile of MMTV-PyMT compared to wild-type mice 
from plasma analysis 
To assess whether MMTV-PyMT is a suitable model to study the metabolic transformation in 
cancer, the metabolomic profile of peripheral plasma from these animals was compared with 
the non-disease mice using 1H NMR spectroscopy. The plasma samples were collected from 
11 week-old tumour-bearing mice and age-matched wild-type healthy mice. Comparing the 
concentration of each metabolite obtained from wildtype and from MMTV mice, we 
observed a number of significant differences. We also conducted a supervised partial least 
squares discriminant analysis (PLS-DA) and used the loadings plot to determine distinct 
metabolic changes in tumour tissue. 
 
The PLS-DA results for the two groups of mice are shown in Figure 5-1 and Figure 5-2. A 
clear separation was obtained from the first principal component (LV1). This observation 
indicates that there are some metabolic differences between the two groups.  
 
To test for statistical significance of each metabolite, the univariate statistic analyses were 
also conducted (Figure 5-3). Some of the largest differences in the metabolic profiles were 
observed between metabolites such as alanine and lactate. Unexpectedly, a higher 
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concentration of blood serum lactate and alanine were detected in the wild-type mice while 
the level of glucose remains the same. At the same time, the concentration of metabolites 
associated with the TCA cycle such as succinate and fumarate showed higher trends in the 
wild-type blood plasma.  
 
 
Figure 5-1: PLS-DA  scores plot of  11 week-old MMTV-PyMT mice ( blue square, n=4) and wildtype 
mice (black circles, n=4) plasma samples showing good separation between samples from the two tested 






Figure 5-2: Loadings plot of PLS-DA of the 11 week-old MMTV-PyMT mice and wild-type mice plasma 
samples. Positive peak represents metabolite associated to those metabolites that are higher in wild-type 
mice and negative peaks corresponding to those metabolites that are higher in MMTV-PyMT mice. The 












   
   
   
Figure 5-3: Metabolites contributing to PLS-DA separation between the 11 week-old MMTV-PyMT 
(MMTV) and wildtype (WT) mice plasma samples (n=4 mice, ± SD). Metabolites concentration in plasma 
were identified using 1H-NMR spectroscopy. Each data point is the average ± SEM of three independent 
experiments. The p value indicates results of a student’s unpaired two-tailed t-test comparing the wiltype 






























































































































































































































































5.2.2 Glucose infusion method for MMTV-PyMT mouse model  
To investigate the fate of glucose as a metabolic precursor, 13C labelled precursors such as 
[1,2-13C]glucose needed to be injected into the animal. The efficiency of the glucose injection 
method was evaluated. The glucose injection should not disrupt pathways that do not use or 
are independent of glucose and should have good reproducibility. This can be assessed by 
comparing the interquartile range (IQR) for various metabolites from tumour extracts 
obtained from the control group (i.e. without glucose injection) and the glucose injected mice. 
The IQR is a measure of variability, based on dividing measurements in a same group into 
quartiles. Using IQR to represent the variability would have been more significant if a larger 
data set is available. Therefore, with the limited available number of replicates, the absolute 
values of  IQR are not significant and can only give indication about relative variation of the 
collected data. If a metabolite could easily be derived from glucose, its IQR would vary 
considerably after effective IP or IV administration.  
 
Two methods of stable-isotope labelled glucose dosing were used: intravenous (IV) and 
intraperitoneal (IP). The former would result in an immediate bolus of glucose into the 
peripheral blood, whereas the latter would cause a slightly slower but more sustained 
increase. The comparison metabolite concentrations in the MMTV-PyMT mouse tumours are 
shown in Figure 5-4. The IQR were calculated (Figure 5-4) to compare whether the glucose 
injections (either IP or IV) would cause drastic variations to concentration of metabolites that 
are closely link to glucose metabolism or even to concentration of metabolites that are not 
closely link to glucose metabolism.  
 
Comparing the IQR, it is notable that for those metabolites that can be derived from glucose, 
including lactate, alanine, glycine, glutamine and glutamate their metabolite levels were 
similar or higher in both the IV and IP injection groups compared to the control group (Figure 
5-4). The glucose level was observed as being higher in the IP and IV groups most likely 
because of the increased availability of injected or residual intracellular glucose. However, 
for metabolites which are not connected to glucose metabolism, such as phosphocholine, 
phenylalanine, valine and tyrosine; IQR was comparable between the IV and IP with the 
control group with cases that the IQR of IV is larger than IP (such as for  leucine, isoleucine 
and valine). This suggest that both methods did not alter the concentration of metabolites that 
are not directly associated to glucose metabolism. Considering that there were either three or 
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four mice in each group and no outliers were observed, the data showed that metabolite 
concentration measurements has good reproducibility within each group.  
 
The comparison of IQR between IP and IV methods of administration showed comparable 
levels of steady-state metabolites in most metabolites but IP injected mice could have smaller 
IQR for some metabolites such as lactate, glutamate, glycine and valine (Figure 5-4).  
Considering that IP could be more repeatable (likely to have smaller IQR), and that IV could 
cause more stress to the animal where multiple attempts were occasionally needed to achieve 


































































Figure 5-4: Box plots of metabolite concentrations of 11week-old MMTV-PyMT mouse tumours 
comparing IP, IV glucose injection and control group (without glucose injection). The box plots show the 
spreads of the data. For each box plot, interquartile range was marked within the dark grey and light 
grey areas. For the IP and IV injected mice, 1 g/kg D-glucose was administered into the mice. 20 minutes 
post glucose injection, the mice were scarified to obtain the tumours. The tumours were then extracted 
for metabolites and the polar extracts were subjected to 1H-NMR spectroscopy analysis to determine the 















































5.2.3 Time course changes of 13C glucose  
To determine the optimal time for incorporation of [1,2-13C]glucose into downstream 
metabolites in the mammary tumours of MMTV-PyMT mice, we first assessed the evolution 
of 13C-labelled metabolism over time in the peripheral plasma and tumour after IP injection. 
Figure 5-5 shows a representative time course of the 13C label incorporation of glucose into 
lactate in the blood plasma comparing the wildtype and the early carcinoma (11 weeks old 
MMTV) mice. The 13C labelled glucose was observed in both wild type and tumour-bearing 
mice, and decreased rapidly after the injection implying that the labelled glucose was taken 
up and metabolised at a high rate. 13C labelled glucose for both wild type and disease mice 
showed a similar trend and can be approximated to a single-phase exponential decay function 
with a similar decay rate (Figure 5-5). However, more data points would be required in order 
to more accurately determine the rate constant. 
 
We also analysed 13C label incorporation into lactate in the plasma shortly after the IP 
injection for both wild-type and 11 week-old MMT-PyMT mice. In plasma, the 13C labelling 
of lactate reached a maximum of 5-9 % within 20 minutes and could be decreased after 30 
minutes post injection (Figure 5-5). However, similarly, more data points would have been 
needed to obtain a clearer trend. The lactate 13C label incorporation however appeared to be 
almost constant and reflects the role of lactate as an important metabolite to maintain pH and 
energy homeostasis in the blood (Loh, Chen et al. 2002, Aoi and Marunaka 2014). These 
results showing the time course of 13C label incorporation from glucose into lactate in blood 
plasma for both diseased and healthy mice suggest that the optimal duration for the 13C flux 
analysis for 13C isotopomer distribution (CID) analysis should be between 10 to 30 minutes 
post-IP injection. In addition, the blood serum glucose level did not significantly increase 
after the glucose injection (Figure 5-6). This can be observed from the blood glucose 
concentration in both 11 week and 13 week-old mice, which were both close to normal blood 
glucose level of 4.4-6.1 mM (Figure 5-6) at the shortest time point of 10 minutes. 
 
The various tissues of the animal, including tumours, are likely to absorb and metabolise 
glucose at different rates. As the size of the tumour in the MMTV-PyMT mouse model 
significantly increases over time (Figure 5-7), its metabolic requirement is likely to grow or 
change as the disease progresses. We investigated the uptake of glucose by mammary tumour 
in 11 and 13 week-old mice to see if the labelling profile at each time point changed. 
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Interestingly, maximal 13C glucose labelling was observed as early as 10 minutes after IP 
injection with similar levels of 13C glucose incorporation (Figure 5-8a) in both 11 and 13 
week-old mice. Similarly, the rate of conversion of 13C glucose into 13C lactate observed at 
10 minutes post-injection was similar at both tumour stages (Figure 5-8b). Hence, the time 
point chosen for [1,2-13C]glucose injection for these metabolic investigations was 10 minutes. 
Importantly, although the time at which maximal labelling was observed was similar between 
the two tumour sizes, the 13C glucose labelling in tumours of 13 weeks-old mice appeared to 








Figure 5-5: Glucose utilisation and lactate production trends in plasma for a) wild-type and b) early 
carcinoma (11 week-old) mice. The glucose and lactate labelling % in plasma were measured. The 1H 
heteronuclear spin echo experiment (i.e. 13C edited 1H at 5.21 ppm for glucose and 1.32 ppm lactate) was 
used to determine the 13C bound proton to calculate the 13C percentage incorporation. Each data point is 
the average ± SEM of two or three independent experiments except for the wildtype mice at 20 minutes 




Figure 5-6: Plasma glucose concentration in MMTV-PyMT mice at early (11 week-old) and late (13 week-
old) stage carcinoma mice. The glucose concentrations were obtained from a 1H heteronuclear spin echo 
spectrum (i.e.:13Cdecouple 1H at 5.2 ppm). Each data point is the average ± SEM three mice. Mice were 




Figure 5-7: The tumour volume of MMTV-PyMT mice grown over 11 weeks and 13 weeks. The volume 
was measured by using callipers and calculated with the formula: 0.52 × long diameter × short diameter2. 
Each bar represents the mean ± SEM (16 mice at 11week-old and 10 mice at 13 week-old). * Significant 













































Figure 5-8: 13C labelling of glucose (a) and lactate (b) in MMTV-PyMT tumours for mice at early (11 
week-old) and late (13 week-old) stage carcinoma. The glucose and lactate labelling % in tumour were 
measured. The 1H heteronuclear spin echo experiment (i.e. 13C edited 1H at 5.21 ppm for glucose and 1.32 
ppm for lactate) was used to determine the 13C bound proton in order to calculate the 13C percentage 
incorporation.  The individual data points for each time points were aligned. Each time point consists of 
two to four independent experiments except for the 11 week-old mice at 30 minutes and 13 week-old mice 




5.2.4 13C metabolomics of  MMTV-PyMT mice during tumour progression 
We expanded the in vitro metabolic flux analysis shown in previous chapters to the in vivo 
MMTV-PyMT mouse model using tumours grown over 11 and 13 weeks using [1,2-
13C]glucose injected 10 minutes before sacrificing the mice. From the HSQC NMR analysis 
of the extracted tumour, we observed labelling of 13C in central metabolism-associated 
metabolites such as lactate, alanine, glutamate, succinate and aspartate. The isotopomers 
formed from 13C-labelled glucose were resolved by CID analysis in which we focused on 13C 
multiplets and extracted the 13C isotopomer information, which is unique to their pathway 
usage. 
 
As previously described, the C2 signal of [2,3-13C]lactate doublet arising from the JC2C3 
coupling can directly probe relative glycolytic flux. Figure 5-9 shows the result for 11 and 13 
week-old tumour extracts following CID analysis. Unexpectedly, tumours from MMTV-
PyMT mice demonstrated a higher glycolytic relative flux in early carcinoma compared to 
later stages. Non-oxidative PPP flux could be inferred from the labelling of the lactate [3-13C] 
singlet originating from [1,2-13C]glucose infusion (Lee, Boros et al. 1998). The relative 
amount of lactate [3-13C] singlet labelling originating from [1,2-13C]glucose is shown in 
Figure 5-10. In contrast to glycolytic lactate, the non-oxidative PPP-derived [3-13C] lactate 
labelling had a higher trend in the late carcinoma stage mice compared to less advanced 
mammary gland tumour mice, suggesting a higher PPP flux and potentially higher 
proliferative phenotype. 
 
We continued to explore the potential for metabolic pathway differences between the two 
stages of mammary gland tumours by investigating other metabolites. We analysed the 
multiplets of C2 and C4 glutamate. We used the C4 glutamate signal of [4,5-13C]   arising 
from the JC4C5 coupling (Figure 5-11) to probe for the PDH-derived glutamate and the C2 
[2,3-13C]glutamate signal originating from the JC2C3 coupling (Figure 5-12) for PC-derived 
glutamate. There was no apparent preference for [1,2-13C] glucose derived pyruvate usage in 
oxidative metabolism or PC usage in the early and late stage mammary gland tumour mouse 
models. In addition, we also observed similar trends in the labelling pattern of succinate 
where the level of double 13C labelled succinate is comparable for 11 week and 13 week-old 
mice. These results suggest a similar requirement for mitochondrial metabolism, judged by 
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similar relative fluxes of PDH derived glutamate and similar relative flux of succinate in the 




Figure 5-9: MMTV-PyMT mice at early stage carcinoma have a higher relative glycolytic flux. The data 
was generated using CID analysis on the C3 lactate doublet arising from [2,3-13C]lactate for 11 and 13 
week-old MMTV-PyMT mice, using an IP injection of 0.1 mmoles [1,2-13C]glucose. The mice were 
sacrificed to dissect tumour at the mammary gland 10 minutes after the glucose injection; n=3 


































Figure 5-10: MMTV-PyMT mice at late carcinoma stage have higher relative PPP flux. The data was 
generated using the CID analysis on the C3 singlet for 11 and 13 week-old MMTV-PyMT mice, using an 
IP injection of 0.1 mmoles [1,2-13C]glucose. The mice were sacrificed to dissect tumour at the mammary 
gland 10 minutes after the glucose injection; n=3 independent experiments, bars represent mean ± SEM.  
 
 
Figure 5-11: Relative PDH flux in MMTV-PyMT mice. The data was generated using the CID analysis on 
C4 glutamate and quantifying the population of [4,5-13C]doublet for 11 and 13 week-old MMTV-PyMT 
mice, using an IP injection of 0.1 mmoles [1,2-13C]glucose. The mice were sacrificed to dissect tumour at 
the mammary gland 10 minutes after the glucose injection; n=3 independent experiments, bars represent 




























































Figure 5-12: MMTV-PyMT mice relative PC flux. The data were generated using the CID analysis on C2 
glutamate and quantifying the population of [2,3-13C]doublet for 11 and 13 week-old MMTV-PyMT mice, 
using an IP injection of 0.1 mmoles [1,2-13C]glucose. The mice were sacrificed to dissect tumour at the 
mammary gland 10 minutes after the glucose injection; n=3 independent experiments, bars represent 




































Figure 5-13: MMTV-PyMT mice succinate isotopomer from C2 or C3 succinate. The data was generated 
using the CID analysis on the NMR signal of C2 or C3 succinate (this two signals are identical in a HSQC 
spectrum) for 11 and 13 week-old MMTV-PyMT mice, using an IP injection of 0.1 mmoles [1,2-
13C]glucose. The mice were sacrificed to dissect tumour at the mammary gland 10 minutes after the 




The transfer of metabolic techniques from in vitro studies to mouse models is an important 
advancement for the better understanding of the metabolic phenotype(s) of cancer. Animal 
tumour models avoid the selection of tumour cells best adapted to an artificial cell culture 
environment and maintain the heterogeneous microenvironment of the native tumour. The 
MMTV-PyMT model is an attractive model to investigate the metabolic profile of breast 
cancer due to its similarity to some breast cancer phenotypes in human patients. However, at 
present, experimental protocols are not well established for performing in vivo analysis using 
stable isotope tracers. We therefore developed a new protocol for performing NMR in vivo 
using 13C stable isotope tracer studies. 
 
Here we demonstrated that tumour-bearing and control mice have distinct metabolic 
phenotypes distinguishable even in the peripheral plasma as indicated by PLS-DA analysis 







































separation between the two groups of animals, we showed that a number of those might be 
caused by a change in glucose metabolism, involving lactate and alanine (Figure 5-3). This 
observation motivated us to use 13C glucose as a precursor to examine the transformation of 
metabolism in mammary tumours. We therefore focused on central carbon  metabolism and 
chose [1,2-13C]glucose due to its suitability for assessing the flux of glycolysis, PPP and TCA 
cycle fluxes (Metallo, Walther et al. 2009). 
 
Introduction of 13C glucose into the mice presented a series of challenges. Due to the high 
relative steady-state concentration of glucose in the peripheral plasma, large amounts of 13C 
labelled glucose are required in order to observe significant levels of label incorporation. This 
could create severe stress to the animal. In general, the limit for the maximum injection 
volume is 10 ml/kg body mass (i.e.: 200ul for a 20 g mouse) (Buerge and Weiss 2004, Jo, 
André et al. 2010). IV injection into conscious animals requires the use of restraining 
assembly, which on its own induces a level of short term stress (Khubchandani, Mallick et al. 
2003). Longer-term infusion in conscious mice will also induce increased stress and may alter 
the metabolism of the animal. Although a higher label incorporation could be achieved by 
infusion of glucose over longer time periods, the requirement for anaesthesia under these 
conditions would also be expected to alter metabolism (Tanaka, Kawano et al. 2009). We 
therefore used a method that minimised stress to the animal by minimising the duration of 
glucose injection. This required the evaluation of whether IV or IP glucose injection is more 
suitable for metabolic flux analysis (Tanaka, Kawano et al. 2009).  
 
In our model, IP injection appeared to produce a better reproducible metabolomic profile 
(Figure 5-4) compared to IV injections. Also, IP injection represented a lower stress method. 
This is because to achieve a successful IV tail vein injection, multiple IV attempts could be 
needed while IP injection is more straight forward and has fewer potential side effects such as 
hyperglycaemic shock (Shimizu 2004). Glucose concentrations in the tumours using both IP 
and IV were similar 20 minutes after injection compared to the control group (Figure 5-4). 
Indeed, plasma glucose concentrations remained at levels very close to that maintained 
physiologically in the 11 or 13 week-old mice after the IP injection (Figure 5-6). 
 
A significant issue of studying metabolism in tissues with stable isotope labelled nutrients is 
the interplay between the organs of the whole organism. An example pertinent to this study is 
the activity of the Cori cycle: the oxidisation of lactate produced in other tissues (such as the 
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skeletal muscle) back to form glucose in the liver. Although the Cori cylce is likely to play a 
role, our analysis of the non-tumour bearing animals provided a baseline rate of incorporation 
of glucose into lactate in this system. If the majority of the 13C glucose that is converted into 
13C lactate by the tumour was excreted into blood and oxidised by the liver to convert it back 
into 13C glucose before being used again by the tumour to convert again into 13C lactate, the 
13C incorporation of lactate would be expected to exceed that of glucose. This effect was not 
observed: as illustrated in Figure 5-8, the tumours from mice at 11 and 13 week-old showed 
13C glucose labelling exceeding that of 13C lactate labelling, especially for the 10 minutes 
time point that was used in later experiments. In addition, tumours are known for 
metabolising large amounts of glucose, a phenomenon that has been exploited for 
fludeoxyglucose positron emission (FDG-PET) (Kelloff, Hoffman et al. 2005). 
 
In our model, 10 minutes [1,2-13C]glucose IP injection was conducted to trace the 13C glucose 
metabolism of early and late carcinoma stage MMTV-PyMT mice by analysing the 13C 
isotopomers present in the tumour. This time point was chosen because of the 13C glucose 
percentage incorporation in the tumour was similar at this time point (Figure 5-8). However, 
the tumour isolation method in our case was rudimentary. Indeed, although the tumour cells 
formed patches of cell mass at the mouse mammary gland when the MMTV-PyMT mice 
were 11 to 13 week-old, purification of tumour cells would have given further confidence in 
the relevance of our results. Furthermore, luciferase staining of tumour mass would have 
been assisted with the isolation of tumour cells and should had been conducted. 
 
Using CID analysis from tumour extracts obtained 10 minutes after [1,2-13C]glucose 
injection, the analysis showed that 13C derived from glucose had already been incorporated 
into metabolites in glycolysis and the TCA cycle, including lactate, glutamate, succinate and 
aspartate (Figure 5-9 to Figure 5-13). It is worth noting that compared to the rate of 
metabolism of glucose observed in the previous chapters in vitro (using  at least one hour as 
time point), this represents a hugely increased rate of metabolism. Although the short list of 
metabolites reflects the limited sensitivity of NMR, it does provide a useful snapshot of 
central carbon metabolism and allows for quantitative isotopomer analysis. The high level of 
lactate observed in the tumour may reflect the Warburg effect, a common feature of solid 
tumours (Warburg 1930, Walenta, Wetterling et al. 2000). In addition, a few key metabolites 
in the TCA cycle were detected demonstrating that even in late stage carcinoma, 
mitochondrial oxidative metabolism is intact. The same observation has also been reported 
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using 13C-NMR in vivo analysis of human brain tumours (Maher, Marin-Valencia et al. 
2012).  
 
The comparison of tumour metabolism in early and late stage mammary gland models 
demonstrated some interesting features. The most striking of these features was higher 
relative flux of the PPP as detected by label incorporation into the C3 of lactate in the late 
carcinoma tumour (Figure 5-10). The measurement of [3-13C]lactate isotopomer from [1,2-
13C]glucose flux experiment represents the flux of carbons from glucose both into (oxidative 
PPP) and importantly out of (non-oxidative PPP) the PPP. This suggests that the reason for 
high carbons fluxes through PPP is not solely for increasing proliferation, but also for 
producing of more reducing equivalents in the form of NADPH (discussed in Section 3.3, 
paragraph 5). Unexpectedly, the glycolytic rate as assessed through lactate production in the 
late carcinoma group was lower compared to the early carcinoma stage. The lower 
glycolysis-derived lactate in the late carcinoma group (Figure 5-9) is not consistent with 
previous reports which suggest that higher levels of lactate correlated with higher malignancy 
(Walenta, Wetterling et al. 2000). However, as we had only measured a single output of 
glycolysis (i.e. lactate), the lower lactate flux could not guarantee a lower rate of glycolysis. 
Other output of glycolysis such as the incorporation of carbons from glucose into precursors 
such as serine, glycerol 3-phosphate and ribose 5-phosphate would be needed to confirm the 
lower flux through glycolysis. The lower 13C incorporation into lactate could also suggest a 
stromal/tumour interaction as demonstrated by the research group of Pierre Sonveaux, who 
showed that lactate produced by cancer cells may be taken up and oxidised by stomal cells 
surrounding the hypoxic tumour cells - a form of metabolic symbiosis (Sonveaux, Gran et al. 
2008). It is likely be that the 13 week-old mice (the more advanced carcinoma stage breast 
cancer) have more hypoxic cancer cells as hypoxic condition has strong correlations with 
malignant progression in multiple studies (Höckel, Schlenger et al. 1996, Nordsmark and 
Overgaard 2004). And the metabolic symbiosis event could be present in the 13 week-old 
mice to produce the lower glycolysis-derived lactate flux. However, further immunostaining 
analysis with hypoxic tumour microenvironment and stomal cells markers would be required 







The analysis in this chapter compared the [1,2-13C]glucose administration protocols in the 
MMTV-PyMT mouse model with a chosen IP injection over IV injection. However, the 
current experimental protocol requires further refinement in the infusion method to minimise 
stress to the animal, in the tumour isolation method to ensure high purity of isolated tumour 
cells and in the detection method for 13C-NMR to achieve better signal-to-noise ratios. From 
the [1,2-13C]glucose in-vivo mice labelling experiments, we also found that the MMTV-
PyMT late carcinoma mice have significantly increased non-oxidative PPP flux relative to the 








This work started with a straightforward approach: monitoring the metabolic alterations of 
early stage breast cancer cell line (MCF7 cells) as a consequence of reduced environmental 
oxygen. We used NMR as a detection technique to measure changes in metabolite production 
and usage: either through steady-state concentrations or through the 13C incorporation into 
metabolites from isotopically labelled precursors. This work showed that such unbiased 
analysis can advance the understanding of metabolic alteration observed in breast cancer as a 
consequence of hypoxia. The 13C labelling strategy started with the use of [1,2-13C]glucose as 
a significant number of metabolites connected to glucose metabolism such as lactate, alanine, 
glutamine and acetate had significant changes in their steady-state concentration in hypoxia 
(Figure 3-6). Also, studying the site-specific incorporation of the 13C isotope permitted the 
study of the use of some  pathways such as the PPP and TCA cycle (Metallo, Walther et al. 
2009). From the labelling studies using [1,2-13C]glucose, indications of metabolic changes 
induced by hypoxia such as increased glycolysis and reduced mitochondrial oxidative 
metabolism were observed (Figure 3-8), consistent with the commonly found metabolic 
alteration events in hypoxia in multiple cancer cell lines (Robin, Murphy et al. 1984, Kim, 
Tchernyshyov et al. 2006, Guillaumond, Leca et al. 2013).  
 
By following the build-up of [3-13C]lactate using the CID analysis of MCF7 cells, we found 
higher PPP flux in hypoxia (Figure 3-20). The direct measurement of PPP flux though 13C 
labelling in ribose molecules were not possible due to the low 13C intensities of these 
molecules. However, measuring the [3-13C]lactate isotopomer from [1,2-13C]glucose flux 
experiment would be informative. [3-13C]lactate isotopomer represents the flux of carbons 
from glucose both into oxidative PPP and out of the non-oxidative PPP (Figure 1-11). 
Therefore, the detected [3-13C]lactate isotopomer links the PPP to both production of ribose 
molecules (oxidative PPP) and to generation of other PPP end products such as F6P and G3P.  
F6P, the downstream product of PPP, could regenerate by isomerisation into G6P, and 




The MCF7 cells have reduced proliferation rate in hypoxia (Figure 3-2). This suggests that 
the high carbons fluxes through PPP are likely not for producing ribose molecules, but for 
producing other PPP end products such as F6P and  to subsequently re-enter PPP to generate 
more reducing equivalents in the form of NADPH (discussed in Section 3.3, paragraph 5). 
The tumour microenvironment is known to be not only hypoxic but also increase ROS (Guzy, 
Hoyos et al. 2005, Storz 2005, LaMonte, Tang et al. 2013, Justus, Sanderlin et al. 2015). 
Indeed, a number of reports have demonstrated that hypoxic condition is associated with 
excess production of ROS (Chandel, Maltepe et al. 1998, Guzy, Hoyos et al. 2005, Bensaad, 
Cheung et al. 2009, Reuter, Gupta et al. 2010, Anastasiou, Poulogiannis et al. 2011). The 
influence of ROS on cancer cells could occur via the alteration of mutagenic potential, 
through the activation of intracellular signalling pathways that control cell survival and 
through an impact on cell motility and invasiveness (Pani, Galeotti et al. 2010, Toullec, 
Gerald et al. 2010). Therefore, we suggested that the high glucose metabolism through PPP in 
our case could be to provide more NADPH as reducing power due to the high ROS 
microenvironment in hypoxia. However, immunofluorescence analysis with ROS marker 
should have also been conducted to validate the reason for higher PPP in hypoxia. 
 
Instead of relying on percentages of 13C labelling for individual metabolites as a readout, a 
method to understand the contribution of individual pathways was explored. A method for 
comparing the flux of those pathways of interest, i.e. glycolysis, PPP, TCA oxidation of 
acetyl-CoA and anaplerotic reactions was developed. This method is termed 13C isotopomer 
distribution (CID) analysis. Both the 13C site-specific label incorporation and isotopomer 
analysis were used to follow the evolution of specific isotopomers to probe the flux of a 
metabolic pathway. For example, the incorporation of 13C from glucose to form [2,3-
13C]JC2C3 labelling of glutamate was used to follow the PC flux. In contrast to the commonly 
used tool for estimating flux from NMR data, tcacalc (Malloy, Sherry et al. 1987, Malloy, 
Sherry et al. 1988), CID does not assume an isotopic steady-state to form the basis of input 
and output equations. Instead, CID analysis is conducted by using 13C  labelling experiments 
at various time points to determine the isotope incorporations and fits were generated to 
obtain the rate constant and pool size (plateau of the curve) for individual fluxes. This 
strategy is a model free analytical solution for flux estimation based on specific isotopomer 
evolution. In this work, experimental data was used to provide an analytical solution rather 
than an isotopomer modelling algorithm to solve the flux (Jeffrey, Rajagopal et al. 1991). 
CID has some similarities to the kinetic modelling method developed by Yuan et. al (Yuan, 
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Bennett et al. 2008). In their method, the intracellular concentrations of downstream 
metabolites are plotted after the unlabelled nutrient is switched to labelled nutrient. In that 
case, the resulting unlabeled metabolites follow an exponential decay and the flux can be 
obtained from the decay rate multiplied by the intracellular metabolite concentration. 
 
The primary advantage of the method developed here is its simplicity: the use of direct 
measurements and ability to distinguish alternative metabolic fates based on an isotopomer 
analysis. As demonstrated with [1,2-13C]glucose we could follow the isotopomers that are 
contributing to pathways such as glycolysis, PPP (non-oxidative part), PDH and PC using a 
single stable isotope nutrient rather than combinations of labelled nutrients to solve the 
metabolic network. The isotopic steady-state is not assumed, meaning that CID can be readily 
applied to human studies (also because of the non-toxic nature of 13C labelled nutrients in 
comparison to the use of 2H label), as the isotopic steady-state would be highly expensive to 
achieve and may not be ethically justified. Furthermore, this method could be used to 
correlate with regional localisation in different tissues in order to interrogate the association 
between isotopomers and tissue heterogeneity. However, the CID analysis is more 
demanding from an experimental perspective as experiments at multiple time points would be 
needed to obtain the time series plot. Also, this method can only examine limited metabolic 
pathways because a specific isotopomer that describes a metabolic pathway needs to be 
chosen. Therefore, this method could not be used as a stand-alone method to solve the 
metabolic network but could be potentially integrated with other modelling suits for a more 
complete metabolic flux analysis. As we report the flux value in terms of 13C percentage, 
absolute concentration quantification using an alternative analytical method such as MS 
would have been useful to verify and convert the flux value into a millimolar concentration 
rate value. 
 
To gain a global overview of interrelationships between metabolic alterations in hypoxia, 
gene expression analysis using RNA sequencing was conducted. Analysis of both the 
individual genes and the gene ontology of the overall changes showed that a number of the 
alterations noted in metabolic fluxes were accompanied by changes in gene expression - in 
particular in genes related to glycolysis and the PPP (Figure 3-3). This indicated that gene 
expression at the pathway levels could be a surrogate for the flux measurement; similar 
findings have been recently demonstrated by Merhmohamadi et al. (Mehrmohamadi, Liu et 
al. 2014) in the analysis of usage of serine metabolic networks in human cancer. However, in 
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the integration of gene expression and 13C metabolic flux data (as described in Section 3.2.5), 
a numerical quantitative correlation between fluxes and expression of pathways from gene 
expression data would have been more informative to represent their relationships. 
Interestingly, apart from the common features (such as upregulated glycolysis in hypoxia) 
found within the gene expression and 13C metabolic flux analysis, the flux measurements 
picked up PC as a potential hypoxic metabolic regulator that could have been missed when 
using solely gene expression analysis.   
 
The changes in various metabolic pathways that we observed suggested that there could be 
some form of network coordination among the various pathways in order to achieve the 
metabolic flexibility for cancer cells to adapt to the hypoxic microenvironment (Section 
3.2.6). As previously described for the glycolytic pathway in the fly, there could be a 
supramolecular complex of metabolic enzymes that permits substrate channelling (Wojtas, 
Slepecky et al. 1997). The metabolic enzymes complex has also been described for the 
binding of hexokinase II to the outer mitochondrial membrane via the voltage-dependent 
anion channel (VDAC) (Nakashima, Mangan et al. 1986, Colombini 2004, Mathupala, Ko et 
al. 2006). In conjunction, Brekke et al. found that the PPP-derived glucose carbon accounts 
for 4 - 6% of glucose in active neurons glutamate 13C labelling (Brekke, Walls et al. 2012). 
This value is too large to explain by probability of 13C glucose through PPP before detected 
as 13C labelled glutamate and could indicate separate compartments of metabolites for various 
cellular functions. Taking these observations together, the existence of a supramolecular 
complex bound to mitochondria contributing to the metabolic flexibility to channel carbon 
glucose from PPP to TCA was tested. Interestingly, analysis of mitochondrial associated 
proteins using native PAGE and immunofluorescence co-localization suggested the existence 
of a large protein complex including G6PD (PPP enzyme) in normoxia (Figure 3-26 and 
Figure 3-27). However, more biological replicates were required to confirm our initial 
findings and optimisation of immunofluorescence were needed before more screening 
analysis using LCMS or protein complex immunoprecipitation (co-IP) analysis to be 
conducted. 
 
The clear activation of PC in hypoxic conditions was of particular interest. Examining this 
across multiple breast cancer cell lines allowed us to compare an association of PC activity 
with more advanced breast cancers. The PC activity was only detected in hypoxia in non-
transformed or early carcinoma breast cancer cell lines, whereas in late carcinoma breast 
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cancer cell lines it was present regardless of O2 tension (Figure 4-10). However, a larger scale 
screening analysis across various breast cancer stages is required to stratify PC as a marker 
for a more advanced breast cancer signature as our analysis were confined to few breast 
cancer cell lines. Recently, Sellers et al. showed the selective activation of PC over 
glutaminase to enable tumour growth in early stage non-small-cell lung cancer, which 
reinforced the importance of PC as a TCA cycle anaplerotic pathway mediator (Sellers, Fox 
et al. 2015). 
 
To clearly distinguish the contribution of PC to the cell phenotype, shRNA and siRNA 
knockdown systems were constructed and assessed based on NMR isotopomer analysis. 
However, the PC activity assessed with NMR C2 of [2,3-13C]JC2C3 glutamate using the 
knockdown systems showed no significant difference in hypoxia (Figure 4-17). This could be 
because despite much reduced PC expression, there was still considerable activity to provide 
sufficient PC flux to support normal metabolic function in the two cell lines (Minet and 
Gaster 2010). However, we did note that oxamate (a pharmacological PC inhibitor) was 
highly effective in suppressing cell growth in hypoxia. The treatment of oxamate reduced cell 
viability marginally to around 70% in normoxia but to a much larger extent of 40% in 
hypoxia (Figure 4-24), thereby demonstrating the potential of PC inhibition as a 
pharmacologically lethal agent selective to hypoxic breast cancer cells. However, we found 
some off-target effect of oxamate from the [3-13C]glutamine labelling experiments (Section 
4.2.6). Further testing using more breast cancer cell lines and other PC inhibitors would need 
to be confirmed our findings. 
 
In this work, we also aimed to develop a method to investigate stable isotope labelling of 
tumours in animal models as a step toward translating findings from in-vitro systems into a 
clinical setting. Cell cultures grown in 2D environments lack many of physical and chemical 
interaction observed in the normal tissue environment such as cell-cell adhesions, 
extracellular matrix interaction, and cell-cell communication (Cukierman, Pankov et al. 
2001). In addition, tissue culture cells are maintained in a complete media that is 
supplemented not only with high concentrations of metabolites, but growth factors, cytokines 
and other protein components. Cells growing in such rich media have been shown to 
upregulate oxidative phosphorylation, nucleotide synthesis and pyruvate metabolism when 
the gene expression profiles of cell line models, primary tumour cells and normal cells were 




The implementation of 13C labelling studies in mouse models requires some practical and 
technical considerations. These include the choice of 13C labelled nutrient, route and duration 
of infusion. 13C labelled glucose was demonstrated to be a good candidate for this pilot study 
because of the high uptake of glucose especially in cancer models (Hamanaka and Chandel 
2012). However, our analysis would have been better served if it had been expanded to 
include glutamine and fatty acids to add information from those metabolic precursors. We 
found that the tumour glucose concentrations rapidly rose following the IP injection and was 
then depleted from the tumour mass, with a faster drop in 13 week-old (Figure 5-7 and Figure 
5-8). Therefore, the input of 13C labelled in the tumour mass is not a step function. However, 
to avoid infusion under anaesthesia, we conducted the glucose 13C enrichment without 
achieving steady-state at various time points for the 11 and 13 week-old MMTV-PyMT mice 
in order to obtain an optimal level of 13C glucose isotopic enrichment.  
 
We were able to compare a few glucose-derived pathways using the 13C isotopomer analysis. 
Our data suggested that the progression of the tumours in the MMTV-PyMT model from 11 
to 13 weeks involves some changes in their metabolic profiles that are not necessarily just 
associated with change in tumour size. Firstly, by quantifying the glucose derived recycling 
of PPP 13C into lactate, a higher PPP activity was detected in the older mice (Figure 5-10). 
This is unlikely to be solely for the production of nucleotides. The higher PPP in the 13 
week-old MMTV-PyMT mice might be generating a higher level of reducing equivalents in 
the form of NADPH that can serve to scavenge ROS, enhancing the ability to survive in its 
more hypoxic environment of the late stage breast cancer tumours. However, further 
validation of our results with staining agents such as CellROX (intracellular ROS 
fluorescence probe) and pimonidazole (hypoxia immunohistochemical marker) are required 
to confirm the higher ROS and hypoxic tumour microenvironment of the tumour. Secondly, 
the relative flux of glycolysis quantified from isotopomer analysis of lactate appeared to be 
higher at the earlier disease stage (Figure 5-9). It was hypothesised that the 11 week old 
MMTV mice might have a lower proportion of stromal to tumour cells compared to the more 
advanced mammary gland tumours resulting in less lactate being oxidised by the stromal 
cells. Numerous studies have shown that the invasiveness and progression of breast cancer 
can be assessed by stromal cells (Vrana, Stang et al. 1996, Jung, Moon et al. 2007, Polyak 
and Kalluri 2010). Correlation of the flux results with immunostaining of cancer-associated 
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stromal cells would be able to clarify our findings of a lower concentration of lactate in the 
older MMTV-PyMT mice. 
 
The 13C metabolic fluxes are dependent on the delivery of 13C stable isotope into the cell, the 
rate of cellular glucose uptake and on the kinetics of the enzymatic reactions. It should be 
noted that the data in Chapter 5 illustrated the potential of using stable isotopes in animal 
models to determine metabolic changes by measuring isotopomers using NMR. The 
isotopomer-derived 13C flux is proportional to the kinetic parameters. The similar glucose 
uptake in 11 and 13 week-old mice was assumed based on the similar level of 13C glucose 
labelling in the tumour at 10 minutes post-IP injection (Figure 5-8). However, the purity of 
the extracted tumour and the distribution of 13C label due to the availability of blood vessels 
in tumour should also be considered to ensure a similar glucose uptake and availability of 13C 
stable isotope into the tumour. Thus, a firm conclusion about the metabolic difference using 
13C in vivo labelling should not be drawn before additional studies are conducted. 
 
In summary, the present work has demonstrated the usefulness of NMR 13C isotopomer 
analysis (CID) to reveal metabolic pathway alterations caused by hypoxia in vitro and by 
tumour growth in vivo. This work emphasises the use of experimentally derived isotopomers 
to elucidate the metabolic pathway fluxes without prior assumption of isotopic steady-state. 
This work also demonstrated the applicability of this method in the context of hypoxic breast 
cancer cell lines and identified the higher flux through PPP and PC in hypoxic MCF7 cells. In 
addition, the inhibition of PC flux by oxamate could suppress hypoxic breast cancer cell 
growth but had some off-target effects. Finally, it was possible to extend the use of flux 
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8.2 Appendix 2 
Table 8-1: The potential peaks contributing to PCAseparation of normoxia and hypoxia MCF7 cells after 
48 hours treatment. The metabolites concentration were measured using 1H-NMR spectroscopy and 
showed in Figure 3-6. The statistical significance was established by the Student's unpaired two-tailed t-
test with p-value less than 0.05 considered to be statistical significant. 
1H Chemical shift (ppm) Metabolites P-value of unpaired t-test 
0.93 Isoleucine 0.1939 
0.95 Leucine 0.1631 
0.98 Valine 0.1112 
1.32 Lactate 0.0496 
1.33 Threonine 0.1303 
1.48 Alanine 0.0408 
1.91 Acetate 0.0124 
2.35 Glutamate 0.5940 
2.40 Succinate 0.4779 
2.47 Glutamine 0.0312 
2.53 Glutathione 0.0451 
2.64 Methionine 0.0065 
2.69 Citrate 0.4120 
2.79 Aspartate 0.0242 
3.03 Creatine 0.1958 
3.28 Taurine 0.3412 
3.57 Glycine 0.5616 
4.08 Myo-inositol 0.0336 
5.25 Glucose 0.0006 
6.51 Fumarate 0.6258 
6.90 Tyrosine 0.2911 
8.44 Formate 0.6258 
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8.3 Appendix 3 
 
Figure 8-1: Annotated pathways (KEGG map id: 00010) for glycolysis from gene expression data. The 
upregulated genes are highlighted in red. 5.4.2.2, phosphoglycerate mutase 1 (PGM1); 5.3.1.9, glucose 6-
phosphate isomerase  (GPI); 2.7.1.11 , phosphofructokinase (PFKP); 4.1.2.13, aldolase (ALD); 5.3.1.1, 
(triose phosphate isomerase 1)TPI1; 1.2.1.12, glyceraldehyde 3-phosphate dehydrogenase (GAPDH); 




8.4 Appendix 4 
 
Figure 8-2: Annotated pathways (KEGG map id: 00051) for fructose and mannose pathway from gene 
expression data. The upregulated genes are highlighted in red. 3.1.3.46, fructose-2,6-biphosphatase 4 
(PFKFB4); 5.3.1.8, mannose-6-phosphate isomerase (MPI); 2.7.1.11, phosphofructokinase (PFKP); 






8.5 Appendix 5 
 
 
Figure 8-3: Annotated pathways (KEGG map id: 00030) for pentose phosphate pathway from gene 
expression data. The upregulated genes are highlighted in red. 5.3.1.9, glucose 6-phosphate isomerase 




8.6 Appendix 6 
 
Figure 8-4: Spin system of glutamate acquired with double edited TILT TOCSY-HSQC for a MCF7 cells 
sample labelled for 3 hour with [1,2-13C]glucose in hypoxia. No cross peaks except those for those between 
protons 3A, 3B  and 2 are detected. The predicted chemical shifts were marked in black crosses, the 
picked peaks were marked in red crosses and the peaks that had already picked in the same spectrum 






8.7 Appendix 7 
 
Figure 8-5: Spin system of glutamate acquired with double edited TILT TOCSY-HSQC for MCF7 cells 
labelled for 3 hours with [1,2-13C]glucose in normoxia. Cross peak at C2,C3 and C2,C4 are apparent. The 
predicted chemical shifts were marked in black crosses, the picked peaks were marked in red crosses and 






8.8 Appendix 8 
 
Figure 8-6: [3-13C]aspartate incorporation % of MCF7 cells in normoxia and hypoxia when cells were 
labelled with [2-13C]aspartate for 24 hours. Each data point is the average ± SEM of three independent 
experiments. *p <0.05. 
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